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I have been involved in clinical research in the field of diagnostic biomarkers of diabetic 
neuropathy since I joined Prof. Rayaz Malik’s team in January 2010 at the University of 
Manchester and subsequently as a clinical researcher in Weill Cornell Medicine in Qatar 
(WCM-Q). I have published (50) papers, 18% of which I am the lead author. According to 
Google Scholar, as of July 2020, I have a h-index of 20 and i10-index of 29. I have established 
the study ‘prevalence and risk factors of diabetic neuropathy and painful diabetic neuropathy 
in Qatar’. I have studied the effect of a GLP-1 agonist and insulin sensitizer compared to insulin 
on corneal nerve regeneration in poorly controlled T2DM patients in a clinical trial. I have 
assessed the diagnostic ability of corneal confocal microscopy (CCM) as a biomarker for 
neurodegeneration in dementia and schizophrenia. I have been involved in the writing of 
successful grant proposal: for the Dementia Project (NPRP12S-0213-190080) awarded 
$695,903 by Qatar Foundation, the DELPHIC-Qatar (delirium) project (IRGC-04-SI-17-153) 
awarded $234,000, and the Schizophrenia study (IRGC-04-SI-17-166) awarded $122,000 by 





Background: Diabetic peripheral neuropathy (DPN) affects ~50% of people with diabetes and 
leads to painful DPN (pDPN), diabetic foot ulceration (DFU) and amputation imposing a 
significant health and economic burden. Given that there are currently no European 
Medicines Agency (EMA) and FDA approved therapies for DPN it is important to establish the 
current prevalence and modifiable risk factors for DPN and assess the benefit of treatments 
utilizing corneal confocal microscopy (CCM), a sensitive technique to quantify early nerve 
regeneration in DPN. Furthermore, CCM has shown corneal nerve loss in central 
neurodegenerative disorders such as Parkinson’s disease and multiple sclerosis, therefore the 
diagnostic utility of this technique was assessed in subjects with mild cognitive impairment 
(MCI) and dementia. 
Aims: This work established the prevalence and risk factors of DPN and those at high risk of 
DFU in Chapter 3; the prevalence and risk factors of pDPN in Chapter 4 and the prevalence of 
DPN and pDPN in both primary (PHC) and secondary health care (PHC) in type 2 diabetes (T2D) 
in Qatar in Chapter 5. It investigated the effect of hypertension on neuropathic symptoms 
and deficits in type 1 diabetes (T1D) in Chapter 6, the association between metformin induced 
B12 deficiency and DPN in Chapter 7, and the effect of exenatide and pioglitazone or basal-
bolus insulin on DPN in patients with poorly controlled T2D as an exploratory sub-study of the 
Qatar study, an open-label, randomized controlled trial (clinicaltrials.gov identifier 
NCT02887625) in Chapter 8. It assessed the association of corneal nerve morphology with 
cognitive impairment in MCI and dementia in Chapter 9 and compared the diagnostic ability 
of CCM to visual rating of medial temporal lobe atrophy (MTA) on brain MRI to distinguish 
subjects with MCI or dementia from subjects with no cognitive impairment (NCI) in Chapter 
10. 
Methods: All the research work was conducted in Qatar apart from Chapter 6 which was 
performed in Manchester, UK. The study design, inclusion and exclusion criteria, diagnosis 
and assessments for each study are described in detail in the methods section in each chapter. 
Subjects were randomly enrolled and screened for eligibility on the day they attended the 
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clinic. Demographic, clinical and metabolic characteristics and list of medications were 
recorded. Subjects underwent assessment of DPN and pDPN (Chapter 3-7), CCM (Chapter 6, 
8-10), intraepidermal nerve fiber density (Chapter 6), autonomic neuropathy (Chapter 6), 
quantitative sensory testing (QST) for warm and cold perception (Chapter 6), nerve 
conduction studies (NCS) (Chapter 6), diagnosis of NCI, MCI and dementia (Chapter 9 & 10), 
cognitive screening (Chapter 9 & 10), functional independence screening (Chapter 9 & 10), 
brain MRI and MTA visual rating (Chapter 10). 
Results: Chapter 3 established that the prevalence of DPN and high risk of DFU in those with 
DPN were 23.0% and 33.7%, respectively in SHC (n=1,095) and the risk factors were age, 
duration of diabetes, poor glycemic control, hyperlipidemia and hypertension. Chapter 4 
established that the prevalence of pDPN was 34.5% in SHC and the risk factors were DPN, 
obesity, physical activity and smoking. Chapter 5 shows that PHC (n=298) had a significantly 
lower prevalence of DPN (14.8%, P=0.001) and pDPN (18.1%, P<0.0001) but comparable high 
risk for DFU (31.8%, P=0.3) compared to SHC. Alarmingly, 79.5-82.3% of patients with DPN 
were undiagnosed in PHC and SHC. Chapter 6 shows that hypertension affects NCS in patients 
with T1D after controlling for HbA1c, cholesterol, triglycerides, and BMI but has no impact in 
subjects without diabetes. Chapter 7 shows no difference in DPN or pDPN between those 
with and without B12 deficiency and between metformin and non-metformin users. Chapter 
8 shows that a combination of exenatide once weekly and pioglitazone or basal-bolus insulin 
leads to corneal nerve regeneration detected by CCM, but no change in neuropathic 
symptoms or sudomotor function. Chapter 9 shows that CCM identified corneal nerve loss 
and associated it with cognitive and functional decline in MCI and dementia. Chapter 10 
shows that CCM had comparable diagnostic ability for dementia with MTA whilst only CCM 
can distinguish MCI from NCI, after adjustment for diabetes. 
Conclusions: Despite DPN affecting 23% of adults with T2D in SHC and 15% in PHC, ~80% of 
patients with DPN were undiagnosed in both PHC and SHC, highlighting the need for 
implementing annual DPN screening. The lower prevalence of DPN and pDPN in PHC 
compared to SHC may be attributed to better overall risk factor control in PHC and referral 
bias as patients who are poorly managed with complications are referred to SHC. The 
identification of hyperglycemia, hyperlipidemia and hypertension as modifiable risk factors 
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for DPN and obesity and physical activity as modifiable risk factors of pDPN provide potential 
treatments for the management of DPN and pDPN. The association between hypertension 
and NCS further supports the role of hypertension in DPN. Our study does not confirm that 
DPN was associated with B12 levels and metformin use in Qatar. Treatment with exenatide 
and pioglitazone or basal-bolus insulin resulted in corneal nerve regeneration, but no change 
in neuropathic symptoms or sudomotor (control of sweat glands activity) function over 
1 year, highlighting the importance of selecting appropriate endpoints to show treatment 
efficacy in DPN. CCM had a better diagnostic outcome for identifying subjects with MCI and 
comparable with dementia compared to MTA rating and should be considered as an objective 
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Chapter 1: General introduction 
1.1 Diabetic peripheral neuropathy 
Diabetic peripheral neuropathy (DPN) is a common complication of diabetes, affecting ~50% 
of people with diabetes (Tesfaye and Selvarajah, 2012). It is a progressive neurodegenerative 
disorder of the peripheral nervous system involving sensory, autonomic and motor nerve 
fibers. The clinical diagnosis of DPN is challenging due to the insidious onset of disease and 
gradual decline of peripheral nerve function (Malik, 2020). Damage to the peripheral nerve 
fibers occurs in a distal symmetrical manner. It imposes a significant health and economic 
burden to both the patient and health care providers (Raghav et al., 2018). DPN leads to 
painful DPN (pDPN) in 18-65% (Ponirakis et al., 2019b), erectile dysfunction in 53-73% 
(Kouidrat et al., 2017) and diabetic foot ulceration (DFU) in 2-17% (Raghav et al., 2018) of 
patients with type 2 diabetes (T2D). Painful DPN has a significant impact on the patient’s 
quality of life (Girach et al., 2019) as it is accompanied by depression, anxiety and sleep 
disturbance. The prevalence of DPN increases with age and duration of diabetes (Young et al., 
1993, Cabezas-Cerrato, 1998). 
1.1.1 Prevention 
The management of DPN and its consequences has primarily focused on: 1. Screening to 
identify early DPN; 2. Management of risk factors to prevent or delay DPN; 3. Screening for 
those at risk of DFU to prevent ulceration and amputation. 
Screening annually for symptoms and signs of DPN starting at diagnosis of T2D and 5-years 
after the diagnosis of type 1 diabetes (T1D) is recommended by the 2017 American Diabetes 
Association (ADA) position statement on DPN (Pop-Busui et al., 2017) (Figure 1.1). Screening 
for DPN in prediabetes is also advocated based on the higher prevalence of impaired glucose 
tolerance and metabolic syndrome in people presenting with painful neuropathy. DPN 
(Boulton and Malik, 2010) and small nerve fiber damage (Azmi et al., 2015) have been 
reported in patients with impaired glucose tolerance (IGT). However, despite having a serious 
impact on the patient’s quality of life and outcomes, screening for DPN and pDPN remains 
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inadequate. An alarmingly high prevalence of undiagnosed DPN 51-82% (Wang et al., 2011, 
Herman and Kennedy, 2005) and pDPN 13-62% (Ziegler et al., 2018, Daousi et al., 2004) have 
been reported. The diagnosis of DPN is often made during diabetic foot screening or after the 
occurrence of diabetic foot ulceration in which case DPN has not been diagnosed for some 
time. Patients with painful symptoms are often unaware that the pain is related to diabetes 
and do not report it to their clinician (Daousi et al., 2004, Eichholz et al., 2017). 
The key to prevention of DPN is the identification and optimal management of risk factors 
(Pop-Busui et al., 2017), given the lack of disease modifying treatments for DPN (Malik, 2016, 
Malik, 2014). Optimization of glycemic control may prevent DPN onset and delay DPN 
progression (Pop-Busui et al., 2017). In the DCCT, intensive insulin treatment reduced the 
incidence of clinical DPN by 60% (Diabetes et al., 1993) and prevented peroneal nerve 
conduction velocity slowing over a 5-year period in patients with T1D. The Kumamoto study 
(Ohkubo et al., 1995) showed that intensive treatment prevented nerve conduction slowing 
over 6 years and the ACCORD trial (Ismail-Beigi et al., 2010) showed a reduction in the 
incidence of loss of ankle reflexes but no effect on VPT over 6-years (Callaghan et al., 2012). 
However, in patients with T2D the UKPDS (UK Prospective Diabetes Study (UKPDS) Group, 
1998) and VA-CSDM trial (Azad et al., 1999) reported that intensive treatment had no effect 
on the incidence of DPN and CAN compared with conventional treatment, suggesting possible 
other important factors. These involve cardiovascular risk factors including hypertension 
(Kesavamoorthy et al., 2015, Yang et al., 2015) and hyperlipidemia (Tesfaye et al., 2005, Smith 
and Singleton, 2013), the management of which may also prevent DPN; angiotensin 
converting enzyme (ACE) inhibitors (Malik et al., 1998, Ruggenenti et al., 2011, Reja et al., 
1995) and statins (Davis et al., 2008, Villegas-Rivera et al., 2015) have both shown to prevent 
or slow the progression of DPN. Lifestyle interventions are also important, including physical 
activity (Al-Kaabi et al., 2014, Smith et al., 2006) and avoidance of smoking (Al-Mahroos and 
Al-Roomi, 2007, Tesfaye et al., 2005). Weight loss may improve symptoms of pDPN (Jambart 
et al., 2011, Van Acker et al., 2009, Ziegler et al., 2018) and a study by Smith et al. reported 
that lifestyle intervention in patients with pre-diabetes reduced neuropathic symptoms and 
improved small fiber function and structure (Smith et al., 2006). 
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Figure 1.1. Proposed screening protocol for DPN in clinical practice.  
Screening annually for DPN starting at diagnosis of T2D and 5-years after the diagnosis of T1D 
is recommended by the American Diabetes Association (ADA). If the screening result shows 
DPN, further assessments are required to confirm diagnosis of DPN. After further assessments 
of DPN if the symptoms and signs do not meet the criteria for diagnosis of DPN, further annual 
screening for DPN is recommended. However if the symptoms and signs meet the criteria for 
diagnosis of DPN, annual screening for diabetic foot is recommended. Abbreviation: Diabetic 
peripheral neuropathy (DPN), type 1 diabetes (T1D), type 2 diabetes (T2D). 
One in four patients with DFU are at risk of amputation (Apelqvist and Agardh, 1992). 
Screening annually for patients at risk of DFU is advocated by the International Working Group 
on the Diabetic Foot (IWGDF) include regular examinations for DFU, educating the patient 
and family about appropriate foot care, routine wearing of appropriate footwear and treating 
risk factors for DFU (Bus et al., 2020). The National Diabetes Foot Care Audit (NDFA) in the UK 
showed that patients who referred themselves directly to a foot care clinic had higher healing 
rates after 12 weeks compared to those referred by a health professional (56% vs 32-48%) 
(Mayor. S, 2017). Despite the 5-year mortality of people with a DFU being higher than many 
common cancers (Moulik et al., 2003, Armstrong et al., 2007), the development of DFU in 
patients who have not been screened remains alarmingly high (Wang et al., 2011, Herman 
and Kennedy, 2005). 
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1.1.2 Screening and diagnosis 
The purpose of screening for DPN is to use a single rapid test routinely for all patients with 
diabetes in a busy clinic and identify patients with DPN (Figure 1.1). Screening tests for DPN 
should be able to detect incipient nerve damage before the development of overt clinical 
diabetic neuropathy especially in pre-diabetes or early diabetes. Potential screening methods 
for DPN include: Sudomotor function (Sudoscan (2 minutes) (Selvarajah et al., 2015) or 
Neuropad test (10 minutes) (Ponirakis et al., 2014), quantitative sensory tests (QST) including 
vibration perception threshold (VPT) (3 minutes) (Bril and Perkins, 2002a) or NerveCheck for 
testing vibration, cold, warm perception and hyperalgesia to thermal induced pain (10 
minutes) (Ponirakis et al., 2016); composite scoring systems that include symptoms, signs, or 
both to quantify neuropathic deficits including the Neuropathy Disability Score (NDS) (5 
minutes) (Young et al., 1993), modified Toronto Clinical Neuropathy Score (mTCNS) (5-10 
minutes) (Bril and Perkins, 2002b) and Michigan Neuropathy Screening Instrument (MNSI) (10 
minutes) (Feldman et al., 1994).. However, the most commonly advocated test is the 
evaluation of pressure sensation using the 10g-monofilament which assesses severe 
neuropathy and those at risk of diabetic foot ulceration (Pop-Busui et al., 2017), but continues 
to be recommended for DPN screening (Perkins et al., 2010). Moreover, the validity of this 
method as a screening test for DPN is further challenged given that a study has shown that it 
failed to detect DPN in ~80% of patients with DPN regardless of the number of sites 3, 4 or 10 
tested on each foot (Zhang et al., 2018).  
The diagnosis of DPN is based on a comprehensive assessment of history, symptoms and signs 
to rule out other causes of peripheral neuropathy including autoimmune diseases (Sjogren’s 
syndrome, lupus, rheumatoid arthritis), infections (HIV, hepatitis B and C), inherited (Charcot-
Marie-Tooth), inflammatory (CIDP), tumors, vitamin B12 deficiency, hypothyroidism, 
alcoholism and injury or pressure on the nerve. Symptoms of DPN include burning pain, 
numbness, tingling, pins and needles like pain, electric shocks, cold pain, allodynia (pain due 
to a stimulus that does not usually provoke pain) and hyperalgesia (increased pain from a 
stimulus that usually provokes pain). Early DPN is caused predominantly by small fiber 
neuropathy, especially in pre-diabetes (Azmi et al., 2015, Divisova et al., 2012) with 
involvement of large fibers as the disease progresses. Assessments for small fiber neuropathy 
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(Azmi et al., 2019d) include QST for warm and cold perception threshold (Bril and Perkins, 
2002a, Ponirakis et al., 2016), pDPN assessment (Spallone et al., 2012), diabetic autonomic 
neuropathy (DAN) (Spallone et al., 2011), corneal nerve fiber morphology using corneal 
confocal microscopy (CCM) (Petropoulos et al., 2013c, Petropoulos et al., 2014, Petropoulos 
et al., 2013a, Malik et al., 2003, Ahmed et al., 2012) and intra-epidermal nerve fiber density 
(IENFD) from skin biopsy (Lauria et al., 2010a, Lauria et al., 2010b). Assessments for large fiber 
neuropathy (Azmi et al., 2019d) include VPT testing and nerve conduction studies 
(NCS)/electrophysiological studies (Kahn, 1992, Bril et al., 1998). DAN, results from the 
impairment of the sympathetic and parasympathetic nervous system and affects the 
cardiovascular, gastrointestinal, genitourinary and sudomotor systems (Spallone et al., 2011). 
Cardiovascular autonomic neuropathy (CAN) is the most studied and clinically important form 
of DAN. CAN is assessed by a battery of autonomic function tests including deep breathing 
heart rate variability (DB-HRV), Valsalva maneuver or postural blood pressure change (Olney, 
1998). CAN is associated with an increased risk of silent myocardial ischemia and mortality 
(Vinik et al., 2003). Other techniques for testing DAN include sudomotor function testing and 
laser doppler imager flare response. Composite scoring systems that quantify neuropathic 
deficits of both small and large fiber neuropathy include the NDS (Young et al., 1993), mTCNS 
(Bril and Perkins, 2002b), Neuropathy Impairment Score of the lower limb (NIS-LL) (Bril, 1999), 
Total Neuropathy Score-clinical (TNS-C) (Cornblath et al., 1999), Michigan Diabetic 
Neuropathy Score coupled with the MNSI (Feldman et al., 1994) and Utah Early Neuropathy 
Score (UENS) (Singleton et al., 2008). 
The screening and diagnosis of pDPN is based on a subjective description of specific painful 
symptoms experienced in the distal parts of the limbs and expressed in relation to intensity 
and frequency by the patient. Screening for pDPN should distinguish neuropathic pain from 
nociceptive or other types of chronic pain. Screening methods for pDPN include the Douleur 
Neuropathique 4 (DN4) questionnaire (Spallone et al., 2012), the Leeds Assessment of 
Neuropathic Symptoms and Signs (LANSS) pain scale (Bennett, 2001), the Neuropathic Pain 
Scale (NPS) (Jensen et al., 2006), the Neuropathic Pain Symptom Inventory (NPSI) (Bouhassira 
et al., 2004), and the Diabetic Peripheral Neuropathic Pain Impact measure (DPNPI) (Brod et 




The purpose of diabetic foot screening is to identify patients with advanced DPN who are at 
high risk of DFU and amputation. Those at risk of diabetic foot ulceration can be screened by 
testing pressure perception using the 10-g monofilament or Ipswich Touch Test by touching 
the tips of the toes of both feet with the index finger (Sharma et al., 2014), testing vibration 
perception using the 128-Hz tuning fork or Neurothesiometer to assess for VPT >25 Volts and 
absence of ankle reflexes (Boulton et al., 2008). 
1.1.3 Management 
There are currently no European Medicines Agency (EMA) and FDA approved disease 
modifying treatments for DPN (Malik, 2016, Malik, 2014) and only three approved 
medications for painful neuropathy, including duloxetine, pregabalin and tapentadol (Javed 
et al., 2015). Treatment with angiotensin converting enzyme (ACE) inhibitor (Malik et al., 
1998, Ruggenenti et al., 2011, Reja et al., 1995) may improve neuropathy and statins (Arya et 
al., 2018, Hsu et al., 2017) and fibrates (Rajamani et al., 2009) may reduce amputation. Whilst 
optimization of glycemic control may prevent DPN onset and delay DPN progression in type 
1 diabetes (T1D) (Pop-Busui et al., 2017), there are conflicting data on the benefits of 
improved glycemic control on DPN in T2D (Ohkubo et al., 1995, Ismail-Beigi et al., 2010, Pop-
Busui et al., 2013, Azad et al., 1999, Gaede et al., 2003). Modification of cardiovascular risk 
factors including hypertension (Kesavamoorthy et al., 2015, Yang et al., 2015) and 
hyperlipidemia (Tesfaye et al., 2005, Smith and Singleton, 2013) may prevent DPN onset and 
delay DPN progression. Lifestyle interventions, including physical activity (Al-Kaabi et al., 
2014, Smith et al., 2006), avoidance of smoking (Al-Mahroos and Al-Roomi, 2007, Tesfaye et 
al., 2005) and weight loss (Jambart et al., 2011, Van Acker et al., 2009, Ziegler et al., 2018) 
may reduce the incidence of DPN. 
1.1.4 The contribution of this PhD thesis to the current knowledge on DPN prevention and 
management 
According to the International Diabetes Federation, the prevalence of diabetes in adults aged 
20-79 years in Qatar was 15.5% in 2020 (IDF Middle East and North Africa Region, 2020, ), 
which is almost two-fold greater than the 2019 reported prevalence of 8.3% in the rest of the 
world (International Diabetes Federation, 2019, ). The high prevalence of diabetes can be 
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translated into an increase in the prevalence of DPN. Indeed, in Qatar, 25% of patients 
attending secondary care were being seen for foot problems (Al-Thani et al., 2019). In 2015, 
Qatar launched the National Diabetes Strategy to improve the management of people with 
diabetes and its complications by establishing common clinical care pathways within and 
between primary and secondary health care. 
The prevalence and risk factors of DPN have not been systematically studied in Qatar. Whilst 
the prevalence and risk factors of DPN from other countries is relevant, identifying the 
prevalence and risk factors of DPN in Qatar is key to planning the National Diabetes Strategy 
on preventing the complications of diabetes. Chapter 3 has established the prevalence and 
risk factors in patients with T2D for DPN and those at high risk of DFU in secondary health 
care. Chapter 4 has established the prevalence and risk factors of pDPN in patients with T2D 
in secondary health care. Chapter 5 has compared the prevalence and risk factors of DPN and 
pDPN between primary and secondary health care. 
Clinical and experimental studies suggest that hypertension is an independent risk factor for 
DPN in patients with T1D (Tesfaye et al., 2005, Forrest et al., 1997, Cavusoglu et al., 2015, 
Elliott et al., 2009, Sanada et al., 2015, Gregory et al., 2012) and T2D (Cardoso et al., 2015, De 
Visser et al., 2014, Kesavamoorthy et al., 2015, Yang et al., 2015). ACE inhibitors have been 
shown to improve NCS but there are conflicting data on the effect on neuropathic symptoms 
and other neuropathy measures (Malik et al., 1998, Ruggenenti et al., 2011, Reja et al., 1995). 
Chapter 6 has identified the impact of hypertension on both large and small fiber measures 
in patients with and without T1D. 
Most international guidelines recommend metformin after lifestyle intervention for T2D 
patients. This rationale is based on its 40-year long-term safety record and the fact that it has 
shown a 31% reduced incidence of T2D and 17% reduced incidence of metabolic syndrome at 
2.8-years (Knowler et al., 2002). Despite conflicting data regarding the effect of metformin 
therapy on B12 deficiency (Chapman et al., 2016), a number of observational and placebo-
controlled studies have confirmed that metformin may reduce vitamin B12 levels. A potential 
consequence of B12 deficiency is that it could result in or exacerbate DPN. However, there are 
conflicting reports on the association between metformin induced B12 deficiency and 
neuropathy, with some reports showing an association (Singh et al., 2013, Roy et al., 2016) 
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whilst others have refuted this (Khan et al., 2017, Russo et al., 2016, Ahmed et al., 2016, Ma 
et al., 2015). Chapter 7 has determined whether treatment with metformin is associated with 
B12 deficiency and whether B12 deficiency is associated with DPN and painful diabetic 
neuropathy.    
1.2 Development of disease-modifying agents for diabetic peripheral neuropathy 
In total, 423 interventions have been evaluated for DPN in clinical trials between February 
1998 to June 2020 (clinicaltrials.gov). There were 42 (9.9%) disease modifying agents, 183 
(43.3%) agents for neuropathic pain, 143 (33.8%) agents for diabetic foot and 55 (13.0%) 
interventions such as diet, lifestyle, wound dressings, education, procedures and devices. Of 
concern, all trials of disease modifying agents have failed and the focus of interventions has 
shifted to agents for management of diabetic foot disease (Malik, 2016). Figure 1.2 shows 
that the proportion of disease modifying agents and symptom-reducing agents have been 
reduced by half, whilst the proportion of agents for diabetic foot have doubled and alternative 
non-drug interventions have increased 4-fold between 2000-2014 and the current pipeline. 
The lack of progress in developing an effective disease modifying agent have been attributed 
to late intervention in advanced neuropathy and inadequate trial duration as well as the 




Figure 1.2. The proportion of disease modifying agents, symptom-reducing agents, diabetic foot agents and 
alternative interventions for DPN in 423 trials from February 1998 to June 2020 as shown on clinicaltrials.gov. 
 
1.2.1 The role of biomarkers in drug development 
Biomarkers provide direct or indirect evidence of the underlying pathology of the disease, 
reflect disease progression and identify the benefit of therapeutic intervention. Biomarkers 
have two significant roles in the process of drug development: 1. Identify disease for 
recruitment selection and 2. Determine drug efficacy as primary and secondary outcome 
measures. 
Disease-modifying treatments are likely to respond better in early or mild neuropathy by 
intervening and halting pathological progression. Trials of patients with established DPN are 
destined to fail. Early DPN involves predominantly small fiber dysfunction/damage (Azmi et 
al., 2015, Divisova et al., 2012) and as neuropathy progresses large fiber neuropathy develops. 
Hence, recruiting patients with small fiber or asymptomatic neuropathy may allow evaluation 
of a drug in preventing DPN or repairing small nerve fiber damage. Composite scoring systems 
and assessments of large fiber neuropathy are useful to confirm the presence of mild DPN for 
recruitment and to assess the development of symptoms or disease progression as outcome 
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most of the trials were assessing large fiber neuropathy. Whilst 74% of trials undertook large 
fiber assessment using NCS, only 31% of trials assessed small fiber neuropathy using either 
IENFD or CCM. 
Corneal confocal microscopy (CCM) is an ophthalmic imaging technique to quantify small 
fiber neuropathy (Petropoulos et al., 2013c, Petropoulos et al., 2014, Petropoulos et al., 
2013a, Malik et al., 2003, Ahmed et al., 2012). It has been used as an outcome measure for 
DPN and other peripheral neuropathies in 22 trials from January 2018 to June 2020 as shown 
in Clinicaltrial.gov. Damage to corneal nerve fibers is associated with the severity of 
neuropathic symptoms (Kalteniece et al., 2020). CCM also has the ability to detect nerve 
repair at 6 months, whilst NCS and neuropathic symptoms improved after 24 months 
(Tavakoli et al., 2013, Azmi et al., 2019b). CCM can also predict DPN development (Pritchard 
et al., 2015, Lovblom et al., 2015, Edwards et al., 2017). Therefore, CCM has considerable 
merit to enrich trial cohorts, monitor neurodegeneration over time and reduce the length of 
trials that assess the effectiveness of disease modifying therapies. 
IENFD was the gold standard as an objective measure for small fiber neuropathy (Lauria et 
al., 2010a, Lauria et al., 2010b). However, it’s utility in clinical trials is limited due to it being 
an invasive and costly procedure, which does not allow repeated assessment of the same 
nerves. Whilst there is a correlation between IENFD and CCM measures, nerve fiber loss 
detected from different patients (Ziegler et al., 2014). The diagnostic accuracy expressed as 
the area under the receiver operating characteristic (ROC) curve for distinguishing small fiber 
neuropathy in patients with T2D from control subjects is 82% with corneal nerve fiber density 
(CNFD) and 66% with IENFD (Chen et al., 2015). 
Nerve conduction studies (NCS) remain an essential technique due to widespread access and 
its objectivity and reproducibility for quantifying large fiber neuropathy (Bril et al., 1998). 
Decreases in sensory nerve action potential amplitude, sensory and motor nerve conduction 
velocity are associated with severity of neuropathic deficits (Dyck and O'Brien, 1989). Motor 
nerve conduction velocity (MNCV) can predict the development of diabetic foot ulceration 
(Carrington et al., 2002). However, the repeatability of NCS in trials varies considerably and 
may be responsible for the inability to identify benefits (Olney, 1998). NCS can vary 
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considerably if limb temperature is not maintained within a specified range throughout the 
test. 
Quantitative sensory testing (QST) of warm and cold perception threshold have been shown 
to be reliable measures for small fiber neuropathy and vibration perception threshold for 
large fiber neuropathy (Azmi et al., 2019d, Dyck, 2014). However, QST is a subjective 
psychophysical test, dependent on patient motivation, alertness, and concentration and may 
not be sufficiently sensitive to detect a change in DPN (Malik, 2016). 
Diabetic autonomic neuropathy (DAN) assessment is non-invasive and reproducible (Vinik et 
al., 2003). CAN assessment, which includes a battery of tests including DB-HRV, Valsalva 
maneuver and postural blood pressure change have been most used widely (Olney, 1998).  
Composite scoring systems, including NDS (Young et al., 1993), mTCNS (Bril and Perkins, 
2002b), NIS-LL (Bril, 1999), TNS-C (Cornblath et al., 1999), MDNS coupled with the MNSI 
(Feldman et al., 1994) and UENS (Singleton et al., 2008) are weighted predominantly to the 
assessment of large fiber neuropathy (Zilliox et al., 2015), which clearly limits their utility to 
assess small fiber neuropathy. These composite scoring systems show association with large 
fiber assessments such as NCS and VPT but no association with IENFD at the distal leg or thigh 
or cold perception threshold (Zilliox et al., 2015).  
1.2.2 The contribution of this PhD thesis to assess the effect of glucose lowering therapies 
on neuropathy using CCM as a primary outcome measure 
Both glucagon-like peptide 1 (GLP-1) receptor agonists (Kan et al., 2012, Himeno et al., 2011) 
and thiazolidinediones (TZDs) (Qiang et al., 1998, Pop-Busui et al., 2013, Yamagishi et al., 
2008, Wiggin et al., 2008) produce a durable reduction in HbA1c (Abdul-Ghani et al., 2017). 
GLP-1 receptor agonists stimulate insulin secretion in response to hyperglycemia, delay 
gastric emptying leading to weight loss and inhibit hepatic glucose production. TZDs are 
potent insulin sensitizers and improve β-cell function.  
There are conflicting data regarding the beneficial effect of GLP-1 receptor agonists on DPN. 
Preclinical studies showed that exendin-4, a GLP-1 receptor agonist prevents sensory (Kan et 
al., 2012) and motor nerve conduction slowing (Himeno et al., 2011) and a reduction in IENFD 
in T1D mice. However, exenatide showed no effect on the incidence of DPN, cardiovascular 
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autonomic neuropathy (CAN) or IENFD in patients with T2D over 18 months (Jaiswal et al., 
2015). Liraglutide failed to show a benefit on DAN or sensory and motor nerve conduction in 
39 patients with T1D and established DPN (Brock et al., 2019).  
There is evidence showing that TZDs might have a neuroprotective effect. In preclinical 
studies, troglitazone prevented nerve conduction slowing and maintained normal myelinated 
fiber architecture and density in T1D rats (Qiang et al., 1998). Pioglitazone prevented nerve 
conduction slowing and reduced macrophage infiltration in the sciatic nerve in T1D rats 
(Yamagishi et al., 2008). Rosiglitazone prevented thermal hypoalgesia and reduced oxidative 
stress in the sciatic nerve of T1D mice (Wiggin et al., 2008). In the BARI 2D trial (Pop-Busui et 
al., 2013), rosiglitazone significantly reduced the 4-year cumulative incidence of DPN 
compared to insulin treatment in patients with T2D. The neuroprotective effect of TZDs may 
be attributed to a reduction in oxidative stress and advanced glycated end products. 
Chapter 8 has assessed the effect of combination treatment of exenatide and pioglitazone or 
basal-bolus insulin on DPN measures in patients with poorly controlled T2D over a 1-year 
period. DPN was measured using CCM as a primary outcome measure and DN4 questionnaire, 
vibration perception threshold (VPT) and sudomotor function as secondary outcome 
measures. This study also evaluated the effect of the treatments on diabetic retinopathy. This 
is a sub-study of the Qatar study (Abdul-Ghani et al., 2017), an open-label, randomized 
controlled trial, which showed a rapid and effective reduction in HbA1c after treatment with 
the combination treatment or basal-bolus insulin in patients with poorly controlled T2D. 
1.3 Application of CCM as a biomarker of neurodegeneration in dementia 
CCM was originally pioneered to identify neurodegeneration in DPN (Petropoulos et al., 
2013c, Petropoulos et al., 2014, Petropoulos et al., 2013a, Malik et al., 2003, Ahmed et al., 
2012) and subsequently in a range of other peripheral neuropathies (Petropoulos et al., 2019) 
and in a large group of healthy people (Tavakoli et al., 2010). It generates in vivo images of 
the sub-basal nerve plexus from which corneal nerve morphology is analysed using validated 
image analysis software (Dabbah et al., 2011) which reduces inter- and intra-rater variability 
and enables objective quantification of the corneal nerve morphology (Vagenas et al., 2012, 
Petropoulos et al., 2013c, Kalteniece et al., 2017). CCM has also been used to identify corneal 
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nerve degeneration in a number of central neurodegenerative diseases, including Parkinson’s 
disease (Kass-Iliyya et al., 2015, Podgorny et al., 2016), amyotrophic lateral sclerosis (Ferrari 
et al., 2014) and multiple sclerosis (Petropoulos et al., 2017, Bitirgen et al., 2017b, Mikolajczak 
et al., 2016). However, the association between corneal nerve fiber pathology and 
neurodegeneration in dementia has not been studied. 
1.3.1 Biomarkers for Alzheimer’s disease 
Dementia is a progressive neurodegenerative disorder currently affecting 40-50 million 
people worldwide (Wu et al., 2017, Prince et al., 2013). Therapeutic and psychological 
interventions for people with early stage dementia can improve cognition, independence, and 
quality of life (Prince et al., 2011). However, the diagnosis of mild cognitive impairment (MCI) 
or early dementia can be challenging due to the insidious onset of disease and gradual 
cognitive decline. A diagnosis of MCI requires a change in cognition, evidence of impairment 
in at least one cognitive domain but with preserved ability to function independently in daily 
life (McKhann et al., 2011). However, cognitive assessment tests are influenced by age, 
educational and cultural background (Albert et al., 2011). Biomarkers that allow for greater 
diagnostic certainty to distinguish normal cognition due to aging from MCI and dementia are 
required. 
The 2011 National Institute on Aging and the Alzheimer’s Association (NIA-AA) diagnostic 
criteria for Alzheimer’s disease (AD) (Albert et al., 2011) included imaging and cerebrospinal 
fluid (CSF) biomarkers to confirm the diagnosis of AD, but not to predict the development of 
AD in patients with MCI or early dementia (McKhann et al., 2011). The 2018 revision of the 
NIA-AA diagnostic criteria has changed the role of biomarkers from confirming the presence 
of AD to identifying the disease in its asymptomatic stages (Jack et al., 2018). Based on 
longitudinal studies, the NIA-AA proposed the A/T/N classification system for AD biomarkers, 
in which A is for amyloid beta (Aß) biomarkers, T for tau biomarkers and N for 
neurodegeneration biomarkers. Biomarkers for Aß and tau include positive Aß deposition in 
the brain utilizing amyloid positron emission tomography (PET) imaging (Forsberg et al., 2008, 
Grimmer et al., 2013), reduced CSF Aß42 or Aß42/Aß40 ratio and increased CSF tau protein 
concentrations (Mattsson et al., 2009). Biomarkers for neurodegeneration include reduced 
[18F] fluorodeoxy-glucose (FDG) uptake on PET in the temporoparietal lobes reflecting 
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reduced brain activity (Landau et al., 2010) and hippocampal or medial temporal lobe atrophy 
(MTA) on MR imaging (Jack et al., 1999, Bouwman et al., 2007). 
1.3.2 Limitations of current biomarkers for Alzheimer’s disease 
NIA-AA proposed biomarkers are relatively accurate, objective and reliable but have 
limitations. Amyloid-PET reflects aggregated Aß within the brain, a neuropathological 
hallmark of AD. However, amyloid-PET is costly and has health hazards because of exposure 
to radioactivity (Clark et al., 2011). Furthermore, the prevalence of amyloid PET positivity 
among elderly subjects without cognitive impairment is also high and is a major limitation 
that reduces diagnostic utility (Jansen et al., 2015). Amyloid deposition can occur decades 
before the manifestation of clinical symptoms (Villemagne et al., 2013) and the degree of 
amyloid deposition does not correlate with cognitive decline in AD (Khosravi et al., 2019). 
There are also practical concerns for amyloid-PET analysis due to variations in protocols and 
a lack of standardized cut-off values for interpretation (Suppiah et al., 2019). FDG-PET is a 
widely available radiotracer with established cutoff values expressed as standardized uptake 
values (SUVs) for disease process quantification (Suppiah et al., 2019). However, FDG PET has 
low accuracy in late-onset AD (≥74 years of age) (Ng et al., 2007) and has no significant 
association with regional Aß deposition in the brain (Altmann et al., 2015). 
CSF biomarkers can identify AD in its asymptomatic stages as metabolic and other 
pathological alterations occurring in the brain can be detected in the CSF. However, there are 
conflicting reports regarding the concentration of these proteins needed to accurately predict 
the development of AD in patients with MCI (Lee et al., 2019). Accessing CSF requires a lumbar 
puncture which is invasive, can be painful and is not routinely undertaken.  
Structural MR imaging for brain atrophy has high diagnostic accuracy for patients with late-
onset AD (Duara et al., 2008, Heo et al., 2013, Cavedo et al., 2014). However, it has poor 
accuracy for distinguishing patients with MCI or early-onset AD from subjects without 
cognitive impairment (Falgas et al., 2019).  
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1.3.3 Areas for improvement in biomarkers for Alzheimer’s disease 
As evidenced by the recent diagnostic accelerator program call from the Alzheimer’s Drug 
Discovery Foundation (ADDF), there is a need for accurate and reliable biomarkers that are 
accurate, non-invasive, simple to perform and inexpensive. Bill Gates and the ADDF have 
committed $30 million to the diagnostic accelerator program to develop biomarkers to better 
understand how the disease progresses, more easily identify people for clinical trials, and 
more accurately monitor their response to treatments.  
The efficiency of a biomarker for AD is evaluated based on its ability to: 1) provide direct or 
indirect evidence of the underlying pathology of the disease; 2) identify subtypes of MCI 
which do or do not progress to dementia (Figure 1.3), and 3) reflect disease progression 
and/or identify the benefit of therapeutic intervention. For a biomarker to be accepted as a 
pathologic, prognostic and/or monitoring marker it must be accurate with sensitivity and 
specificity equal to or higher than 80% (Thies et al., 1999). Biomarkers that have plateaued to 
maximal impairment or have not shown significant changes (ceiling and floor effects, 
respectively) are poor markers. 
Figure 1.3. A theoretical model of progressive cognitive and functional impairment in a patient with MCI that 
may reverse back to normal cognitive function, remain with MCI or progress to dementia. 
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1.3.4 The contribution of this PhD thesis in assessing the association of corneal nerve 
morphology with central neurodegeneration in MCI and dementia 
Chapter 9 has determined whether there is significant corneal nerve fiber loss in patients with 
MCI and dementia compared to age-matched controls and the association between corneal 
nerve fiber measures with cognitive function and functional independence. 
1.3.5 The impact of diabetes in dementia 
A large body of data shows that diabetes has a major influence on corneal nerve pathology 
(Petropoulos et al., 2013c, Petropoulos et al., 2014, Petropoulos et al., 2013a, Malik et al., 
2003, Ahmed et al., 2012). Epidemiological studies also show that individuals with T2D have 
an increased risk of dementia (Zhang et al., 2017a, Gudala et al., 2013); the relative risk for 
AD and vascular dementia (VaD) for people with diabetes compared to people without 
diabetes is 1.53 (95% CI 1.42-1.63) (Zhang et al., 2017a) and 2.27 (95% CI 1.94-2.66) (Gudala 
et al., 2013), respectively. This increased risk of dementia in patients with T2D is attributed to 
non-AD mechanisms of neurodegeneration as T2D is not associated with excess Aß plaques 
and neurofibrillary tangles of hyperphosphorylated tau protein in the brain (Abner et al., 
2016, Dos Santos Matioli et al., 2017). However, patients with T2D have a 1.57-times 
increased odds of an infarct, and 1.71-times increased odds of lacunes, small subcortical 
infarcts in the brain (Abner et al., 2016). Infarcts and lacunes double the risk of dementia 
occurring within 5 years (Vermeer et al., 2003) and could decrease cognitive reserve in 
patients who have accumulating plaques and tangles (Snowdon et al., 1997).  
1.3.6 Brain atrophy measurement on MRI: an established biomarker for 
neurodegeneration in Alzheimer’s disease 
Brain atrophy measurement on MRI is an established biomarker for neurodegeneration in 
Alzheimer’s disease (AD) but not for MCI or dementia (Albert et al., 2011, McKhann et al., 
2011). Brain atrophy occurs as the result of dendritic, myelin and axonal loss (Frisoni et al., 
2010). There is progressive medial temporal lobe atrophy (MTA) in subjects with MCI and 
dementia compared to those with no cognitive impairment (NCI) (Du et al., 2001, Urs et al., 
2009). MTA rating has been shown to have high diagnostic accuracy for probable (Thies et al., 
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1999) and established AD (Heo et al., 2013, Cavedo et al., 2014) but cannot distinguish 
patients with MCI or early-onset AD from subjects with NCI (Falgas et al., 2019). MTA has been 
reported in patients with VaD (Barber et al., 2000, Cho et al., 2009). 
1.3.7 The contribution of this PhD thesis in assessing the diagnostic ability of CCM for MCI 
and dementia compared with MRI 
Chapter 10 has compared the diagnostic accuracy of CCM with MTA rating for MCI and 
dementia, including AD, VaD and mixed AD. MTA was quantified in T1-weighted 3D MPRAGE 
MRI using the Duara visual rating (Duara et al., 2008). Given that diabetes is a confounding 
factor, the effect of diabetes on CCM measures in MCI and dementia was also assessed. 
It is important to assess the diagnostic ability of CCM not only for pure AD but also VaD and 
combined AD with vascular lesions. This is because autopsy studies have reported that 
amyloid deposition and vascular lesions in the brain are the most frequent pathologies 
present concurrently in patients with MCI and dementia (Jellinger and Attems, 2007, 
Schneider et al., 2007, Schneider et al., 2009). Vascular lesions are present in approximately 
50% of patients diagnosed with AD, even in clinical trials of subjects who have been 
extensively screened for pure AD (Wang et al., 2012). Whilst AD is considered to be the most 
common type of dementia accounting for 60-80% of cases (Hebert et al., 2013) followed by 
VaD in approximately, 10% of cases (Fernando et al., 2004), in Qatar the prevalence of VaD 
was 36% (Anoop Sankaranarayanan, 2016). CCM has shown corneal nerve loss in patients 
with TIA and minor (Gad et al., 2019) as well as major ischemic stroke (Khan et al., 2018) and 
corneal nerve loss has been associated with the presence of white matter hyperintensities, 
independent of the presence of diabetes (Kamran et al., 2020).  
1.4 PhD thesis submission in publication format 
The author has been granted permission to submit this PhD thesis in a publication format by 
his Director of Studies Professor Mark Slevin, First Supervisor Dr. Christopher Murgatroyd, 
Mentor Professor Rayaz A. Malik and approved under the Manchester Metropolitan 
University, Faculty of Science and Engineering and Faculty Research Degrees regulations. All 
chapters have been submitted for publication apart from chapters 1, 2 and 11, which are the 
introduction, methods and conclusion, respectively. Chapter 3 was published in 
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Diabetes/Metabolism Research and Reviews on 30/12/19. Chapter 4 was published in the 
Journal of Diabetes Investigation on 3/3/19. Chapter 5 was accepted for publication in the 
Journal of Diabetes Investigation on 16/7/20. Chapter 6 was published in the American 
Journal of Hypertension on 23/04/2019. Chapter 7 was published in Frontiers of 
Endocrinology on 25/05/2019. Chapter 8 was published in BMJ Open Diabetes Research Care 
on 13/5/20. Chapter 9 was published in Annals of Clinical and Translational Neurology on 




Chapter 2: Experimental Design and Methods 
2.1 Project plan and ethical approvals 
This PhD started on September 27th, 2017 and the submission deadline of the PhD thesis was 
on September 25th, 2020 (Figure 2.1). All clinical research activities done in Doha, Qatar were 
approved by the Weill Cornell Medicine in Qatar (WCM-Q) IRB (Ref. # 15-00078, 13-0076, 15-
00019), Hamad Medical Corporation (HMC) IRB (Ref. # 16324/16, IRB#: 13-0076, 
RP14494/14), Manchester Metropolitan University (MMU) ethics committee (EthOS ref. # 
0565). The research work for Chapter 6 done at the NIHR Wellcome Trust Clinical Research 
Facility in Manchester, UK was approved by the NRES Committee North West - Greater 
Manchester West (REC Ref. # 09/H1006/38). All subjects gave informed consent to take part 
in the study. The research adhered to the tenets of the declaration of Helsinki. 
Subject recruitment started before the starting date of the PhD study and completed in 
September 2017 for Chapter 6 and 7, November 2018 for Chapter 8, February 2019 for 
Chapter 3, 4 and 5, and July 2019 for Chapter 9 and 10. Data collection and analysis were 
conducted throughout the study. 
2.2 Contribution and management of this PhD project 
Figure 2.2 outlines the five components used to manage this PhD: 1. Management of the 
studies throughout the course of my PhD, 2. Screening and recruiting subjects, 3. Performing 
study procedures including assessments, data collection and analysis, 4. Dissemination of 
results through presentation and publication and 5. Communication and coordination to 
ensure completion of all tasks. Table 2.1 shows the contribution and management of this PhD. 















Table 2.1. Contribution and management of this PhD. 
  
PhD project management 
Investigators Role Tasks 
Prof. Rayaz Malik PhD. mentor Offered PhD, secured funding for the PhD 
programme, provided resources and personnel for 
the clinical work of this PhD, oversaw the PhD 
project and provided guidance. 
Prof. Mark Slevin Director of PhD study Oversaw the PhD project and provided guidance. 
Dr. Chris Murgatroyd PhD supervisor Oversaw the PhD project and provided guidance. 
Georgios Ponirakis PhD student Generated, collated and analysed data and wrote 
up for publication.  
Dr. Hanadi Al Hamad Co-investigator Oversaw all the research activities in Rumailah 
Hospital. 
Dr. Ziyad Mahfoud Statistician Oversaw all statistical analyses. 
Screening and recruitment 
Investigators Role Tasks 
Physicians Co-investigators Screened and recruited 
Communication & coordination 
Investigator Role Tasks 
Georgios Ponirakis PhD student Ensured everyone involved in the studies 
understood the objectives and were aware of their 
responsibilities, regularly updated my mentor, PhD 
Director and supervisor on study progress, 
recruitment, any issues and study results. 
Project procedures 
Investigators Role Tasks 
Georgios Ponirakis PhD student Consented subjects, performed cognitive function 
assessments for Chapter 9 & 10, CCM for Chapter 
6, 8-10 and neuropathy assessments, data 
collection and statistical analysis. 
Physicians & nurses Co-investigators Performed diagnosis (T2D, normal cognition, MCI, 
dementia), consented subjects, performed 
cognitive function assessment, MRI brain 
interpretation and atrophy analysis, and 
neuropathy assessments. 
Dissemination of the results 
Investigators Role Tasks 
Georgios Ponirakis PhD student Presented the work in national and 
international conferences and wrote up papers. 
Prof. Rayaz Malik Mentor Reviewed and revised PhD thesis, papers, 
presentations. 
Prof. Mark Slevin Director of PhD. study Reviewed and revised PhD thesis, papers, 
presentations. 




2.3 Study sites 
All the research work for this PhD was conducted in Qatar, apart for Chapter 6, which was 
done in Manchester, UK. 
In Weill Cornell Medicine in Qatar (WMC-Q), I worked on the Institutional Review Board (IRB) 
applications and amendments, submitted conflict of interests, performed data quality and 
analysis, wrote papers and my PhD thesis. 
In primary health care (PHC) centres of Umm Ghuwailina, Al Khor, Al Daayen and Al Rayyan 
and the National Diabetes centres in Qatar, Hamad General Hospital (HGH) and Al-Wakra 
Hospital, subjects with T2D were screened, recruited, consented and assessed.  
In Rumailah Hospital, subjects with no cognitive impairment (NCI), mild cognitive impairment 
(MCI), dementia with and without T2D were screened, recruited, consented and assessed. 
In the Manchester Diabetes Centre, Manchester Royal Infirmary, subjects with T1D and 
control subjects were screened and recruited, and in the NIHR Wellcome Trust Clinical 
Research Facility in Manchester, UK, subjects with T1D and control subjects were screened, 
recruited, consented and assessed. 
2.4 Project population 
The recruitment selection, inclusion and exclusion criteria for each study are described in 
detail in the methods section in each chapter. There were some common exclusion criteria in 
all chapters: 
• Other causes of peripheral neuropathy than diabetes such as vitamin-B12, folate 
deficiency, hypothyroidism and severe kidney impairment. 
• Unable to undergo CCM assessment due to lack of cooperation. 
• Unable to understand English or Arabic.  
• Unable to write or sign the consent/assent form.  
• Pregnant women and prisoners. 
For studies that included CCM assessments: 
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• Ineligible for CCM assessments due to history of ocular trauma or previous ocular surgery 
in the preceding six months, corneal dystrophy, severe dry eyes or allergic reactions to 
local eye anesthetic. 
2.5 Recruitment method 
Subjects were screened for eligibility and invited for the study by clinicians involved in the 
study on the day they attend the clinic. Eligible subjects were required to give informed 
written consent to take part in the study. 
2.6 Procedures and assessments 
2.6.1 Demographic, clinical and metabolic characteristics and list of medications 
Gender, ethnicity, age, duration of diabetes and body mass index (BMI) were recorded. The 
average systolic (SBP) and diastolic blood pressure (DBP) of two readings were obtained from 
the subject’s left arm while seated with the arm at heart level, using a standard zero mercury 
sphygmomanometer after 10-15 minutes of rest. A non-fasting blood sample was collected 
through venepuncture from each subject into EDTA tubes and transported within 2 hours to 
a central certified laboratory at HGH. Glycated hemoglobin (HbA1c), total cholesterol and 
triglyceride, vitamin B12 and folate, thyroid stimulating hormone (TSH), free thyroxine (FT4) 
were recorded from Cerner, Hamad Medical Corporation electronic medical records. Poor 
glycemic control was defined as HbA1c ≥9%. Hypertension was defined as average SBP ≥140 
mmHg and/or the use of anti-hypertensive medication, as per WHO/ISH Guidelines (Moser, 
1999). Hyperlipidemia was defined as a total cholesterol level ≥6.2 mmol/L and/or triglyceride 
level of ≥2.3 mmol/L or if the patient was treated with a statin. Obesity was classified 
according to WHO criteria with a BMI ≥30 kg/m2 (Report of a WHO consultation, 2000). 
Current cigarette smoking was defined as having smoked at least one cigarette every day for 
≥1 year preceding the study visit. Physical activity was defined as doing some physical activity 
including walking for ≥30 minutes/day, at least 3 times a week over the last year.  
2.6.2 Assessment of diabetic neuropathy and painful neuropathy (Chapter 3-7) 
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The diagnosis of DPN for the studies done in Qatar was based on the presence of one or more 
neuropathic symptoms such as burning pain, painful cold, electric shocks, tingling, pins and 
needles and numbness, and impaired vibration perception threshold (VPT) in the feet. VPT 
was measured by a Neurothesiometer (Horwell, Scientific Laboratory Supplies, Wilford, 
Nottingham, UK) (Figure 2.3) on the pulp of the large toe on both feet and the average value 
of three measurements was recorded in Volts (V) ranging from 0 - 50V. A VPT ≥15V was 
defined as impaired vibration perception consistent with the presence of DPN (Wiles et al., 
1991) and a VPT ≥25V as high risk for diabetic foot ulceration (DFU) (Young et al., 1994).  
The diagnosis of DPN in Chapter 6 was according to the criteria established by the Toronto 
Diabetic Neuropathy Expert Group (Tesfaye et al., 2010). These criteria include neuropathy 
symptoms or neuropathy signs and an abnormality of NCS or a validated measure of small 
fiber neuropathy (corneal nerve fiber length) (Petropoulos et al., 2013a, Chen et al., 2015). 
Neuropathic symptoms were assessed using the DNS score (Meijer et al., 2002), a four-item 
validated symptom score for symptoms of unsteadiness in walking, neuropathic pain, 
paraesthesia, and numbness, giving a maximum score of 4 points, with a score of  1 defining 
the presence of neuropathic symptoms. Neuropathy signs were defined using the NDS (Young 
et al., 1993) that includes examination of vibration perception using a 128-Hz tuning fork, pin-
prick on the tip of the large toe, temperature perceptions in the dorsum of the feet, and the 
presence or absence of ankle reflexes. Subjects scoring > 2/10 were considered to have signs 
of neuropathy. The techniques to assess for symptoms and signs of DPN in chapter 6 were 
different to Chapter 3-5 because it was part of the LANDMark study that preceded my PhD. 
VPT assessment used for Chapter 3-5 is a subjective psychophysical test, dependent on 
patient motivation, alertness, and concentration (Malik, 2016), whereas CCM (Petropoulos et 
al., 2013c, Petropoulos et al., 2014, Petropoulos et al., 2013a, Malik et al., 2003, Ahmed et al., 
2012) and NCS (Bril et al., 1998) used for Chapter 6 are objective measures of DPN and have 
high reproducibility for quantifying small and large fiber neuropathy, respectively. 
For the studies done in Qatar, pDPN was assessed using the Douleur Neuropathique en 4 
(DN4) questionnaire in Arabic and English as previously described (Azmi et al., 2019c). 
Previously diagnosed DPN and pDPN were self-reported. For Chapter 6, pDPN was defined by 
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a combination of deficits with an NDS score >2 and the presence of painful symptoms using 
the McGill Pain Questionnaire (Melzack, 1975). 
Figure 2.3. Neurothesiometer devices used to assess for impaired vibration perception threshold. Georgios 
Ponirakis (PhD student) in the photo. 
2.6.3 Corneal confocal microscopy (CCM) image acquisition (Chapter 6, 8-10) 
CCM analysis was performed with the Heidelberg Retinal Tomograph III Rostock Cornea 
Module (Heidelberg Engineering GmbH, Heidelberg, Germany) (Figure 2.4). This device uses 
a 670 nm red wavelength diode laser, which is a class I laser and therefore does not pose any 
ocular safety hazard. A 63x objective lens with a numerical aperture of 0.9 and a working 
distance, relative to the applanating cap (TomoCap, Heidelberg Engineering GmbH, 
Heidelberg, Germany) of 0.0 to 3.0 mm was used. The images produced using this lens are 
384 μm × 384 μm with a 15° × 15° field of view and 10 μm/pixel transverse optical resolution. 
The cornea was locally anesthetized by instilling 1 drop of 0.4% benoxinate hydrochloride 
(Chauvin Pharmaceuticals, Chefaro, UK) and Viscotears (Carbomer 980, 0.2%, Novartis, UK) 
was used as the coupling agent between the cornea and the TomoCap as well as between the 
TomoCap and the objective lens. Subjects were asked to place their chin on the chin rest and 
press their forehead against the forehead support. They were asked to fixate with the eye not 
being examined on an outer fixation light to enable examination of the central cornea. Images 
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of the sub-basal nerve plexus were captured using the “section” mode. Multiple images were 
taken from the sub-basal nerve plexus.  
2.6.4 CCM image extraction and analysis 
CCM image extraction was performed at a separate time by the PhD student, Georgios 
Ponirakis who was blinded to patient diagnosis. Three to five representative sharp images of 
the sub-basal nerve plexus were selected per eye by filtering out blurred images or pressure 
lines caused by the pressure applied between the TomoCap and cornea or out of focus 
images. Manual CCM image analysis was performed using CCMetrics, a validated image 
analysis software (Dabbah et al., 2011). Corneal nerve morphology was quantified as corneal 
nerve fiber density (CNFD, fibers/mm2), branch density (CNBD, branches/mm2) and fiber 
length (CNFL, mm/mm2). 
Figure 2.4. The Heidelberg Retinal Tomograph III device coupled with the Rostock Cornea Module used for 
corneal confocal microscopy (CCM). Prof. Rayaz Malik (PhD mentor) on the far right and Georgios Ponirakis (PhD 
student) performing CCM analysis in the photo. 
2.6.5 Intraepidermal nerve fiber density (Chapter 6) 
A 3 mm punch skin biopsy was taken from the dorsum of the left foot under 1% lidocaine local 
anaesthesia. Skin samples were immediately fixed in 4% (wt/vol.) paraformaldehyde for 24 
hours and then cryoprotected in sucrose, frozen and cut into 50 𝜇m sections. 
Immunohistochemistry was performed as previously described (Azmi et al., 2015). A Zeiss 
AxioImager M2 microscope (Carl Zeiss, Jena, Germany) was used to quantify intra epidermal 
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nerve fiber density (IENFD), which is the total number of nerve fibers per millimetre length of 
epidermis (no./mm), in accordance with established criteria (Lauria et al., 2010b). 
2.6.6 Autonomic neuropathy (Chapter 6) 
Cardiovascular autonomic neuropathy (CAN) was evaluated using the ANX 3.0 autonomic 
nervous system monitoring device (ANSAR Medical Technologies Inc. Philadelphia, US) (Orlov 
et al., 2012). Deep Breathing-Heart Rate Variability (DB-HRV) was assessed by R-R interval 
variation via surface electrodes over 1 minute at a frequency of 6 breaths/minutes. 
Sudomotor dysfunction was assessed using the Neuropad plaster (Miro Verbandstoffe, Wiehl-
Drabenderhöhe, Germany) applied to the plantar aspect of the 1st metatarsal head for 10 
minutes, followed by quantification of the percentage colour change of the Neuropad 
(Ponirakis et al., 2014). 
2.6.7 Quantitative sensory testing for warm and cold perception (Chapter 6) 
Quantitative sensory testing (QST) included measurement of warm and cold perception 
thresholds (WPT & CPT) on the dorsum of the left foot using the method of limits with the 
MEDOC TSA II (Medoc Ltd. Ramat Yishai 30095, Israel). 
2.6.8 Nerve conduction studies (NCS) (Chapter 6) 
NCS were undertaken using a Dantec “Keypoint” system (Dantec Dynamics Ltd. Bristol, UK) 
equipped with a DISA temperature regulator to keep lower limb temperature constantly 
between 32 and 35oC. Sural nerve action potential (SNAP), sural nerve conduction velocity 
(SNCV), tibial compound motor action potential (TCMAP), tibial motor nerve conduction 
velocity (TMNCV), peroneal compound motor action potential (PCMAP) and peroneal motor 
nerve conduction velocity (PMNCV) were assessed in the right lower limb by a consultant 
neurophysiologist. Sural sensory responses were measured using a bipolar bar electrode 
(inter-electrode distance 3 cm) attached over the sural nerve at the lateral malleolus. 
Stimulation was performed 140 mm proximal to the active recording electrode in the calf. 
Abnormal nerve conduction was defined based on two abnormal nerve conduction velocities 
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of either SNCV, TMNCV or PMNCV. The cut-off values of the nerve conduction velocities were 
defined on the – 2 SD from the mean based on our control population. 
2.6.9 Diagnosis of normal cognition, MCI and dementia (Chapter 9 & 10) 
The diagnosis of MCI and dementia was based on the ICD-10 criteria (International Advisory 
Group for the Revision of and Behavioural, 2011). A joint consultative model in the 
Department of Geriatric Medicine run by geriatricians and geriatric psychiatrists with advice 
and consultation from the neurologists was applied to ensure the correct diagnosis, especially 
to exclude reversible, complex and young-onset dementia. The diagnosis of MCI and 
dementia was based on a patient history and examination, which includes (1) presenting 
complaint and history of illness; (2) comprehensive history of each of the cognitive domains; 
(3) psychiatric history for ruling out depression, mood disorders, and psychosis; (4) medical 
history including episodes of delirium and other medical comorbidities; (5) medication 
history; (6) functional history of basic daily living activities; (7) components of comprehensive 
geriatric assessment; (8) detailed psychiatric mental status examination and cognitive 
screening using MoCA. A comprehensive organic work-up including blood investigations and 
brain imaging was undertaken to exclude other potentially reversible causes of cognitive 
decline such as tumors, subdural hematoma or normal pressure hydrocephalus. The final 
diagnosis of no cognitive impairment (NCI), mild cognitive impairment (MCI) and dementia 
was made according to consensus decision by geriatricians, geriatric psychiatrists and 
neurologists. The diagnosis of AD was based on radiological evidence, including volume loss 
of hippocampi, entorhinal cortex, and amygdala on MRI as described by Dubois et al. (Dubois 
et al., 2009). Diagnosis of probable or possible vascular dementia (VaD) was based on the 
NINDS-AIREN criteria (Roman et al., 1993), which specifies evidence of cerebrovascular 
disease by brain MRI, including multiple large vessel infarcts, a single strategically placed 
infarct (angular gyrus, thalamus, basal forebrain, posterior [PCA] or anterior cerebral artery 
[ACA] territories), multiple basal ganglia white matter lacunes, extensive periventricular white 
matter lesions, or combinations thereof. Mixed dementia was based on AD combined with 
evidence of vascular lesions in the brain. 
2.6.10 Cognitive screening (Chapter 9 & 10) 
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Cognitive function was assessed by the occupational therapist using the Montreal cognitive 
assessment (MoCA) Arabic and English version. The MoCA assesses seven cognitive domains 
including visuospatial/executive, naming, memory, attention, language, abstraction and 
delayed recall giving a total score of 30. A score of  26 indicates cognitive impairment 
(Nasreddine et al., 2012). Educational level was recorded. A point was added for individuals 
with formal education below 6th grade. Cognitive symptom duration was estimated from the 
clinical history obtained from the participant and family members. 
2.6.11 Functional independence screening (Chapter 9 & 10) 
The Functional Independence Measure (FIM) was administered by the occupational therapist. 
FIM is an 18-point screening test of which 13 are for motor and 5 for cognitive function. Each 
point was scored from 1 to 7. The total FIM score ranges from 18 to 126. There is no cut-off 
point for FIM, but a high score indicates greater independence (Talmelli et al., 2013). 
2.6.12 Brain MRI acquisition (Chapter 10) 
MRI was performed on a superconductive magnet operated at 3T (Skyra, Siemens) at the MRI 
unit in Rumailah Hospital (Figure 2.5). The subject’s head was immobilized with a head holder 
to minimize motion artifacts. A T1-weighted 3D magnetisation prepared rapid acquisition 
gradient echo sequence (MPRAGE) was obtained in the sagittal plane with a 1 mm slice 
thickness, repetition time of 1900 ms, echo time of 2.67 ms and 2.46 ms, inversion time of 
1100 ms and 900 ms, flip angle of 9 degree and 15 degree, and FOV= 240 x 100. Coronal and 
axial reformatted MPRAGE images were reconstructed from the sagittal 3D sequence. 
2.6.13 Medial temporal lobe atrophy visual rating (Chapter 10) 
T1-coronal images at the level of the midbrain were used to score for right and left medial 
temporal lobe atrophy (MTA). The right and left hippocampi, entorhinal cortices, perirhinal 
cortices were separately rated by a certified neuroradiologist according to the five-point scale 
developed and validated by Duara et al, and a combined visual MTA score for each 
hemisphere was calculated averaging the three measurements (Duara et al., 2008). The 
coronal reformatted MRI slice at the level of the mammillary bodies seen in the sagittal plane 
was used to define the outline of the medial temporal lobe. The outline of the entorhinal 
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cortex in this slice was defined by the anterior parahippocampal gyrus and adjacent white 
matter (seen medial to the collateral sulcus and inferior to the hippocampus). The outline of 
the perirhinal cortex was defined by the fusiform gyrus and adjacent white matter (seen 
lateral to the collateral sulcus and medial to the occipitotemporal sulcus).  
Figure 2.5. MRI brain performed on a superconductive magnet operated at 3T (Skyra, Siemens) at the MRI unit 
in Rumailah Hospital. 
2.7 Data management  
All data were stored in a spreadsheet in password protected and encrypted computers in 
Rumailah Hospital and WCM-Q. Data are to be retained for 3 years after project completion 
as it is an IRB requirement. 
2.8 Statistical analysis 
Statistical analysis applied to the specific study are described in detail in the methods section 
in each chapter.  
Patients’ demographic and clinical characteristics were summarized using means and 
standard deviations for numeric variables and frequency distribution for categorical variables. 
Continuous parametric variables were compared using unpaired t-test or non-parametric 
variables when the distribution had skewness of < -1 or > 1 with Mann-Whitney test. 
32 
 
Categorical variables were compared using Chi-squared test or Fisher’s exact test when 
expected cell counts fell below 5. Changes between baseline and 1-year follow-up were 
compared using a paired t-test. 
Multiple linear regression analysis was performed for continuous dependent variables and 
included all variables with P≤0.05 at the bivariate level. Residual plots were used to determine 
for linearity, normality, constant variance, and independence. The regression coefficient 
(beta) and the corresponding 95% confidence intervals (95% CI) are presented.  
Multiple logistic regression analysis was performed for categorical dependent variables and 
included all variables with p-value of 0.10 or less at the bivariate level. Adjusted odds ratios 
and their corresponding 95% confidence intervals are presented. 
Receiver operating characteristic (ROC) curve analysis was used to determine the ability of 
CNFD, CNBD and CNFL to distinguish patients with MCI and dementia from healthy controls. 
The area under curve (AUC), and two cut-off point with the maximal sum of sensitivity and 
specificity was calculated. 
A two-tailed P value of ≤0.05 was considered significant. 
2.9 Risk assessment and mitigation 
The risk of recruitment delays was low since an established system of recruitment was in place 
before the start of the PhD project.  
For CCM assessment, drops used to numb the eyes may cause some mild discomfort, which 
should subside within ~5-10 seconds. As oxybuprocaine hydrochloride is an ester that may 
rarely cause any allergic reaction. Undertaking MRI is safe and causes no pain but having to 
lie still for about 20 minutes might cause some discomfort or pain, particularly in the case of 
a recent injury. Although benign, risks of MRI include magnetic/quench hazard and 
claustrophobia. People suffering from claustrophobia or with a metallic implant in the body 
were excluded from having an MRI. Having a blood sample taken may cause some discomfort. 
Rarely, there could be bruising or a minor infection. If this happens, it can be easily treated. 
The risk of malfunction of the CCM device was low. We have an active maintenance license 






Chapter 3: Prevalence and management of diabetic neuropathy in 
secondary care in Qatar 
Authors: Ponirakis G, Elhadd T, Chinnaiyan S, Dabbous Z, Siddiqui M, Al-Muhannadi H, 
Petropoulos IN, Khan A, Ashawesh KAE, Dukhan KMO, Mahfoud ZR, Murgatroyd C, Slevin M, 
Malik RA. Diabetes/Metabolism Research and Reviews. 2020 May;36(4):e3286. DOI: 
10.1002/dmrr.3286 
3.1 Abstract 
Introduction: Diabetic peripheral neuropathy (DPN) is a ‘Cinderella’ complication, particularly 
in the Middle East. A high prevalence of undiagnosed DPN and those at risk of diabetic foot 
ulceration (DFU) is a major concern.  
Objectives: We have determined the prevalence of DPN and its risk factors, DFU and those at 
risk of (DFU) in patients with T2D in secondary care in Qatar. 
Methods: Adults with T2D were randomly selected from the two National Diabetes Centers 
in Qatar. DPN was defined by the presence of neuropathic symptoms and a vibration 
perception threshold (VPT)≥15V. Participants with a VPT≥25V were categorized as high risk 
for DFU. Painful DPN was defined by a DN4 score ≥4. Logistic regression analysis was used to 
identify predictors of DPN. 
Results: In 1,082 adults with T2D (age 54 ±11 years, duration of diabetes 10.0 ±7.7 years, 
60.6% males) the prevalence of DPN was 23.0% (95% CI: 20.5%-25.5%), of whom 33.7% (95% 
CI: 27.9%-39.6%) were at high risk of DFU and 6.3% had DFU. 82.0% of the patients with DPN 
were previously undiagnosed. The prevalence of DPN increased with age and duration of 
diabetes and was associated with poor glycemic control (HbA1c≥9%) AOR=2.1 (95%CI: 1.3-
3.2), hyperlipidemia AOR=2.7 (95%CI: 1.5-5.0) and hypertension AOR=2.0 (95%CI: 1.2-3.4).  
Conclusions: Despite, DPN affecting 23% of adults with T2D, 82% had not been previously 
diagnosed with 1/3 at high risk for DFU. This argues for annual screening and identification of 
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patients with DPN. Furthermore, we identify hyperglycemia, hyperlipidemia and 
hypertension as predictors of DPN. 
3.2 Introduction 
Diabetic peripheral neuropathy (DPN) imposes a significant health and economic burden to 
both the patient and health care providers (Raghav et al., 2018). DPN leads to painful DPN 
(pDPN) in 18-65% (Ponirakis et al., 2019b), erectile dysfunction in 53-73% (Kouidrat et al., 
2017) and diabetic foot ulcers in 2-17% (Raghav et al., 2018) of patients with Type 2 diabetes 
(T2D). One in four patients with diabetic foot ulcer are at risk of amputation (Apelqvist and 
Agardh, 1992). The prevalence of diabetes in Qatar is almost two-fold higher than the global 
average of 8.3% and is associated with an increasing prevalence of the long-term 
complications (IDF Middle East and North Africa Region, 2020, , International Diabetes 
Federation, 2019, ) and is associated with an increasing prevalence of the long term 
complications (Bener and Al-Hamaq, 2016). Estimates of the prevalence of DPN in people with 
T2D vary from 17-53% in the Middle East and North Africa (MENA) region (AlAyed et al., 2015, 
Al-Kaabi et al., 2014, Al-Mahroos and Al-Roomi, 2007), 27-32% in Europe (Young et al., 1993, 
Salvotelli et al., 2015, Cabezas-Cerrato, 1998), 21-45% in the US (Mold et al., 2004, Cheng et 
al., 2006) and 17-62% in China (Lu et al., 2010, Liu et al., 2010). This high variability may be 
attributed to the heterogeneity of the populations studied and differing criteria for the 
diagnosis of DPN. 
Screening annually for symptoms and signs of DPN starting at diagnosis of T2D is 
recommended by the 2017 American Diabetes Association position statement on DPN (Pop-
Busui et al., 2017). However, the prevalence of undiagnosed DPN and those at risk of diabetic 
foot ulceration (DFU) remains alarmingly high (Wang et al., 2011, Herman and Kennedy, 
2005), despite the 5-year mortality of people with a diabetic foot ulcer being higher than 
many common cancers (Moulik et al., 2003, Armstrong et al., 2007). Indeed in Qatar, 25% of 
patients attending secondary care were being seen for foot problems (Al-Thani et al., 2019). 
Given the lack of disease modifying treatments for DPN (Malik, 2016, Malik, 2014), the 
identification of risk factors for DPN is key in optimizing treatment and delaying the 
development and progression of DPN (Pop-Busui et al., 2017). Age and duration of diabetes 
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are established risk factors for DPN (Al-Kaabi et al., 2014, Young et al., 1993, Cabezas-Cerrato, 
1998, Al-Mahroos and Al-Roomi, 2007). Whilst, poor glycemic control is associated with DPN 
(Al-Mahroos and Al-Roomi, 2007, Boru et al., 2004), there are conflicting data on the benefits 
of improved glycemic control on DPN (Ohkubo et al., 1995, Ismail-Beigi et al., 2010, Pop-Busui 
et al., 2013, Azad et al., 1999, Gaede et al., 2003). Studies also suggest that modifiable 
cardiovascular risk factors including hypertension (Mold et al., 2004, Cardoso et al., 2015, 
Kesavamoorthy et al., 2015, Yang et al., 2015) and hyperlipidemia (Tesfaye et al., 2005, Smith 
and Singleton, 2013) are associated with DPN and treatment with angiotensin converting 
enzyme (ACE) inhibitor (Malik et al., 1998, Ruggenenti et al., 2011, Reja et al., 1995) may 
improve neuropathy and statins (Arya et al., 2018, Hsu et al., 2017) and fibrates (Rajamani et 
al., 2009) may reduce amputation.  
The objectives of this study were to establish the prevalence of DPN and its risk factors, those 
at risk of DFU and with DFU in a large cohort of randomly selected people with T2D attending 
the National Diabetes Centers in Qatar. 
3.3 Materials and Methods 
Subjects aged 18 - 85 years old with T2D were enrolled from the National Diabetes Centers in 
Hamad General Hospital (HGH) and Al-Wakra Hospital. 1,161 subjects were randomly 
enrolled between June 2017 and February 2019. Exclusion criteria included type 1 diabetes, 
other causes of neuropathy including severe vitamin B12 deficiency, chronic hypothyroidism 
and chemotherapy.  
This study was approved by the Institutional Review Board (IRB) of Weill Cornell Medicine-
Qatar (WCM-Q) and Hamad Medical Corporation (HMC), and all subjects gave informed 
consent to take part in the study. The research adhered to the tenets of the declaration of 
Helsinki. 
3.3.1 Demographic and metabolic measures 
Age, gender, duration of diabetes and body mass index (BMI) were recorded. Ethnicity was 
categorized as Qatari Arabs, other Arabs, South Asians, and other ethnic groups. The average 
systolic (SBP) and diastolic blood pressure (DBP) of two readings were obtained from the 
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subject’s left arm while seated with the arm at heart level, using a standard zero mercury 
sphygmomanometer after 10-15 minutes of rest. A non-fasting blood sample of 10 ml was 
collected through venepuncture from each subject into EDTA tubes. The samples were kept 
at room temperature and transported within 2 hours to a central certified laboratory at HGH. 
Glycated hemoglobin (HbA1c), total cholesterol and triglyceride were measured by an 
autoanalyzer (Hitachi 747 autoanalyzer, Japan). Poor glycemic control was defined as HbA1c 
≥9%. Hypertension was defined according to either an average SBP ≥140 mmHg and/or the 
use of anti-hypertensive medication, as described in the WHO/ISH Guidelines (Moser, 1999). 
Hyperlipidemia was defined according to a total cholesterol level ≥6.2 mmol/L and/or 
triglyceride level of ≥2.3 mmol/L or if the patient was treated with a statin. Obesity was 
classified according to WHO criteria with a BMI ≥30 Kg/m2 (Report of a WHO consultation, 
2000). Current cigarette smoking was defined as having smoked at least one cigarette every 
day for ≥1 year preceding the study visit. Physical activity was defined as doing some physical 
activity including walking for ≥30 minutes/day for at least 3 times a week.  
3.3.2 Assessment of diabetic neuropathy and neuropathic complications 
DPN was diagnosed clinically based on the presence of one or more neuropathic symptoms 
and impaired vibration perception in the feet. Neuropathic symptoms included burning pain, 
painful cold, electric shocks, tingling, pins and needles and numbness. Vibration perception 
was measured by a Neurothesiometer (Horwell, Scientific Laboratory Supplies, Wilford, 
Nottingham, UK) on the pulp of the large toe on both feet. The amplitude of the vibration was 
slowly increased until it was felt by the participant, and the vibration perception threshold 
(VPT) was recorded. The average value of three VPT measurements was recorded in Volts (V) 
ranging from 0 - 50V. A VPT ≥15V was defined as impaired vibration perception (Wiles et al., 
1991) and a VPT ≥25V as high risk for diabetic foot ulceration (DFU) (Young et al., 1994). 
Previously diagnosed DPN was self-reported. Painful DPN (pDPN) was diagnosed using the 
Douleur Neuropathique en 4 (DN4) questionnaire as previously described (Ponirakis et al., 
2019b). 
3.3.3 Statistical analysis 
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The estimated minimum sample size was 937 based on the assumption that the prevalence 
of DPN was around 25% in a population of 5,000 patients with T2D in SHC with ±2.5 % the 
acceptance absolute deviation of sample rate from population rate and 95% confidence level. 
The overall prevalence of DPN and those at high risk of DFU were computed along with their 
95% confidence intervals. Prevalence of DPN across different demographic and health factors 
as categorical variables was summarized using frequency distributions. Continuous variables 
were summarized using means and standard deviations. Variables were compared between 
patients with and without DPN using a Chi-squared test of independence.  
Binary logistic regression analysis was performed with age, duration of diabetes, gender, poor 
glycemic control, obesity, hyperlipidemia, hypertension, physical activity, smoking and ethnic 
groups as independent variables, and DPN as the dependent variable. Collinearity was tested 
to minimize its potential effect by selecting variables whose correlation coefficients was <0.7. 
The multiple logistic regression model included all independent variables associated with DPN 
with a P value of ≤0.05 at the bivariate level. Adjusted odds ratios, their corresponding 95% 
confidence intervals (CI) and P value are presented. 
All analyses were performed using IBM-SPSS (version 23; SPSS Inc, Armonk NY). A two-tailed 
P value of ≤0.05 was considered significant. 
3.4 Results 
3.4.1 Prevalence of DPN and those at risk of DFU 
1,082 subjects with T2D (60.6% male) were recruited. We excluded 75 subjects with T1D and 
4 subjects with T2D <20 years old. The mean age and duration of diabetes were 54.3 ±11.4 
years and 10.0 ±7.7 years, respectively.  
The prevalence of DPN was 23.0% (n=249/1,082) (95% CI: 20.5%-25.5%) of whom 33.7% 
(n=84/249) (95% CI: 27.9%-39.6%) were at high risk of DFU (VPT≥25V) and 6.3% (n=15/237) 
had diabetic foot ulcers (Table 3.1). Impaired vibration perception in the feet (VPT≥15V) was 
detected in all subjects with clinical DPN but was also present in 7.2% (n=60/833) of subjects 
without DPN. A high risk of DFU was detected in 2.2% (n=18/833) of subjects without DPN. 
Foot ulcers were observed in more subjects with DPN compared to subjects without DPN 
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(6.3% vs 2.1%, P=0.001) and in more subjects at high risk of DFU compared to subjects at low 
risk of DFU (11.1% vs 2.2%, P<0.0001). Painful diabetic neuropathy (DN4 score≥4) was present 
in 24.4% (n=203/833) of subjects without DPN and in 78.7% (n=196/249) of subjects with 
DPN. 82.0% (n=201/249) of patients with DPN were previously undiagnosed, even though 
62.7% of them were aware that they had foot numbness and 7.6% were at high risk of DFU. 
In those with DPN, 20.5% (n=51/249) were unaware they had impaired vibration perception 
and 4.8% (n=12/249) were unaware they were at high risk of DFU. The mean total cholesterol 
(4.3±1.1 vs 4.5±1.2, P<0.01) and low-density lipoprotein (LDL) (2.4±0.9 vs 2.6±0.9, P=0.01) in 
patients with DPN were significantly lower compared to patients without DPN. Triglycerides 
(1.7±0.9 vs 1.8±1.3, P=0.14) and high-density lipoprotein (HDL) (1.1±0.4 vs 1.1±0.3, P=0.89) 
were comparable between patients with and without DPN. 
3.4.2 Prevalence of diabetic neuropathy in relation to clinical and demographic factors 
(Table 3.2) 
The prevalence of DPN was lower in those with increasing physical activity (P=0.004, Cramer’s 
V = 0.13) and higher with increasing age (P<0.0001, Cramer’s V = 0.21), duration of diabetes 
(P<0.0001, Cramer’s V = 0.29), poor glycemic control (P<0.0001, Cramer’s V = 0.08), 
hyperlipidemia (P<0.0001, Cramer’s V = 0.85) and hypertension (P<0.0001, Cramer’s V = 0.17) 
and was comparable between genders. The prevalence of DPN was significantly higher in 
Qatari Arabs (29.5%) compared to South Asians (17.1%) (P=0.001).  
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Table 3.1. Prevalence of diabetic neuropathy, impaired vibration perception, high risk of diabetic foot ulcers, 





n % 833 77.0% 249 23.0% 
Impaired vibration perception (VPT ≥15V) 60/833 7.2% 249/249 100.0% 
High risk of diabetic foot ulceration (VPT ≥25V) 18/833 2.2% 84/249 33.7% 
Diabetic foot ulcers 17/809 2.1% 15/237 6.3% 
Painful diabetic neuropathy (DN4 ≥4) 203/833 24.4% 196/249 78.7% 
Undiagnosed with diabetic neuropathy   201/249 82.0% 
Undiagnosed with diabetic neuropathy but aware of foot numbness   156/249 62.7% 
Undiagnosed with diabetic neuropathy but at high risk of foot ulceration   19/249 7.6% 
Unaware of impaired vibration perception (VPT ≥15V)   51/249 20.5% 
Unaware of impaired vibration perception but at high risk of foot ulceration   12/249 4.8% 
 
Table 3.2. Prevalence of diabetic neuropathy in relation to clinical and demographic factors. 
 
Total Diabetic neuropathy 
P value No Yes 
n (%) 1082 100.0% 833 77.0% 249 23.0% N/A 
Gender Male 651 60.6% 496 76.2% 155 23.8% NS 
 Female 424 39.4% 333 78.5% 91 21.5%  
Age 20-50 years 440 41.4% 392 89.1% 48 10.9% <0.0001 
 51-60 years 375 35.3% 269 71.7% 106 28.3%  
 >60 years 247 23.3% 156 63.2% 91 36.8%  
Duration of  ≤10 years 682 63.7% 588 86.2% 94 13.8% <0.0001 
diabetes 11-20 years 302 28.2% 201 66.6% 101 33.4%  
 >20 years 86 8.0% 37 43.0% 49 57.0%  
Poor glycemic  No 695 70.8% 562 80.9% 133 19.1% <0.0001 
control Yes 287 29.2% 197 68.6% 90 31.4%  
Obesity No 442 46.6% 350 79.2% 92 20.8% NS 
 Yes 507 53.4% 383 75.5% 124 24.5%  
Hyperlipidemia No 236 24.7% 209 88.6% 27 11.4% <0.0001 
 Yes 721 75.3% 526 73.0% 195 27.0%  
Hypertension No 366 35.5% 318 86.9% 48 13.1% <0.0001 
 Yes 664 64.4% 472 71.0% 193 29.0%  
Physical activity Yes 321 38.1% 268 83.5% 53 16.5% 0.004 
 No 522 61.9% 389 74.5% 133 25.5%  
Smoking No 742 82.6% 572 77.1% 170 22.9% NS 
 Yes 156 17.4% 128 82.1% 28 17.9%  
Ethnic groups Qatari Arabs 322 30.0% 227 70.5% 95 29.5% 0.001 
 Other Arabs 300 28.0% 233 77.7% 67 22.3%  
 South Asians 397 37.0% 329 82.9% 68 17.1%  
 Others 54 5.0% 38 70.4% 16 29.6%  
Variables were summarized in frequency distribution and compared using χ2.  
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3.4.3 Diabetic neuropathy risk factors 
The results of binary logistic regression used to explore the odds of developing DPN in relation 
to age, duration of diabetes, poor glycemic control, hyperlipidemia, hypertension, physical 
activity and ethnic groups are shown in Table 3.3. Obesity and smoking were not associated 
with DPN (P=0.2). The odds of developing DPN were 2.5 (95% CI 1.4 – 4.3) times greater 
among subjects aged 51-60 years (P=0.001) and 3.1 (95% CI 1.7 – 5.7) times greater among 
subjects aged >60 years compared to subjects aged 20-50 years (P<0.0001). The odds 
increased from 2.2 (95% CI 1.4 – 3.4) times greater with 11-20 years of diabetes (P=0.001) to 
7.2 (95% CI 3.8 – 13.9) times greater with >20 years of diabetes (P<0.0001) compared to those 
with ≤10 years of diabetes. The odds of developing DPN were 2.1 (95% CI 1.3 – 3.2) times 
greater with poor glycemic control (P=0.001), 2.7 (95% CI 1.5 – 5.0) times greater with 
hyperlipidemia (P=0.002) and 2.0 (95% CI 1.2 – 3.4) times greater with hypertension (P=0.01) 
compared to subjects with HbA1c <9%, without hyperlipidemia and without hypertension. 
Physical activity was associated with a reduced prevalence of DPN (odds ratio 0.6; 95% CI: 0.4 
to 0.8; P=0.002), but after controlling for other significant predictors of DPN, physical activity 
had no impact on DPN (adjusted odds ratio 0.9; 95% CI: 0.6 to 1.4; P>0.05).  
The odds of developing DPN in Qatari Arabs was 1.4 times greater compared to other Arabs 
(P=0.04) and 2.0 times greater compared to South Asians (P<0.0001). However, these 
associations with DPN were lost after controlling for other significant predictors of DPN. When 
comparing the prevalence of risk factors across the ethnic groups, there were more Qataris 
aged ≥60 years (37.5% vs 24.4% and 11.0%, P<0.0001) and less Qataris aged 20-50 years 
(30.0% vs 43.5% and 48.7%, P<0.0001) compared to other Arabs and South Asians, 
respectively. There were also more Qataris with 11-20 years of diabetes compared to other 
Arabs and South Asians (40.1% vs 23.4% and 22.0%, P<0.0001) whilst there were less Qataris 
with ≤10 years of diabetes (47.5% vs 69.9% and 72.5%, P<0.0001). The prevalence of 
hypertension in Qataris was higher compared to other Arabs (72.5% vs 56.4%, P=0.001) but 




Table 3.3. Predictors for diabetic neuropathy using multiple logistic regression analysis. 
Independent variables AOR 95% CI P value 
Age 20-50 years 1    
 51-60 years 2.5 1.4 – 4.3 0.001 
 >60 years 3.1 1.7 – 5.7 <0.0001 
Duration of diabetes ≤10 years 1    
 11-20 years 2.2 1.4 – 3.4 0.001 
 >20 years 7.2 3.8 – 13.9 <0.0001 
Poor glycemic control 2.1 1.3 - 3.2 0.001 
Hyperlipidemia  2.7 1.5 - 5.0 0.002 
Hypertension  2.0 1.2 - 3.4 0.01 
Physical activity  0.9 0.6 - 1.4 NS 
Ethnic groups Qatari Arabs 1    
 Other Arabs 1.0 0.6 - 1.6 NS 
 South Asians 0.7 0.4 - 1.1 NS 
 Others 1.4 0.5 – 3.9 NS 
Outcome variable: diabetic neuropathy. Independent variables: Age, duration of diabetes, poor glycemic 
control, hyperlipidemia, hypertension, physical activity and ethnic groups were considered in the fitted model 
with a P value ≤0.05. AOR=Adjusted odd ratio; CI= confidence interval. 
3.5 Discussion 
In adults with T2D attending secondary care in Qatar the prevalence of DPN was 23%, of 
whom one-third were at high risk of DFU, and 6% had diabetic foot ulcers. However, 82% of 
patients with DPN had not been previously diagnosed, even though 63% were aware they had 
foot numbness. Age, duration of diabetes, poor glycemic control, hyperlipidemia and 
hypertension are risk factors for DPN in this population.  
The prevalence of DPN varies in different countries and clinical settings. In a large clinic based 
study of 6487 patients in the UK, the prevalence of DPN was 32.1% in patients with T2D and 
increased with increasing age and duration of diabetes (Young et al., 1993). It has been 
reported to be as high as 45% in the US (Mold et al., 2004) and 62%, in China (Lu et al., 2010), 
but their mean age of 73 and 66 years, respectively was much higher than our cohort aged 54 
years. The higher prevalence of DPN in Bahrain (37%)(Al-Mahroos and Al-Roomi, 2007) and 
Turkey (60%)(Boru et al., 2004) compared to Qatar (23%) may be attributed to poorer 
glycemic control as the proportion with a HbA1c ≥9% in Bahrain (65%) and Turkey (79%) was 
much higher compared to our cohort in Qatar (29%).  
We show an alarmingly high prevalence of undiagnosed DPN in 82% of patients attending 
secondary care in Qatar. Indeed, Wang et. al. (Wang et al., 2011) have also previously 
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reported that 79% of patients with T2D have undiagnosed DPN and Herman et al. (Herman 
and Kennedy, 2005) reported that 62% of patients with T2D have undiagnosed DPN in the US 
had not been previously diagnosed. Wang et. al. (Wang et al., 2011) did not specify what 
diagnostic criteria for DPN they used for the study. Herman et al. (Herman and Kennedy, 2005) 
used monofilament test to screen for DPN, which only detects advanced large fiber 
neuropathy. This may explain why the percentage of underdiagnosed DPN is lower compared 
to our study. The high prevalence of undiagnosed DPN in secondary care in Qatar can be 
attributed to the lack of annual screening for DPN and use of the 10-g monofilament which 
will identify only those with advanced neuropathy (Pop-Busui et al., 2017). The prevalence of 
DFU in Qatar was comparable to the global prevalence of 6.3% (Zhang et al., 2017b). 
The early diagnosis and treatment of DPN is key in preventing DFU and amputation (Pop-Busui 
et al., 2017). Indeed, in line with previous studies (Al-Mahroos and Al-Roomi, 2007, Boru et 
al., 2004) we show that poor glycemic control is an independent risk factor for DPN. The 
Kumamoto trial (Ohkubo et al., 1995) reported that tight glucose control prevents progression 
of DPN and the ACCORD (Ismail-Beigi et al., 2010) and the BARI 2D (Pop-Busui et al., 2013) 
trials reported a reduced incidence of DPN with better glycemic control. However, the UKPDS 
(UK Prospective Diabetes Study (UKPDS) Group, 1998), VA-CSDM (Azad et al., 1999) and 
Steno-2 trial (Gaede et al., 2003) have shown a limited effect of intensive glucose control on 
DPN. This study shows an association of DPN with hyperlipidemia and hypertension, which is 
consistent with previous studies showing that DPN is associated with hypertension (Mold et 
al., 2004, Cardoso et al., 2015, Kesavamoorthy et al., 2015, Yang et al., 2015), hyperlipidemia 
(Tesfaye et al., 2005, Smith and Singleton, 2013), BMI (Al-Mahroos and Al-Roomi, 2007, 
Salvotelli et al., 2015, Mold et al., 2004), cigarette smoking (Al-Mahroos and Al-Roomi, 2007, 
Tesfaye et al., 2005) and physical activity (Al-Kaabi et al., 2014). Indeed, treatment with 
angiotensin converting enzyme (ACE) inhibitors (Malik et al., 1998, Ruggenenti et al., 2011, 
Reja et al., 1995) and statins (Davis et al., 2008, Villegas-Rivera et al., 2015) may slow the 
progression of DPN. We also show a relationship between reduced physical activity and the 
prevalence of DPN, which is consistent with a study showing that diet and exercise can 
improve neuropathy in subjects with impaired glucose tolerance (Smith et al., 2006). 
Previously, we reported that South Asians, have a lower prevalence of DPN compared to 
Caucasians (Abbott et al., 2010), particularly small fiber neuropathy (Fadavi et al., 2018). This 
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study shows that South Asians have a lower prevalence of DPN compared to Qatari Arabs but 
the association between ethnic groups and DPN was lost after controlling for significant 
predictors of DPN including, age, duration of diabetes, poor glycemic control, hyperlipidemia, 
hypertension and physical activity as these factors differed in the different ethnicities. 
There are several limitations of this study including the diagnosis of DPN which was based on 
symptoms and assessment of VPT as reflected by the finding that 7.2% of participants without 
clinical DPN had an abnormal VPT. This may reflect issues with the reliability and validity of 
establishing a vibration perception threshold value which like all psychophysical tests relies 
on standardization and the participants concentration and ability to detect a sensation. We 
acknowledge that recruiting patients with T2D from secondary health care centers and not 
primary care centers limits the generalizability of the results to all people with T2D in Qatar. 
However, the recruited participants were of diverse backgrounds. Whilst we show 
associations between risk factors and DPN, the cross-sectional design of this study limits the 
predictive validity of these risk factors.  
In conclusion, although the prevalence of DPN was relatively low compared to previous 
studies from the Middle East region, alarmingly 82% were undiagnosed and one-third of 
patients with DPN were at high risk of DFU, highlighting the need for screening for DPN. This 
study argues for annual screening and identification of patients with DPN for more aggressive 
treatment of hyperglycemia, hyperlipidemia and hypertension..  
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4.1 Abstract 
Introduction: Painful diabetic peripheral neuropathy (pDPN) has a significant impact on the 
patient’s quality of life. The prevalence of pDPN in the Middle East and North Africa (MENA) 
region has been reported to be almost double that of populations in the UK.  
Objectives: We sought to determine the prevalence of pDPN and its associated factors in T2D 
patients attending secondary care in Qatar. 
Methods: This is a cross-sectional study of 1095 participants with T2D attending Qatar’s two 
national diabetes centers. PDPN and impaired vibration perception on the pulp of the large 
toes were assessed using the DN4 questionnaire with a cut-off ≥4 and the Neurothesiometer 
with a cut-off ≥15V, respectively. 
Results: The prevalence of pDPN was 34.5% (95% CI: 31.7%-37.3%), but 80% of these patients 
had not previously been diagnosed or treated for this condition. Arabs had a higher 
prevalence of pDPN compared to South Asians (P<0.05). PDPN was associated with impaired 
vibration perception AOR=4.42 (95%CI: 2.92-6.70), smoking AOR=2.43 (95%CI: 1.43-4.15), 
obesity AOR=1.74 (95%CI: 1.13-2.66), being female AOR=1.65 (95%CI: 1.03-2.64) and duration 
of diabetes AOR=1.08 (95%CI: 1.05-1.11). Age, poor glycemic control, hypertension, physical 
activity and proteinuria showed no association with pDPN.  
Conclusions: PDPN occurs in 1/3 of T2D patients attending secondary care in Qatar, but the 
majority have not been diagnosed. Arabs are at higher risk for pDPN. Impaired vibration 




Painful diabetic peripheral neuropathy (pDPN) has a significant impact on the patient’s quality 
of life (Van Acker et al., 2009, Bohlega et al., 2010, daCosta DiBonaventura et al., 2011) as it 
is accompanied by depression, anxiety and sleep disturbance (Bohlega et al., 2010). Estimates 
of the prevalence of pDPN in patients with T2D vary and range from 17.9%-65.3% (Van Acker 
et al., 2009, Abbott et al., 2011, Jambart et al., 2011, Halawa et al., 2010). In a large 
population-based study (n=15,692) from the UK (Abbott et al., 2011), we previously showed 
that pDPN occurred in 21.5% of patients with T2D and was more common in South Asians. In 
the Middle East and North Africa (MENA) region, Jambart et al. (Jambart et al., 2011) reported 
a much higher prevalence of pDPN of 61.3% in Egypt, 57.5% in Jordan, 53.9% in Lebanon and 
37.1% in the United Arab Emirates.  
Despite having a serious impact on the patient’s quality of life, pDPN is underdiagnosed and 
undertreated (Ziegler et al., 2018, Daousi et al., 2004). Patients with painful symptoms are 
often unaware that the pain is related to diabetes and do not report it to their clinician (Daousi 
et al., 2004, Eichholz et al., 2017). Screening patients at high risk for pDPN should allow timely 
identification and treatment. Previous studies have shown that older age, a longer duration 
of diabetes, being female and the presence of diabetic peripheral neuropathy (DPN) increases 
the risk for pDPN (Davies et al., 2006, Jambart et al., 2011, Halawa et al., 2010, Van Acker et 
al., 2009, Abbott et al., 2011, Jacovides et al., 2014). Additionally, obesity (Jambart et al., 
2011, Van Acker et al., 2009, Ziegler et al., 2018, Aslam et al., 2015), low physical activity 
(Ziegler et al., 2009, Smith et al., 2006), smoking (Abbott et al., 2011, Aslam et al., 2015), poor 
glycemic control (Harris et al., 1993, Smith and Singleton, 2008), low HDL cholesterol (Van 
Acker et al., 2009), raised LDL cholesterol, triglycerides and creatinine (Ziegler et al., 2009), 
are also independent risk factors of pDPN. 
The aim of this study was to establish the prevalence of pDPN in patients with T2D in 
secondary care in Qatar and explore the association with ethnicity and risk factors for this 
condition. We have undertaken a large cross-sectional cohort study using DN4, a validated 
and highly sensitive and specific questionnaire for the diagnosis of pDPN (Spallone et al., 
2012, Terkawi et al., 2017). 
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4.3 Materials and Methods 
This is a cross-sectional cohort study. Patients with diabetes aged 18 years and above were 
recruited from the two National Diabetes & Endocrine Centers in Qatar, Hamad General 
Hospital and Al-Wakra Hospital. Participating clinicians reported on all patients satisfying the 
inclusion criteria, examined between March 2017 to March 2018. No refusals were recorded 
as the procedure was quick, simple and potentially valuable to the patient health. Participants 
with other causes of neuropathy including vitamin B12 deficiency, hypothyroidism, HIV 
infection, leprosy, hepatitis C and chemotherapy were excluded from the study. We enrolled 
1,163 individuals and after excluding 66 patients with T1D and 2 patients who did not 
complete the assessments were left with a sample size of 1,095.  
This study was approved by the Institutional Review Board (IRB) of WCM-Q and HMC and all 
participants gave informed consent to take part in the study. The research adhered to the 
tenets of the declaration of Helsinki. 
4.3.1 Demographic and metabolic measures 
Age, gender, duration of diabetes, height, weight and BMI were recorded. Ethnicity was 
categorized as Qatari Arabs, other Arabs, South Asians, and other ethnic groups. The average 
of two readings of the systolic (SBP) and diastolic (DBP) blood pressure taken from the 
subject’s left arm while seated with his/her arm at heart level, using a standard zero mercury 
sphygmomanometer after 10-15 minutes of rest was obtained. A non-fasting blood sample 
of 10 ml was collected through venepuncture from each participant into vacutainer tubes 
containing EDTA. The samples were kept at room temperature and transported within 2 hours 
to a central certified laboratory at Hamad General Hospital, HMC, Doha, Qatar. Glycated 
hemoglobin (HbA1c), total cholesterol, HDL, LDL and triglycerides were measured by an 
autoanalyzer (Hitachi 747 autoanalyzer, Japan). Urinary albumin and creatinine levels were 
assessed on a random spot urine sample to evaluate the albumin-to-creatinine ratio (ACR). 
Patients with an HbA1c ≥9% were considered to be poorly controlled. Hypertension was 
defined according to either an average systolic blood pressure (SBP) ≥ 140 mmHg and/or the 
use of antihypertensive medication, as described in the WHO/ISH Guidelines (Moser, 1999). 
Current cigarette smoking was defined as having smoked at least one cigarette every day for 
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30 days preceding the study visit. Physical activity was defined as doing physical activity 
including walking for 30 minutes or more in a day for at least 3 times a week. Obesity was 
classified according to WHO criteria (Report of a WHO consultation, 2000) with a BMI ≥30 
Kg/m2. Proteinuria was defined as an ACR >30mg/g. 
4.3.2 Painful diabetic peripheral neuropathy assessment 
The Douleur Neuropathique en 4 (DN4) questionnaire has been validated for painful diabetic 
peripheral neuropathy (pDPN) (Spallone et al., 2012) and can distinguish between nociceptive 
and neuropathic pain (Harifi et al., 2011). It consists of 10 questions: 7 questions relating to 
the pain description (burning, painful cold, electric shocks) and associated abnormal 
sensations (tingling, pins and needles, numbness, itching) and the other 3 questions relate to 
a neurological examination in the painful area (hypoesthesia to touch and prick using 
disposable examination pins and allodynia to brushing). The scoring is based on a yes (1 point) 
or no (0 point) answer and each question is equally weighted. A score ≥4 has a high sensitivity 
(80%) and specificity (92%) for pDPN (Spallone et al., 2012). The questionnaire was 
administered by the investigator spoken in either English or Arabic. Previously diagnosed 
pDPN was self-reported. Medications for painful neuropathy were recorded. 
4.3.3 Impaired vibration perception assessment 
Vibration perception threshold (VPT) was measured bilaterally on the pulp of the large toe 
using a Neurothesiometer (Horwell, Scientific Laboratory Supplies, Wilford, Nottingham, UK). 
The strength of the vibration stimulus was gradually increased from null intensity to a value 
in voltage at which vibration was first detected by the participant. The test was repeated three 
times and the average value was recorded. The range for VPT readings is 1 to 50V. Impaired 
vibration perception was defined on a mean VPT ≥15V (Wiles et al., 1991, Garrow and 
Boulton, 2006). 
4.3.4 Statistical analysis 
The estimated minimum sample size was 1027 based on the assumption that the prevalence 
of pDPN was around 30% in a population of 5,000 patients with T2D in SHC with ±2.5 % the 
acceptance absolute deviation of sample rate from population rate and 95% confidence level. 
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Patients’ demographic and clinical characteristics were summarized using means and 
standard deviations for numeric variables and frequency distribution for categorical variables. 
Continuous parametric variables were compared between patients with and without pDPN 
using unpaired t-test or non-parametric variables when the distribution had skewness of < -1 
or > 1 with Mann-Whitney test.  Categorical variables were compared using Chi-squared test 
or Fisher’s exact test when expected cell counts fell below 5.  
Binary and multiple logistic regression analysis was performed with age, duration of diabetes, 
diabetic neuropathy, gender, poor glycemic control, hypertension, obesity, physical activity, 
smoking, proteinuria and ethnic groups as independent variables, and pDPN as the dependent 
variable. The multiple logistic regression model included all variables with p-value of 0.10 or 
less at the bivariate level. Adjusted odds ratios and their corresponding 95% confidence 
intervals are presented.  
Demographic and clinical characteristics of the patients were compared between the 
different ethnic groups using the chi-square test for categorical variables such as hypertension 
and one-way ANOVA for numeric variables such as age. Multiple comparisons when needed 
were done using the Bonferroni’s method.  
All analyses were performed using IBM-SPSS (version 23; SPSS Inc, Armonk NY). A two-tailed 
P value of ≤0.05 was considered significant. 
4.4 Results 
4.4.1 Prevalence of pDPN 
The cohort (n=1095) was aged 20 to 86 years (mean±SD, 54.3±11.4), 60.6% were male. The 
clinical and demographic characteristics of T2D subjects with and without painful diabetic 
peripheral neuropathy (pDPN) are compared in Table 4.1. The prevalence of pDPN was 34.5% 
(95% CI: 31.7%-37.3%). 80.2% of the subjects with pDPN had not been previously diagnosed 




Table 4.1. Demographic characteristics of adults with T2D stratified by pDPN status. Patients’ demographic and 
clinical characteristics summarized using means and standard deviations for numeric variables and frequency 
distribution for categorical variables. Continuous parametric and non-parametric variables were compared using 




Painful diabetic neuropathy 
P value No Yes 
n (%) 717 (65.5) 378 (34.5) N/A 
Age, years, mean (SD) 52.6 ± 11.4 57.5 ± 10.7 <0.0001* 
Gender, n (%) Male 453 (68.7) 206 (31.3) <0.01 
 Female 261 (60.7) 169 (39.3)  
Diabetes duration, years, mean (SD) 8.2 ± 7.0 13.6 ± 7.9 <0.0001* 
HbA1c, mean (SD) % 8.0 ± 2.0 8.4 ± 2.0 0.02 
   mmol/mol 64.9 ± 22.3 67.9 ± 21.8 0.02 
Poor glycemic control  Yes 174 (60.4) 114 (39.6) <0.05 
    No 474 (67.6) 227 (32.4)  
Cholesterol, mmol/l, mean (SD) 4.5 ± 1.2 4.4 ± 1.1 NS 
Triglyceride, mmol/l, mean (SD) 1.9 ± 1.3 1.7 ± 1.0 NS* 
HDL, mmol/l, mean (SD) 1.3 ± 0.2 1.1 ± 0.0 NS 
LDL, mmol/l, mean (SD) 2.6 ± 0.0 2.5 ± 0.0 NS 
Systolic blood pressure, mmHg, mean (SD) 131.1 ± 17.7 135.4 ± 18.3 <0.001 
Diastolic blood pressure, mmHg, mean (SD) 78.5 ± 10.5 77.6 ± 9.5 NS 
Hypertension, n (%) Yes 371 (61.0) 237 (39.0) 0.001 
 No 294 (71.5) 117  (28.5)  
Weight, Kg, mean (SD) 83.4 ± 21.4 87.6 ± 18.6 <0.0001* 
BMI, Kg/m2, mean (SD) 30.7 ± 6.8 32.7 ± 7.0 <0.0001 
Obesity, n (%), n (%) Yes 314 (60.2) 208 (39.8) <0.0001 
 No 318 (73.3) 116 (26.7)  
Physical activity, n (%) Yes 240 (74.5) 82 (25.5) 0.001 
 No 330 (63.2) 192 (36.8)  
Smoking, n (%) Yes 107 (69.0) 48 (31.0) NS 
 No 501 (67.2) 244 (32.8)  
Proteinuria, n (%) Yes 33 (51.6) 31 (48.4) <0.01 
 No 300 (67.1) 147 (32.9)  
Vibration perception threshold, V, mean (SD) 9.8 ± 7.5 17.4 ± 10.6 <0.0001 
Impaired vibration perception, n 
(%) 
 
Yes 126 (39.1) 196 (60.9) <0.0001 
 No 586 (76.8) 177 (23.2)  
Previously diagnosed with pDPN, n (%) 28 (4.0) 73 (19.8) <0.0001 
Treated for pDPN, n (%) 22 (3.1) 53 (14.0) <0.0001 
Ethnic groups, n (%) Qataris 181 (54.7) 150  (45.3) <0.0001 
   Other Arabs 196 (64.3) 109  (35.7)  
   South Asians 299 (74.2) 104  (25.8)  
   Others 41 (73.2) 15  (26.8)  
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4.4.2 Factors associated with pDPN 
Subjects with pDPN had a higher mean age (P<0.0001, Cohen’s d = 0.43), duration of diabetes 
(P<0.0001, Cohen’s d = 7.28), HbA1c (P=0.02, Cohen’s d = 1.99), systolic blood pressure 
(P<0.001, Cohen’s d = 0.26), weight (P<0.0001, Cohen’s d = 0.21) and BMI (P<0.0001, Cohen’s 
d = 0.31), compared to subjects without pDPN. Vibration perception threshold (VPT) was 
significantly higher (17.4V vs 9.8V, P<0.0001). Total cholesterol, triglycerides, HDL, LDL and 
diastolic blood pressure were comparable between the two groups. Subjects with pDPN had 
a higher percentage of subjects with impaired vibration perception (60.9% vs 23.2%, 
P<0.0001), a greater proportion of females (39.3% vs 31.3%, P<0.01), poorer glycemic control 
(39.6% vs 32.4%, P<0.05), more hypertension (39.0% vs 28.5%, P=0.001), greater proportion 
with proteinuria (48.4% vs 32.9%, P<0.01), more obesity (39.8% vs 26.7%, P<0.0001) and a 
lower percentage of those undertaking physical activity (25.5% vs 36.8%, P=0.001).  
Logistic regression analysis showed that five factors were independently and significantly 
associated with pDPN (Table 4.2). Impaired vibration perception adjusted odds ratio 
(AOR)=4.42 (95%CI: 2.92-6.70), smoking AOR=2.43 (95%CI: 1.43-4.15), obesity AOR=1.74 
(95%CI: 1.13-2.66), being female AOR=1.65 (95%CI: 1.03-2.64) and duration of diabetes =1.08 
(95%CI: 1.05-1.11) were associated with pDPN. Age, poor glycemic control, hypertension, 




Table 4.2. Logistic regression analysis between painful diabetic peripheral neuropathy and risk factors. Outcome 
variable: Painful diabetic peripheral neuropathy. Independent variables: Age, duration of diabetes, impaired 
vibration perception, female, poor glycemic control, hypertension, obesity, physical activity, smoking, 
proteinuria and ethnic groups were considered in the fitted model with a P value ≤0.05. 
 AOR (95% CI) P value 
Age 1.01 (0.99 - 1.03) 0.28 
Duration of diabetes 1.08 (1.05 - 1.11) <0.0001 
impaired vibration perception 4.42 (2.92 - 6.70) <0.0001 
Female  1.65 (1.03 - 2.64) <0.05 
Poor glycemic control 1.40 (0.93 - 2.11) 0.28 
Hypertension 1.16 (0.77 - 1.76) 0.64 
Obesity 1.74 (1.13 - 2.66) <0.01 
Physical activity 0.83 (0.55 - 1.26) 0.09 
Smoking 2.43 (1.43 - 4.15) 0.001 






Other Arabs 1.05 (0.64 - 1.73) 0.44 
South Asians 0.95 (0.57 - 1.59) 0.80 
Others 0.81 (0.31 - 2.07) 0.37 
4.4.3 Ethnicity and pDPN 
The prevalence of pDPN differed between ethnic groups (Figure 4.1 and Table 4.3). Qataris 
(45.3%) and other Arabs (35.7%) had a higher prevalence of pDPN compared to South Asians 
(25.8%). However, the prevalence of impaired vibration perception was comparable between 
ethnic groups. The prevalence of obesity was comparable between Qataris (66.8%) and other 
Arabs (70.9%), but significantly higher than in South Asians (34.2%). The percentage of Qataris 
(20.8%) and other Arabs (35.5%) who undertook physical activity was significantly lower than 
in South Asians (54.3%). The percentage of Qataris with proteinuria was significantly higher 
than in South Asians (9.4% vs 3.0%) and comparable with other Arabs and other ethnicities. 
Qataris were significantly older than other Arabs, South Asians and other ethnicities (58.2 vs 
53.8 vs 51.8 and 52.5 years, respectively) and had a significantly longer duration of diabetes 
(13.4 vs 9.1 vs 8.1 and 9.9 years, respectively). The percentage of Qataris with hypertension 
was significantly higher than other Arabs (65.3% vs 53.9%). There were significantly less 
smokers amongst Qataris compared to other Arabs (10.4% vs 23.9%). 
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Table 4.3. Differences in the prevalence of painful diabetic peripheral neuropathy and other risk factors between 
different ethnic groups. a,b,c,d within each row, columns with similar letters are not statistically significant and 
those with different letters are significantly different. 
Figure 4.1. Prevalence of painful diabetic peripheral neuropathy between ethnic groups. 
 
4.5 Discussion 
This is the first large observational study to establish the prevalence of painful diabetic 
peripheral neuropathy (pDPN) and its associated factors in secondary care in Qatar. PDPN 
occurs in approximately one third of patients with T2D, however, alarmingly, 4/5 had not 
been previously diagnosed or treated. PDPN, a manifestation of small fiber damage (Sorensen 
 Qataris Other Arabs South Asians Others 
n 331 305 403 56 
Painful DPN, n (%) 150 (45.3)a 109 (35.7)a 104 (25.8)b 15 (26.8)ab 
Age, years, mean (SD) 58.2 (12.0)a 53.8 (11.7)b 51.8 (9.7)b 52.5 (10.5)b 
Duration of diabetes, years, mean 
(SD) 
13.4 (7.8)a 9.1 (7.2)b 8.1 (7.0)b 9.9 (8.4)b 
Impaired vibration perception, n (%) 108 (33.0)a 91 (30.0)a 102 (25.6)a 21 (37.5)a 
Female, n (%) 211 (64.1)a 109 (35.9)b 89 (22.3)c 21 (39.5)bc 
Poor glycemic control, n (%) 100 (33.8)a 86 (31.5)a 152 (41.4)a 21 (39.6)a 
Hypertension, n (%) 196 (65.3)a 153 (53.9)b 229 (59.9)ab 30 (56.6)ab 
Obesity, n (%) 185 (66.8)ab 188 (70.9)b 125 (34.2)c 24 (49.0)ac 
Physical activity, n (%) 52 (20.8)a 87 (35.5)b 170 (54.3)c 13 (36.1)abc 
Smoking, n (%) 27 (10.4)a 62 (23.9)b 57 (16.9)ab 9 (20.5)ab 
Proteinuria, n (%) 31 (9.4)a 15 (4.9)a,b 12 (3.0)b 6 (10.7)a 
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et al., 2006, Vlckova-Moravcova et al., 2008, Quattrini et al., 2007b), occurred in more than 
one in four patients without impaired vibration perception, and in one in two patients with 
impaired vibration perception. Impaired vibration perception, obesity and smoking were 
associated with pDPN. Arabs also have a higher prevalence of pDPN compared to Asians. This 
may be attributed to the higher percentage of women and obesity, and a lower percentage 
undertaking physical activity in the Arab population. 
The prevalence of pDPN in T2D patients in Qatar was lower than previous studies from the 
MENA region, even though they also used the Douleur Neuropathique 4 (DN4) pain 
questionnaire and showed that the prevalence of pDPN was 65.3% in Saudi Arabia (Halawa 
et al., 2010), 61.3% in Egypt (Jambart et al., 2011), 57.5% in Jordan, 53.9% in Lebanon and 
37.1% in United Arab Emirates and Kuwait. This difference could be attributed to different 
populations and control of various risk factors, although age, duration of diabetes and the 
percentage of those with obesity were comparable to this study. However, the percentage of 
those with poor glycemic control in Saudi Arabia was higher compared to the current study 
(59.5% vs 39.6%) (Akbar et al., 2000). Poor glycemic control is common in the Middle East 
(Akbar et al., 2000, Youssef et al., 2006, Uddin et al., 2001, Habib and Aslam, 2003) and has 
been reported to be a significant risk factor for both DPN and pDPN (Harris et al., 1993, Smith 
and Singleton, 2008). In the UK, the prevalence of pDPN in T2D patients is lower (21.5% - 
26.4%) than in Qatar (Abbott et al., 2011, Davies et al., 2006) and may be attributed to a lower 
HbA1c (7.26% vs 8.14%) and shorter duration of diabetes (4-8 years vs 10.1 years). One of the 
earlier UK studies (Davies et al., 2006) was conducted in patients with T1D and T2D in primary 
care and the prevalence of pDPN is known to be lower in primary care (Aslam et al., 2015) 
and in T1D patients (Abbott et al., 2011, Van Acker et al., 2009, Ziegler et al., 2018).  
The physical quality of life of patients with pDPN decreases at a significantly faster rate over 
3 years compared to T2D patients without pDPN (daCosta DiBonaventura et al., 2011). 
Patients with pDPN are also at high risk for depression, anxiety and sleep disturbance 
(Bohlega et al., 2010). However, the under-diagnosis and treatment of pDPN continues to 
pose a considerable problem for patients. Other studies have also reported that a large 
proportion of patients with pDPN were not diagnosed, 61.5% in Germany (Ziegler et al., 2018) 
and 12.5% in the UK (Daousi et al., 2004). Major hurdles limiting the diagnosis of pDPN are 
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that patients with painful symptoms do not attribute them to diabetes and fail to report them 
to their physician (Daousi et al., 2004, Eichholz et al., 2017) and of course screening is not 
currently advocated for pDPN, only for those at high risk of foot ulceration (Pop-Busui et al., 
2017). Given that we have identified age, duration of diabetes and the presence of impaired 
vibration perception as major determinants for pDPN (Davies et al., 2006, Jambart et al., 2011, 
Halawa et al., 2010, Van Acker et al., 2009) one could advocate screening for pDPN in at least 
diabetic patients who are older, have a longer duration of diabetes and impaired vibration 
perception. Furthermore, we have identified that obesity is associated with pDPN, which has 
also been reported in some (Jambart et al., 2011, Van Acker et al., 2009, Ziegler et al., 2018, 
Aslam et al., 2015), but not other studies (Halawa et al., 2010, Jacovides et al., 2014). Low 
physical activity has been reported as a risk factor (Ziegler et al., 2009, Smith et al., 2006), but 
in this study we show no association after adjusting for other risk factors. Smoking has also 
been associated with pDPN in some (Abbott et al., 2011, Aslam et al., 2015) but not other 
studies (Halawa et al., 2010, Jambart et al., 2011, Jacovides et al., 2014, Abbott et al., 2011, 
Van Acker et al., 2009). Improved glycemic control reduces the development and progression 
of DPN in T1D (Klein et al., 1996), but has shown limited benefit in T2D (Callaghan et al., 2012). 
Low HDL cholesterol raised LDL cholesterol and triglycerides have been independently 
associated with pDPN (Van Acker et al., 2009). Creatinine is associated with pDPN, whilst 
albuminuria (Ziegler et al., 2009) and proteinuria have no association. A previous study of 
subjects with pre-diabetes showed that lifestyle intervention reduced neuropathic symptoms 
and improved small fiber function and structure (Smith et al., 2006). 
The prevalence of painful neuropathic symptoms (Abbott et al., 2011) and pDPN (Eichholz et 
al., 2017) differs between ethnic groups. In our previous study in the UK (Abbott et al., 2011), 
we showed that South Asians were 50% more likely to have painful neuropathic symptoms 
compared to Europeans and Afro-Caribbean’s, after adjusting for age and duration of 
diabetes. However, in the present study, South Asians had a lower prevalence of pDPN 
compared to Qatari Arabs and other Arabs, which may be attributed to a lower proportion 
with obesity, less women and higher physical activity in this group. Indeed, this and other 
studies (Jambart et al., 2011, Abbott et al., 2011) have shown that women have a 50-65% 
increase in the odds for pDPN. The ethnic difference may also reflect genetic differences in 
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the prevalence of abnormalities in voltage gated channels on nociceptors in different ethnic 
groups (Wadhawan et al., 2017, Blesneac et al., 2018). 
We recognize that recruiting patients with diabetes from secondary health care centers and 
not primary care centers as a major limitation of this study and limits the generalizability of 
the results to all people with diabetes in Qatar. However, those two hospitals are the only 
National Diabetes & Endocrine centers in Qatar and the recruited participants were of diverse 
backgrounds. The cross-sectional design of this study also limits the interpretation of cause 
and effect in relation to risk factors. The strength of this study is the large sample size and the 
inclusion of a wide range of risk factors to identify those associated independently with pDPN. 
Furthermore, pDPN was diagnosed using the DN4 questionnaire, which has been validated in 
Arabic (Harifi et al., 2011) and used in other studies in the MENA region to establish the 
prevalence of pDPN (Jambart et al., 2011, Halawa et al., 2010).  
In conclusion, one in three patients with T2D attending secondary care in Qatar have pDPN. 
It remains a neglected complication of diabetes as ~80% of patients were not diagnosed or 
treated for this condition. Impaired vibration perception, obesity and smoking are associated 
with pDPN, suggesting that patients with these risk factors should be screened for pDPN and 
treated for relief of symptoms and with life-style interventions to limit progression. 
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5.1 Abstract 
Introduction: Diabetic peripheral neuropathy (DPN) can result in painful DPN (pDPN) and 
diabetic foot ulceration (DFU).  
Objectives: This study determined the prevalence and risk factors for DPN and pDPN in 
patients with type 2 diabetes (T2D) in primary health care (PHC) and secondary health care 
(SHC) in Qatar.  
Methods: This is a cross-sectional multi-center study. Adults with T2D aged 18-85 years old 
were randomly enrolled from four PHC centers and two Diabetes Centers in SHC in Qatar. 
Subjects underwent assessment of clinical and metabolic parameters, DPN and pDPN. 
Results: 1,386 subjects with T2D were recruited, with 297 from PHC and 1,089 from SHC. The 
prevalence of DPN (14.8% vs 23.9%, P=0.001) and pDPN (18.1% vs 37.5%, P<0.0001) was 
significantly lower in PHC compared to SHC and those with DPN at high risk for DFU (31.8% vs 
40.0%, P=0.3) was comparable. The prevalence of undiagnosed DPN (79.5% vs 82.3%, P=0.66) 
was comparably high but undiagnosed pDPN (24.1% vs 71.5%, P<0.0001) was lower in PHC 
compared to SHC. The odds of DPN and pDPN increased with age and diabetes duration and 
DPN increased with poor glycemic control, hyperlipidemia and hypertension, whilst pDPN 
increased with obesity and reduced physical activity. 
Conclusions: The prevalence of DPN and pDPN in T2D is lower in PHC compared to SHC and 
is attributed to overall better control of risk factors and referral bias due to patients with 
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poorly managed complications being referred to SHC. However, approximately 80% of 
patients had not been previously diagnosed with DPN in PHC and SHC. Further, we identify a 
number of modifiable risk factors for PDN and pDPN. 
5.2 Introduction 
Diabetic peripheral neuropathy (DPN) is the most common complication of diabetes and yet 
often remains undiagnosed (Pop-Busui et al., 2017). Late diagnosis can lead to significant 
morbidity in the form of painful DPN (pDPN) (Ponirakis et al., 2019b), erectile dysfunction 
(Kouidrat et al., 2017), diabetic foot ulceration (DFU) (Raghav et al., 2018) and amputation 
(Apelqvist and Agardh, 1992), as well as increased mortality (Azmi et al., 2019a).  
Early diagnosis and management of DPN may limit or reduce disease progression (Pop-Busui 
et al., 2017). However, screening for DPN and pDPN is inadequate (Herman and Kennedy, 
2005, Wang et al., 2011, Ponirakis et al., 2020b). The prevalence of DPN and pDPN have been 
shown to range from 2.4-24.1% (Cabezas-Cerrato, 1998, Kostev et al., 2014) and 16-19% 
(Davies et al., 2006, Daousi et al., 2004) in primary care and 32.1% (Young et al., 1993) and 
21.0% (Abbott et al., 2011) in secondary care in patients with type 2 diabetes (T2D), 
respectively. This wide range has been attributed to differing populations and methods used 
to identify DPN and pDPN. We have recently reported that approximately 80% of patients 
with DPN (Ponirakis et al., 2020b) and pDPN (Ponirakis et al., 2019b) have not previously been 
diagnosed in hospital clinics in secondary health care (SHC) in Qatar, which may lead to late 
presentation with DFU. Indeed, in Qatar it has been reported that 25% of patients with 
diabetes in SHC have foot problems (Al-Thani et al., 2019). This has serious consequences 
given that one in four patients with DFU are at risk of amputation (Apelqvist and Agardh, 
1992) and the 5-year mortality of people with a DFU is higher than many common cancers 
(Armstrong et al., 2007). Currently, the ADA recommends annual screening of DPN at 
diagnosis of T2D and 5 years after the diagnosis of type 1 diabetes (T1D) by neurological exam 
or monofilament testing, but there is no specific recommendation for pDPN (Pop-Busui et al., 
2017). 
There are currently no FDA approved therapies for DPN (Azmi et al., 2019a). Lifestyle 
interventions, including physical activity (Al-Kaabi et al., 2014) and avoidance of smoking (Al-
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Mahroos and Al-Roomi, 2007, Tesfaye et al., 2005) are advised and optimization of glycemic 
control (Al-Mahroos and Al-Roomi, 2007, Boru et al., 2004), treatment of hypertension (Malik 
et al., 1998, Reja et al., 1995) and hyperlipidemia (Tesfaye et al., 2005, Smith and Singleton, 
2013) may improve DPN. FDA approved medications for treating painful symptoms include 
duloxetine, pregabalin and tapentadol (Javed et al., 2015). 
According to the International Diabetes Federation, the prevalence of diabetes in adults aged 
20-79 years in Qatar was 15.5% in 2020 (IDF Middle East and North Africa Region, 2020, ), 
which is almost two-fold greater than the 2019 reported prevalence of 8.3% in the rest of the 
world (International Diabetes Federation, 2019, ). Given the high prevalence of diabetes, in 
2015 Qatar launched the National Diabetes Strategy to improve the management of people 
with diabetes and its complications by establishing common clinical care pathways within and 
between primary and secondary health care. We have therefore applied the same methods 
and diagnostic criteria in patients with T2D to establish the prevalence and risk factors for 
DPN and pDPN in primary and secondary health care. We believe the findings of this study 
will be key to planning strategies to enable earlier diagnosis and optimal management of the 
often-forgotten complication of diabetic neuropathy, in Qatar and the region. 
5.3 Materials and methods 
This is a cross-sectional multi-center study. Subjects aged 18 - 85 years old with T2DM were 
enrolled from four primary health care (PHC) centers (Umm Ghuwailina, Al Khor, Al Daayen 
and Al Rayyan) and the only two National Diabetes centers in Qatar (Hamad General Hospital 
(HGH) and Al-Wakra Hospital). Subjects were randomly enrolled and screened for eligibility 
on the day they attended the clinic their diabetes review between June 2017 and February 
2019. Exclusion criteria included T1D, other causes of neuropathy including severe vitamin 
B12 deficiency, chronic hypothyroidism and chemotherapy. 
This study was approved by the Institutional Review Board (IRB) of Weill Cornell Medicine-
Qatar (WCM-Q) and Hamad Medical Corporation (HMC). All subjects gave informed consent 
to take part in the study. The research adhered to the tenets of the declaration of Helsinki. 
5.3.1 Demographic and metabolic measures 
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Gender, ethnicity, age, duration of diabetes and body mass index (BMI) were recorded. The 
average systolic (SBP) and diastolic blood pressure (DBP) of two readings were obtained from 
the subject’s left arm while seated with the arm at heart level, using a standard zero mercury 
sphygmomanometer after 10-15 minutes of rest. A non-fasting blood sample was collected 
through venepuncture from each subject into EDTA tubes and transported within 2 hours to 
a central certified laboratory at HGH. Glycated haemoglobin (HbA1c), total cholesterol and 
triglyceride were measured by an autoanalyzer (Hitachi 747 autoanalyzer, Japan). Poor 
glycemic control was defined as HbA1c ≥9%. Hypertension was defined according to either an 
average SBP ≥140 mmHg and/or the use of anti-hypertensive medication, as described in the 
WHO/ISH Guidelines (Moser, 1999). Hyperlipidemia was defined according to a total 
cholesterol level ≥6.2 mmol/L and/or triglyceride level of ≥2.3 mmol/L or if the patient was 
treated with a statin. Obesity was classified according to WHO criteria with a BMI ≥30 kg/m2 
(Report of a WHO consultation, 2000). Current cigarette smoking was defined as having 
smoked at least one cigarette every day for ≥1 year preceding the study visit. Physical activity 
was defined as doing some physical activity including walking for ≥30 minutes/day, at least 3 
times a week over the last year.  
5.3.2 Assessment of diabetic neuropathy and painful neuropathy 
The diagnosis of DPN was based on the presence of one or more neuropathic symptoms and 
impaired vibration perception threshold (VPT) in the feet. Subjective neurological symptoms 
such as burning pain, painful cold, electric shocks, tingling, pins and needles and numbness 
were acquired through a face-to-face interview with the investigators. VPT was measured by 
a Neurothesiometer (Horwell, Scientific Laboratory Supplies, Wilford, Nottingham, UK) on the 
pulp of the large toe on both feet and the average value of three measurements was recorded 
in Volts (V) ranging from 0 - 50V. A VPT ≥15V was defined as impaired vibration perception 
consistent with the presence of DPN (Wiles et al., 1991) and a VPT ≥25V as high risk for 
diabetic foot ulceration (DFU) (Young et al., 1994).  
Painful DPN was assessed using the Douleur Neuropathique en 4 (DN4) questionnaire in 
Arabic and English as previously described (Spallone et al., 2012). The DN4 questionnaire has 
been validated for its ability to distinguish neuropathic pain from non-neuropathic pain 
(Bouhassira et al., 2005) and in the Arabic version (Terkawi et al., 2017), and for pDPN 
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(Spallone et al., 2012). It consists of 10 questions: 7 questions relating to the pain description 
(burning, painful cold, electric shocks) and associated abnormal sensations (tingling, pins and 
needles, numbness, itching) and the other 3 neurological examination outcomes in the painful 
area for hypoesthesia to touch and pin prick using disposable examination pins and allodynia 
to brushing. The scoring is based on a yes (1 point) or no (0 point) answer and each question 
is equally weighted. A score ≥4 has a high sensitivity (80%) and specificity (92%) for pDPN 
(Spallone et al., 2012). The questionnaire was administered by the investigator in either 
English or Arabic. Previously diagnosed pDPN was self-reported. Medications for pDPN were 
recorded. 
All investigators underwent a formal training session on the use and interpretation of the 
Neurothesiometer and DN4 questionnaire. 
5.3.3 Statistical analysis 
The recommended minimum sample size was 937 to estimate the prevalence of DPN and 
1027 to estimate the prevalence of pDPN based on the assumption that the prevalence of 
DPN and pDPN was around 25% and 30% in a population of 5,000 patients with T2D in SHC 
with ±2.5 % the acceptance absolute deviation of sample rate from population rate and 95% 
confidence level. 
The prevalence of DPN and pDPN across different demographics and risk factors as categorical 
variables were summarized using frequency distributions. Variables in patients with DPN or 
pDPN were compared between PHC and SHC using the Chi-squared test of independence.  
Binary logistic regression analysis was performed with age, duration of diabetes, gender, poor 
glycemic control, obesity, hyperlipidemia, hypertension, physical activity, smoking, ethnicity 
and health care as independent variables, and DPN or pDPN as the dependent variable. 
Collinearity was tested to minimize its potential effect by selecting variables whose 
correlation coefficients was <0.7. The multiple logistic regression model included all variables 
with P value of ≤0.05 at the bivariate level. Adjusted odds ratios, their corresponding 95% 
confidence intervals (CI) and P value are presented. 
All analyses were performed using IBM-SPSS (version 26; SPSS Inc, Armonk NY). A two-tailed 




5.4.1 Prevalence of DPN and pDPN in PHC compared to SHC (Figure 5.1 & Table 5.1) 
1,386 subjects with T2D were recruited from primary (PHC) (n=297) and secondary health 
care (SHC) (n=1,089). The prevalence of DPN (14.8% vs 23.9%, P=0.001) was significantly 
lower in PHC compared to SHC. The percentage of patients undiagnosed with DPN was 
comparable (79.5% vs 82.3%, P=0.66) between PHC and SHC. The prevalence of pDPN (18.1% 
vs 37.5%, P<0.0001) and percentage of patients undiagnosed with pDPN (24.1% vs 71.5%, 
P<0.0001) was significantly lower in PHC compared to SHC. The mean VPT (10.4±7.2 V vs 
12.5±9.4 V, P<0.0001), DN4 score (1.0±1.6 vs 2.5±2.6, P<0.0001) and percentage of patients 
with all neuropathic symptoms including burning, painful cold, electric shocks, tingling, pins 
and needles, numbness, itching were significantly lower in PHC compared to SHC (Table 5.2). 
Whilst no patients in PHC had a DFU, 6.2% had DFU in SHC. However, the prevalence of those 
at high risk for DFU was comparable (31.8% vs 40.0%, P=0.3) between PHC and SHC. 
Figure 5.1. Prevalence of diabetic peripheral neuropathy (DPN), painful diabetic neuropathy (pDPN), 




Table 5.1. Prevalence of diabetic peripheral neuropathy (DPN), painful diabetic neuropathy (pDPN), 
undiagnosed DPN and pDPN and those at high risk of DFU and their risk factors in type 2 diabetes in primary and 
secondary health care. 
 Primary health care Secondary health care P value 
PHC vs SHC 
Diabetic peripheral neuropathy 44/297 14.8% 260/1089 23.9% 0.001 
High risk for diabetic foot ulceration 14/44 31.8% 104/260 40.0% 0.30 
Diabetic foot ulcer 0/44 0.0% 16/260 6.2% 0.13 
Painful diabetic neuropathy 54/298 18.1% 410/1092 37.5% <0.0001 
Undiagnosed cases 
Undiagnosed diabetic peripheral neuropathy 35/44 79.5% 214/260 82.3% 0.66 
Undiagnosed painful diabetic neuropathy 13/54 24.1% 293/410 71.5% <0.0001 
Risk factors 
Age 20-50 years 88/295 29.8%a 445/1073 41.5%b 0.001 
 51-60 years 117/295 39.7%a 379/1073 35.3%a  
 >60 years 90/295 30.5%a 249/1073 23.2%b  
Duration of  ≤10 years 204/296 68.9%a 690/1080 63.9%a 0.26 
diabetes 11-20 years 73/296 24.7%a 303/1080 28.1%a  
 >20 years 19/296 6.4%a 87/1080 8.1%a  
Lifestyle modifiable risk factors 
Physical activity 158/275 57.5%a 326/854 38.2%b <0.0001 
Smoking 27/274 9.9% 157/909 17.3% 0.003 
Cardiovascular modifiable risk factors 
Poor glycemic control 98/266 36.8%a 436/991 44.0%b 0.04 
Hyperlipidemia 208/259 80.3%a 738/1008 73.2%b 0.02 
Hypertension 176/274 64.2%a 669/1040 64.3%a 0.98 
Obesity 87/213 40.8%a 510/957 53.3%b 0.001 
Systolic blood pressure (mmHg) 131.7±15.5 132.5±18.0 0.42 
Diastolic blood pressure (mmHg) 78.8±8.0 78.2±10.2 0.32 
BMI (Kg/m2) 29.8±5.4 31.5±7.4 0.0003 
HbA1c (mmol/mol)  63.1±19.7 65.5±21.9 0.08 
HbA1c (%) 7.9±1.8 8.1±2.0 0.08 
Cholesterol (mmol/L) 3.9±1.0 4.4±1.2 <0.0001 
Triglyceride (mmol/L) 1.8±1.0 1.8±1.2 0.96 
Variables were summarized using means and standard deviations for numeric variables and frequency 
distribution for categorical variables. Continues and categorical variables were compared using unpaired t-test 
and x2, respectively. Symbols: a and b in each variable, rows with similar symbols are not statistically significant 
and different symbols are significantly different.  
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Table 5.2. The mean vibration perception threshold, DN4 score and percentage of neuropathic symptoms in 
type 2 diabetes in primary (PHC) and secondary (SHC) health care. 
 PHC SHC P value  
PHC vs SHC 
Vibration perception threshold (Volts) 10.4±7.2 12.5±9.4 <0.0001 
DN4 score 1.0±1.6 2.5±2.6 <0.0001 
Burning pain (%) 22.6 46.7 <0.0001 
Painful cold (%) 7.7 26.5 <0.0001 
Electric shocks (%) 5.1 22.3 <0.0001 
Tingling (%) 20.2 32.0 <0.0001 
Pins and needles (%) 16.2 35.1 <0.0001 
Numbness (%) 12.5 42.0 <0.0001 
Itching (%) 7.8 16.7 <0.0001 
 
Variables were summarized using means and standard deviations for numeric variables and frequency 
distribution for categorical variables. Continues and categorical variables were compared using unpaired t-test 
and x2, respectively. 
5.4.2 Risk factor management in PHC compared to SHC 
More patients with T2D aged above 60 years (30.5% vs 23.2%, P=0.001) and less patients aged 
between 20-50 years (29.8% vs 41.5%, P=0.001) were under the care of PHC compared to 
SHC. The BMI (29.8 Kg/m2 vs 31.5 Kg/m2, P=0.0003) and percentage of patients with obesity 
(40.8% vs 53.3%, P=0.001) was significantly lower in PHC compared to SHC. The HbA1c was 
comparable, but the percentage of patients with poor glycemic control (36.8% vs 44.0%, 
P=0.04) was lower in PHC compared to SHC. In PHC the total cholesterol (3.9 mmol/L vs 4.4 
mmol/L, P<0.0001) was lower and triglycerides were comparable compared to SHC. However, 
hyperlipidaemia was present in a significantly lower percentage of patients in SHC compared 
to PHC (73.2% vs 80.3%, P=0.02). The systolic and diastolic blood pressure and percentage of 
patients with hypertension was comparable between PHC and SHC. More patients undertook 
physical activity (57.5% vs 38.2%, P<0.0001) and less patients smoked cigarettes (9.9% vs 
17.3%, P=0.003) in PHC compared to SHC.  
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5.4.3 Association of risk factors for DPN in PHC and SHC (Table 5.3) 
The odds of developing DPN increased by 2.4 (95% CI 1.6 – 3.5) times in patients aged 51-60 
years (P<0.0001) and 2.9 (95% CI 1.9 – 4.5) times in those aged >60 years compared to 
patients aged 20-50 years (P<0.0001) (Cramer’s V = 0.22). The odds increased 2.2 (95% CI 1.6 
– 3.0) times with 11-20 years of diabetes (P<0.0001) to 3.9 (95% CI 2.4 – 6.4) times with >20 
years of diabetes (P<0.0001) compared to ≤10 years of diabetes (Cramer’s V = 0.30). The odds 
for DPN was 1.4 (95% CI 1.1 – 2.0) times greater in men (P=0.02) (Cramer’s V = 0.02). The odds 
increased 1.5 (95% CI 1.1 – 2.0) times in those with poor glycemic control (P=0.02, Cramer’s 
V = 0.12) and 1.6 (95% CI 1.2 – 2.3) times in patients treated with insulin and other anti-
diabetic therapy compared to patients treated with metformin and other anti-diabetic 
therapy (P=0.006, Cramer’s V = 0.22). The odds increased 1.8 (95% CI 1.2 – 2.8) times in those 
with hyperlipidemia (P=0.006, Cramer’s V = 0.13) and 1.5 (95% CI 1.0 – 2.2) times in those 
with hypertension (P=0.05, Cramer’s V = 0.17). The association with obesity and ethnicity for 
DPN was lost after controlling for risk factors. However, even after adjusting for all risk factors 
the odds of developing DPN in SHC remained 2.1 times higher than in PHC (P=0.001). 
Table 5.3. Predictors for diabetic peripheral neuropathy in primary and secondary health care. 
Diabetic peripheral neuropathy AOR 95% CI P value 
Gender Male 1   
 Female 0.7 0.5 – 0.9 0.02 
Ethnic groups Arabs 1   
 South Asians 0.8 0.5 – 1.1 0.19 
Age 20-50 years 1   
 51-60 years 2.4 1.6 – 3.5 <0.0001 
 >60 years 2.9 1.9 – 4.5 <0.0001 
Duration of diabetes ≤10 years 1   
 11-20 years 2.2 1.6 – 3.0 <0.0001 
 >20 years 3.9 2.4 – 6.4 <0.0001 
Poor glycemic control 1.5 1.1 – 2.0 0.02 
Hyperlipidemia 1.8 1.2 – 2.8 0.006 
Hypertension  1.5 1.0 – 2.2 0.05 
Obesity  1.3 0.9 – 1.8 0.20 
Anti-diabetic therapy Metformin/plus 1   
Insulin/plus 1.6 1.2 – 2.3 0.006 
Primary health care 1   
Secondary health care 2.1 1.4 – 3.2 0.001 
The multiple logistic regression model included all variables with P value of ≤0.05 at the bivariate level. Adjusted 
odds ratios, their corresponding 95% confidence intervals (CI) and P value are presented. 
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5.4.4 Association of risk factors for pDPN in PHC and SHC (Table 5.4) 
The odds of developing pDPN was 1.5 times greater in patients aged >50 years (P=0.02) 
compared to those aged 20-50 years (P<0.0001). The odds increased from 2.2 times with 11-
20 years of diabetes (P<0.0001) to 4.4 times with >20 years of diabetes (P<0.0001) compared 
to ≤10 years of diabetes. The odds also increased by 1.7 times in subjects treated with 
insulin/plus other anti-diabetic therapy compared to those treated with metformin/plus 
other anti-diabetic therapy (P<0.0001). The odds increased 1.6 times with obesity (P=0.002) 
and 1.4 times in Arabs compared to South Asians (P=0.03). However, the odds decreased by 
1.7 times with physical activity (P=0.01). The association of poor glycemic control, 
hyperlipidemia, hypertension and gender with pDPN was lost after controlling for these risk 
factors. However, even after adjusting for all risk factors the odds of developing pDPN in SHC 
was 2.4 times higher than in PHC (P<0.0001). 
Table 5.4. Predictors for diabetic painful neuropathy in primary and secondary health care. 
Painful neuropathy AOR 95% CI P value 
Gender Male 1   
 Female 1.2 0.9 – 1.6 0.32 
Ethnic groups Arabs 1   
 South Asians 0.7 0.5 – 1.0 0.03 
Age 20-50 years 1   
 51-60 years 1.5 1.1 – 2.0 0.02 
 >60 years 1.5 1.1 – 2.2 0.02 
Duration of diabetes ≤10 years 1   
 11-20 years 2.2 1.6 – 3.0 <0.0001 
 >20 years 4.4 2.7 – 7.1 <0.0001 
Poor glycemic control 1.2 0.9 – 1.6 0.2 
Hyperlipidemia 1.1 0.8 – 1.5 0.58 
Hypertension  1.3 0.9 – 1.8 0.13 
Obesity  1.6 1.2 – 2.2 0.002 
Physical activity  0.6 0.4 – 0.9 0.01 
Anti-diabetic therapy Metformin/plus other therapy 1   
Insulin/plus 1.7 1.3 – 2.4 <0.0001 
Primary health care 1   
Secondary health care 2.4 1.6 – 3.5 <0.0001 
The multiple logistic regression model included all variables with P value of ≤0.05 at the bivariate level. Adjusted 




This study shows that the prevalence of DPN is 1.6 times lower and pDPN is 2 times lower in 
primary health care compared to secondary health care. Furthermore, the percentage of 
patients with undiagnosed DPN (~80%) and those at risk of DFU (32-40%) was extremely high 
and comparable between PHC and SHC, despite the institution of national diabetes care 
pathways. DPN was associated with poor glycemic control, hyperlipidemia and hypertension, 
whereas pDPN was associated with obesity and was lower in patients undertaking physical 
activity at least 3 days per week. The higher prevalence of DPN and pDPN in SHC remained 
significant even after controlling for risk factors. This may partly be attributed to referral bias 
with more patients with poorer control of risk factors and diabetic complication being 
referred to SHC.  
The DN4 questionnaire was chosen to define pDPN for three reasons: 1) Its diagnostic ability 
to distinguish neuropathic pain from non-neuropathic pain including osteoarthritis, 
inflammation and mechanical low back pain (common differentials, especially in PHC) for 
which it has been validated with 86% sensitivity and 83% specificity (Bouhassira et al., 2005); 
2) Its diagnostic ability specifically for pDPN with 80% sensitivity and 92% specificity (Spallone 
et al., 2012), and 3) validation using the Arabic version showing 88% sensitivity and 75% 
specificity (Terkawi et al., 2017). The higher prevalence of pDPN compared to DPN may be 
attributed to the criteria used to define these conditions. pDPN was defined according to DN4, 
whereas DPN was based on symptoms and an elevated VPT (>15V). 
There are currently no FDA approved therapies for DPN (Azmi et al., 2019a). However, 
screening annually for symptoms and signs of DPN starting at diagnosis of T2D is advocated 
on the basis that early management of risk factors for DPN may reduce the rate of disease 
progression and treatment to relieve neuropathic symptoms may improve the patient’s 
quality of life (Pop-Busui et al., 2017). We have recently assessed the prevalence of DPN and 
pDPN in SHC in Qatar (Ponirakis et al., 2020b, Ponirakis et al., 2019b). This is the first study to 
compare the prevalence of DPN and pDPN in PHC and SHC using the same criteria and in the 
same population. The prevalence of DPN in both PHC and SHC in Qatar is lower compared to 
the prevalence in SHC in other countries e.g. 37% in Bahrain (Al-Mahroos and Al-Roomi, 
2007), 60% in Turkey (Boru et al., 2004), 49% in Iran (Kiani et al., 2013), 45% in the US (Mold 
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et al., 2004), 32% in the UK (Young et al., 1993), 31% in Italy (Salvotelli et al., 2015) and 62% 
in China (Lu et al., 2010). The prevalence of pDPN is also lower in both SHC and PHC in Qatar 
compared to studies from SHC with a reported prevalence of 65% in Saudi Arabia (Halawa et 
al., 2010), 61% in Egypt (Jambart et al., 2011), 58% in Jordan and 54% in Lebanon.  
Despite the implementation of a referral system from PHC to SHC in May 2011in Qatar, which 
is based on clinical need rather than on a “first come first served” basis and has improved the 
quality and provision of the national diabetes performance, this study confirms an alarmingly 
high prevalence of undiagnosed DPN in PHC and SHC (Ponirakis et al., 2020b, Ponirakis et al., 
2019b). It highlights the considerable need to educate both patients and physicians on DPN 
and pDPN (Malik et al., 2020). This may explain why up to 25% of patients with diabetes in 
SHC in Qatar have foot problems (Al-Thani et al., 2019). Indications for referral of patients 
with T2D from PHC to SHC, include poorly controlled T2D, recurrent or severe hypoglycemia, 
DPN, diabetic retinopathy or nephropathy. Currently, DPN is not assessed systematically even 
using the 10-g monofilament which in itself identifies only those with advanced neuropathy 
(Pop-Busui et al., 2017). Given that one in four patients with DFU are at risk of amputation 
(Apelqvist and Agardh, 1992), this study highlights the need for the National Diabetes Strategy 
to implement annual DPN screening in PHC and SHC. This should be done using evidence 
based screening tests to detect incipient small fiber damage to detect sudomotor dysfunction 
using Sudoscan (Selvarajah et al., 2015) or Neuropad (Ponirakis et al., 2014) or vibration 
perception using a Neurothesiometer (Bril and Perkins, 2002a) or cold or warm perception 
thresholds using NerveCheck (Ponirakis et al., 2016); as opposed to monofilament testing, 
which is convenient but only detects advanced large fiber neuropathy. A common reason for 
the under-diagnosis of pDPN is that patients with symptoms are often unaware that the pain 
is related to DPN and do not report them to their physician (Daousi et al., 2004, Eichholz et 
al., 2017). Although, several screening questionnaires, including the DN4 (Spallone et al., 
2012), the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain scale 
(Bennett, 2001), the Neuropathic Pain Scale (NPS)(Jensen et al., 2006), the Neuropathic Pain 
Symptom Inventory (NPSI) (Bouhassira et al., 2004), and the Diabetic Peripheral Neuropathic 
Pain Impact measure (DPNPI) (Brod et al., 2015) have been developed to rapidly diagnose 
pDPN they remain under-utilized. Reassuringly, we show a much lower prevalence of patients 
with undiagnosed pDPN in PHC which may reflect a more systematic approach to identify 
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neuropathic symptoms as part of a general screen for complications as opposed to SHC where 
there is no formal screening unless the physician refers for further assessment. 
The lack of a European Medicines Agency (EMA) and FDA approved therapy for DPN often 
creates a negative attitude on the need to diagnose early DPN (Malik et al., 2017). However, 
our study has identified a range of modifiable risk factors for DPN including poor glycemic 
control (Al-Mahroos and Al-Roomi, 2007, Boru et al., 2004), hypertension (Malik et al., 1998, 
Reja et al., 1995) and hyperlipidemia (Tesfaye et al., 2005, Smith and Singleton, 2013) and for 
pDPN e.g. obesity (Jambart et al., 2011, Van Acker et al., 2009, Ziegler et al., 2018, Aslam et 
al., 2015) and reduced physical activity (Ziegler et al., 2009, Smith et al., 2006). Although, 
intensive glycemic control is advocated, the data for an impact on DPN in T2D are limited 
(Ohkubo et al., 1995, Ismail-Beigi et al., 2010, Pop-Busui et al., 2013) and other cardiovascular 
risk factors such as hypertension, hyperlipidemia and obesity may play a more important role. 
Indeed, treatment with angiotensin converting enzyme (ACE) inhibitors (Malik et al., 1998, 
Reja et al., 1995), statins (Davis et al., 2008, Villegas-Rivera et al., 2015) or glucagon-like 
peptide 1 (GLP-1) receptor agonists (Kan et al., 2012, Himeno et al., 2011, Ponirakis et al., 
2020a) may have a beneficial effect on DPN. 
A limitation of this study is the relatively small number of participants from PHC, thus limiting 
the generalisability of the findings. A further limitation is the cross-sectional design of this 
study which limits the predictive validity of the observed associations between the various 
risk factors with DPN and pDPN. Another limitation is the reliability and validity of VPT which 
like all psychophysical tests relies on standardization and the participant’s concentration and 
ability to detect a sensation. Whilst we show associations of DPN and pDPN with risk factors, 
the cross-sectional design of this study limits the predictive validity of these risk factors. 
In conclusion, this study has identified a lower prevalence of DPN and pDPN in PHC compared 
to SHC, which may be attributed to better overall risk factor control in PHC and referral bias 
due to patients who are poorly managed with complications being referred to SHC. 
Alarmingly, an equally high proportion approximately 80% of patients with DPN were 
undiagnosed in both PHC and SHC, highlighting the need for the National Diabetes Strategy 
to implement annual DPN screening. The identification of hyperglycemia, hyperlipidemia and 
hypertension as modifiable risk factors for DPN and obesity and physical activity as modifiable 
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risk factors of pDPN provide a robust argument to establish protocols for the early diagnosis 
and management of DPN and pDPN.  
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6.1 Abstract 
Introduction: Diabetic peripheral neuropathy (DPN) can lead to foot ulceration and 
amputation. There are currently no disease modifying therapies for DPN. Previous studies of 
blood pressure lowering therapy have shown an improvement in some but not other 
measures of DPN.  
Objectives: The aim of this study was to determine if hypertension contributes to DPN in 
patients with type 1 diabetes (T1D).  
Methods: Subjects with T1D (n=70) and controls (n=78) aged 18-85 years were recruited from 
the Manchester Diabetes Centre, Manchester Royal Infirmary and the NIHR Wellcome Trust 
Clinical Research Facility. Subjects underwent a comprehensive assessment of DPN.  
Results: Hypertension was present in 40/70 T1D subjects and 20/78 controls. Hypertension 
was associated with abnormal nerve conduction parameters (P=0.03-<0.001), increased 
vibration perception threshold (P=0.01) and reduced corneal nerve fiber density and length 
(P=0.02) in subjects with T1D. However, after adjusting for confounding factors only tibial 
compound motor action potential and nerve conduction velocity were associated with 
hypertension (P=0.03) and systolic blood pressure (P<0.01-<0.0001). Hypertension had no 
effect on neuropathy in subjects without diabetes. 
Conclusions: This study shows that hypertension is associated with impaired nerve 
conduction in T1D. It supports previous small trials showing that ACE inhibitors improve nerve 
conduction and advocates the need for larger clinical trials with blood pressure lowering 




There are currently no European Medicines Agency (EMA) and FDA approved treatments for 
diabetic peripheral neuropathy (DPN) (Pop-Busui et al., 2017). Whilst tight glycemic control is 
advocated for the treatment of DPN, it has only been shown to limit progression of 
neuropathy in patients with type 1 diabetes mellitus (T1D) and has shown no benefit in 
patients with type 2 diabetes mellitus (T2D) (Callaghan et al., 2012). However, clinical and 
experimental studies suggest that hypertension is an independent risk factor for DPN in 
patients with T1D (Tesfaye et al., 2005, Forrest et al., 1997, Cavusoglu et al., 2015, Elliott et 
al., 2009, Sanada et al., 2015, Gregory et al., 2012) and T2D (Cardoso et al., 2015, De Visser et 
al., 2014, Kesavamoorthy et al., 2015, Yang et al., 2015). In relation to the underlying 
pathophysiology, we have previously demonstrated loss of myogenic tone and vascular 
hypertrophy in resistance vessels of hypertensive patients with T2D (Schofield et al., 2002), 
with partial amelioration of these abnormalities after improved glycemic control (Greenstein 
et al., 2009) or treatment with the angiotensin-receptor blocker Candesartan (Malik et al., 
2005). 
Detailed preclinical studies suggest that hypertension predominantly affects the myelinated 
fibers. Hypertensive STZ rats with diabetes show myelinated fiber abnormalities (Sanada et 
al., 2015). Spontaneously hypertensive rats with diabetes show a reduction in sciatic nerve 
blood flow with a reduction in motor and sensory nerve conduction velocity and myelinated 
fiber density, but no loss of intraepidermal nerve fibers (Gregory et al., 2012). In a 
hypertensive T2D model, there was a reduction in sensory nerve conduction velocity and 
increased expression of matrix metalloproteinase at sites of myelin thinning (De Visser et al., 
2014). In non-diabetic hypertensive rats impaired epineurial arteriolar function was shown to 
contribute to reduced endoneurial perfusion and neuropathy (Yorek, 2015) as well as axonal 
atrophy and myelin splitting with endoneurial microangiopathy (Nukada et al., 2016). 
However, treatment with Fosinopril prevented the development and maintenance of tactile 
allodynia (Araiza-Saldana et al., 2015) and a combination of Enalapril, α-lipoic acid and 
menhaden oil improved thermal hypoalgesia, intraepidermal nerve fiber profiles and corneal 
sub-basal nerve fiber length in a normotensive T2D model (Davidson et al., 2015). These 
improvements were related to improved vascular relaxation to acetylcholine and calcitonin 
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gene-related peptide in sciatic nerve epineurial arterioles. Recently, sacubitril/valsartan, a 
combination drug containing a neprilysin inhibitor and angiotensin II receptor blocker has 
been shown to prevent and reverse nerve conduction and intraepidermal and corneal nerve 
abnormalities in type 2 diabetic rats (Davidson et al., 2018). 
We have shown that treatment of diabetic patients with the angiotensin converting enzyme 
(ACE) inhibitor Trandolapril, improved nerve conduction, but had no impact on neuropathic 
symptoms/deficits, vibration perception or autonomic function (Malik et al., 1998). Other 
studies have reported a significant improvement in nerve conduction, neuropathic symptoms 
and thermal thresholds in hypertensive patients with diabetes treated with an ACE inhibitor 
(Ruggenenti et al., 2011, Reja et al., 1995). Treatment of normotensive patients with DPN with 
the angiotensin-receptor blocker Losartan for 12 weeks did not show an improvement in NCS 
(Kubba et al., 2003). In the NATHAN-1 trial, patients treated with α-lipoic acid on ACE 
inhibitors showed improved heart rate variability (DB-HRV) (Ziegler et al., 2016). 
We have undertaken a detailed study to identify the impact of hypertension on both large 
and small fiber measures of DPN in patients with T1D. We believe this may explain the 
disparate results of previous studies assessing the benefits of blood pressure lowering agents 
on DPN. It also helps to identify the neuropathy endpoints which should be used to determine 
the efficacy of blood pressure lowering therapies in DPN. 
6.3 Methods 
Participants with type 1 diabetes mellitus (T1D) and controls without diabetes aged 18-85 
years were recruited from the Manchester Diabetes Centre, Manchester Royal Infirmary and 
the NIHR Wellcome Trust Clinical Research Facility. The study was performed at the NIHR 
Wellcome Trust Clinical Research Facility. 
Exclusion criteria included corneal trauma/ dystrophy, corneal surgery in the last 6 months, 
vitamin B12 deficiency, hypothyroidism, neuropathy from non-diabetic causes and diabetes or 
impaired glucose tolerance in the control group. This study was approved by the Local 
Research Ethics committee and all participants gave informed consent to take part in the 
study. The research adhered to the tenets of the declaration of Helsinki. 
6.3.1 Blood pressure measurement 
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Blood pressure (BP) was assessed in all participants on the non-dominant arm, assuring 
correct cuff size, with an automated device DINAMAP PRO 400 (Critikon, Florida, US) in the 
sitting position after 5 minutes rest on two occasions. Hypertension was defined according to 
either an average systolic blood pressure (SBP) ≥ 140 mmHg from two sets of measurement 
as described in the WHO/ISH Guidelines or if subjects were on anti-hypertensive treatment.  
6.3.2 Clinical measures 
All participants underwent assessment of body mass index (BMI), glycated haemoglobin 
(HbA1c), cholesterol and triglycerides. 
6.3.3 Neuropathy and neuropathic pain assessment 
DPN was diagnosed according to the criteria established by the Toronto Diabetic Neuropathy 
Expert Group (Tesfaye et al., 2010) These criteria include neuropathy symptoms or 
neuropathy signs and an abnormality of nerve conduction studies (NCS) or a validated 
measure of small fiber neuropathy (corneal nerve fiber length) (Petropoulos et al., 2013a, 
Chen et al., 2015). The assessments were performed by different researchers who were 
blinded to subject group and the researchers were acting independently, with no exchange 
of results during the study. 
Neuropathic symptoms were assessed using the DNS score (Meijer et al., 2002), a four-item 
validated symptom score for symptoms of unsteadiness in walking, neuropathic pain, 
paraesthesia, and numbness, giving a maximum score of 4 points, with a score of  1 defining 
the presence of neuropathic symptoms. Neuropathy signs were defined using the NDS (Young 
et al., 1993) that includes examination of vibration perception using a 128-Hz tuning fork, pin-
prick on the tip of the large toe, temperature perceptions in the dorsum of the feet, and the 
presence or absence of ankle reflexes. Subjects scoring > 2/10 were considered to have signs 
of neuropathy. 
Neuropathic pain was defined by a combination of deficits with an NDS score >2 and the 
presence of painful symptoms using the McGill Pain Questionnaire to assess the type of pain 
using descriptors such as throbbing, shooting, distressing, excruciating etc. (Melzack, 1975). 
6.3.4 Corneal Confocal Microscopy 
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Participants underwent examination with the Heidelberg Retina Tomograph (HRT III RCM) in 
vivo corneal confocal microscope (Heidelberg Engineering GmbH, Heidelberg, Germany) using 
our established methodology (Petropoulos et al., 2013c). Three CCM images from the sub-
basal nerve plexus in the central cornea were captured per eye. Corneal nerve fiber density 
(CNFD), number of main nerve fibers per mm2 (no./mm2), branch density (CNBD), number of 
nerve branches per mm2 (no./mm2), and fiber length (CNFL), length of nerve fibers per mm2 
(mm/mm2) were quantified manually using CCMetrics, a validated image analysis software 
(Petropoulos et al., 2013c). The cut-off values of CNFD (≥19 no./mm2), CNBD (≥42 no./mm2) 
and CNFL (≥16 mm/mm2) were based on the study by Petropoulos et al. 2014 that assessed 
the validity of CCM in diagnosing DPN (Petropoulos et al., 2014). 
6.3.5 Intraepidermal Nerve Fiber Density 
A 3 mm punch skin biopsy was taken from the dorsum of the foot under 1% lidocaine local 
anaesthesia. Skin samples were immediately fixed in 4% (wt/vol.) paraformaldehyde for 24 
hours and then cryoprotected in sucrose, frozen and cut into 50 𝜇m sections. 
Immunohistochemistry was performed as previously described (Azmi et al., 2015). A Zeiss 
AxioImager M2 microscope (Carl Zeiss, Jena, Germany) was used to quantify intra epidermal 
nerve fiber density (IENFD), which is the total number of nerve fibers per millimetre length of 
epidermis (no./mm), in accordance with established criteria (Lauria et al., 2010b). 
6.3.6 Autonomic neuropathy 
Cardiovascular autonomic neuropathy (CAN) was evaluated using the ANX 3.0 autonomic 
nervous system monitoring device (ANSAR Medical Technologies Inc. Philadelphia, US) (Orlov 
et al., 2012). Deep Breathing-Heart Rate Variability (DB-HRV) was assessed by R-R interval 
variation via surface electrodes over 1 minute at a frequency of 6 breaths/minute. 
Peripheral autonomic dysfunction was assessed using the Neuropad (Miro Verbandstoffe, 
Wiehl-Drabenderhöhe, Germany) applied to the plantar aspect of the 1st metatarsal head for 
10 minutes, followed by quantification of the percentage colour change of the Neuropad.  
6.3.7 Quantitative sensory testing 
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Quantitative sensory testing (QST) included measurement of vibration perception threshold 
(VPT) on the tip of the large toe using the Neurothesiometer (Horwell, Scientific Laboratory 
Supplies, Nottingham, UK) and warm and cold perception thresholds (WPT & CPT) on the 
dorsum of the left foot using the method of limits with the MEDOC TSA II (Medoc Ltd. Ramat 
Yishai 30095, Israel). 
6.3.8 Nerve conduction 
Electrodiagnostic studies were undertaken using a Dantec “Keypoint” system (Dantec 
Dynamics Ltd. Bristol, UK) equipped with a DISA temperature regulator to keep lower limb 
temperature constantly between 32 and 35oC. Sural sensory nerve action potential (SNAP), 
sural nerve conduction velocity (SNCV), tibial compound motor action potential (TCMAP), 
tibial motor nerve conduction velocity (TMNCV), peroneal compound motor action potential 
(PCMAP) and peroneal motor nerve conduction velocity (PMNCV) were assessed in the right 
lower limb by a consultant neurophysiologist. Sural sensory responses were measured using 
a bipolar bar electrode (inter-electrode distance 3 cm) attached over the sural nerve at the 
lateral malleolus. Stimulation was performed 140 mm proximal to the active recording 
electrode in the calf. Abnormal nerve conduction was defined based on two abnormal nerve 
conduction velocities of either SNCV, TMNCV or PMNCV. The cut-off values of the nerve 
conduction velocities were defined on the - 2SD from the mean based on our control 
population. 
6.3.9 Statistical analysis 
The sample size needed to detect significant differences in CCM and NCS between the groups 
was calculated from our previously published data (Chen et al., 2015). Given a reported 
difference in population means of 8 no./mm2 for CNFD and 5 m/s for PMNCV, estimated 
standard deviation for within group differences of 7 for CNFD and 3 for PMNCV, and aiming 
for a study power of 80% and an alpha of 0.05, we estimated that ~17 participants for each 
group would be needed to conduct this study. 
Differences between normotensive and hypertensive groups in continuous variables were 
compared using unpaired  t-test or categorical variables when the distribution had skewness 
of < -1 or > 1 with Mann-Whitney test. Categorical variables were compared using chi-square 
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or Fisher’s exact test (when sizes were less than 5). Data are expressed, based on the scale of 
measurements, as mean [standard deviation (SD)] or frequency distribution. This analysis was 
done separately for the control group and the diabetic group. The analysis was performed 
using StatsDirect version 3.0. 
The above analysis was repeated while adjusting for baseline imbalances between the two 
groups (normotensive and hypertensive) using multiple linear regression analysis for 
continuous variables and multiple logistic regression analysis for categorical variables. 
Assumptions of linear regression were satisfied for normality, collinearity and outliers. 
Additionally, residual plots were used to determine for linearity, normality, constant variance 
and independence. Finally, a multiple linear regression model was created to test the 
association between SPB and neuropathy measures adjusting for potential confounders. The 
analysis was performed using SPSS (version 23; SPSS Inc, Chicago). 
A two-tailed P value of ≤0.05 was considered significant. 
6.4 Results 
6.4.1 Clinical data (Table 6.1) 
The demographic and clinical characteristics are summarized in Table 6.1. 58 normotensive 
controls, 20 hypertensive controls, 30 normotensive and 40 hypertensive T1D participants 
were studied. All four groups had comparable age and gender. The duration of diabetes was 
comparable between hypertensive and normotensive T1D participants. Both systolic (SBP) 
and diastolic blood pressure (DBP) were significantly higher in the hypertensive controls 
(151.35±12.17 mmHg vs 121.58±12.63 mmHg, P<0.0001 and 82.15±9.75 vs 70.54±8.19 
mmHg, P<0.0001) and subjects with T1D (142.58±17.74 mmHg vs 117.89±10.19 mmHg, 
P<0.0001 and 74.08±9.83 vs 67.68±8.10 mmHg, P<0.01) compared to normotensive controls 
and subjects with T1D, respectively. Hypertensive controls had significantly higher cholesterol 
levels compared to normotensive controls (5.54 ±0.75 mmol/l vs 4.98 ±0.79 mmol/l, P=0.01), 
but HbA1c, triglycerides and BMI were comparable. Hypertensive T1D participants had 
significantly higher triglycerides (1.39 ±0.73 mmol/l vs 0.95 ±0.53 mmol/l, P<0.01) and BMI 
(27.71 ±3.70 Kg/m2 vs 25.55 ±4.12 Kg/m2, P<0.05) compared to normotensive T1D 
participants, but HbA1c and cholesterol were comparable.  
78 
 
Table 6.1. Demographic characteristics of the study population. 
 
Control 
P value  
T1D 
P value Normotensive Hypertensive Normotensive Hypertensive 
n 58 20   30 40  
Age, years 47.84±11.91 53.35±13.40 NS  44.19±11.11 49.52±12.19 NS 
Gender (F, M), n 29 29 10 10 NS  16 14 13 27 NS 
SBP, mmHg 121.58±12.63 151.35±12.17 <0.0001  117.89±10.19 142.58±17.74 <0.0001 
DBP, mmHg 70.54±8.19 82.15±9.75 <0.0001  67.68±8.10 74.08±9.83 <0.01 
Diabetes duration, years N/A N/A   27.23 ±12.89 31.63±15.95 NS 
HbA1c, % 5.63±0.34 5.58±0.33 NS  7.89±1.86 8.30±1.40 
NS  HbA1c, mmol/l 38.06±3.72 37.31±3.57   66.53±14.86 67.24±15.35 
Chol. mmol/l 4.98±0.79 5.54±0.75 0.01  4.40±0.88 4.24±0.90 NS 
Trig. mmol/l 1.42±0.74 1.70±0.73 NS  0.95±0.53 1.39±0.73 <0.01 
BMI, Kg/m2 26.72±4.84 29.01±4.46 NS  25.55±4.12 27.71±3.70 <0.05 
 
Comparing the characteristics between normotensive vs hypertensive control subjects, and normotensive vs 
hypertensive T1D subjects. Values presented as mean ±standard deviation unless otherwise stated. Unpaired t-
test was applied to assess for parametric data. Abbreviations: SBP=systolic blood pressure, DBP=diastolic blood 
pressure. 
6.4.2 Neuropathy and neuropathic pain (Table 6.2) 
The neuropathy findings between normotensive and hypertensive subjects in the T1D and 
control group are summarized in Table 6.2. The prevalence of DPN (53.8% vs 51.7%) and 
painful DPN (38.5% vs 23.3%) were comparable between patients with T1D with and without 
hypertension, respectively. There were no difference in the prevalence of DPN (10.0% vs 









P value* T1D P value/ 
P value* Normotensive Hypertensive  Normotensive Hypertensive 
n 58 20  30 40  
Neuropathy, n (%) 4 (7.0) 2 (10.0) NS/NS 15 (51.7) 21 (53.8) NS/NS 
Neuropathic pain, n (%) 1 (1.8) 1 (5.3) NS/NS 7 (23.3) 15 (38.5) NS/NS 
Nerve fiber morphology      
CNFD, no./mm2 36.99±6.39 35.42±6.69 NS/NS 27.61±7.60 22.04±10.33 0.02/NS 
CNBD, no./mm2 90.95±40.35 84.07±28.65 NS/NS 60.80±30.55 46.83±31.86 NS/NS 
CNFL, mm/mm2 25.99±5.50 25.26±5.10 NS/NS 20.28±5.58 16.40±6.83 0.02/NS 
IENFD, no./mm 9.49±4.21 10.17±1.76 NS/NS 6.89±4.43 5.12±3.77 NS/NS 
Autonomic neuropathy      
HRV-DB, beats/minute 28.88±12.60 27.89±10.97 NS/NS 25.49±10.68 20.11±10.58 NS/NS 
Neuropad, % 84.33±23.16 89.25±14.38 NS/NS 76.46±28.71 70.92±34.31 NS/NS 
Quantitative sensory testings      
VPT, V 6.24±5.11 7.27±5.40 NS/NS 9.40±7.04 15.37±11.38 0.01*/NS 
CPT, oC 28.43±2.06 27.49±2.13 NS/NS 24.51±6.66 25.37±4.50 NS/0.02 
WPT, oC 37.34±3.32 36.63±2.13 NS/NS 39.62±4.06 40.59±4.37 NS/NS 
Nerve conduction      
SNAP, µV 20.82±10.43 14.87±6.92 0.01/NS 11.33±7.31 6.95±6.75 0.01/NS 
SNCV, m/s 51.08±4.81 49.49±4.07 NS/NS 41.98±10.31 39.63±7.84 NS/NS 
TCMAP, mV 12.69±4.18 10.92±4.19 NS/NS 10.87±4.10 6.38±4.62 <0.001/0.03 
TMNCV, m/s 48.96±3.20 48.57±3.95 NS/NS 44.92±4.08 39.39±5.82 <0.001/0.03 
PCMAP, mV 5.12±2.04 4.66±2.22 NS/NS 3.76±2.20 2.56±2.06 0.03/NS 
PMNCV, m/s 49.03±3.63 47.00±4.02 NS/NS 41.87±6.93 39.06±6.52 NS/NS 
 
Characteristics of normotensive vs hypertensive control subjects, and normotensive vs hypertensive T1D 
subjects. Values presented as mean ±standard deviation unless otherwise stated. Unpaired t-test was applied 
to assess parametric data. (*) Mann-Whitney test was applied to assess non-parametric data. P value* were 
adjusted for baseline imbalances in each group according to table 6.1. Abbreviations: CNFD=corneal nerve fiber 
density, CNBD=corneal nerve branch density and CNFL=corneal nerve fiber length, IENFD=intra-epidermal nerve 
fiber density, HRV-DB =heart rate variability with deep breathing, VPT=vibration perception threshold, CPT=cold 
perception threshold, WPT=warm perception threshold, SNAP=sural sensory nerve action potential, SNCV=sural 
nerve conduction velocity, TCMAP=tibial compound motor action potential, TMNCV=tibial motor nerve 
conduction velocity, PCMAP=peroneal compound motor action potential and PMNCV=peroneal motor nerve 
conduction velocity.  
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6.4.3 Corneal and intra epidermal nerve fiber morphology 
The T1D group with hypertension had a significantly lower CNFD (22.04 [SD 10.33] no./mm2 
vs 27.61 ± 7.60 no./mm2, P=0.02) and CNFL (16.40 ± 6.83 mm/mm2 vs 20.28 ± 5.58 mm/mm2, 
P=0.02) compared to the normotensive group. However, these significant differences were 
lost after adjusting for age, gender, triglycerides and BMI. There was no difference in CNBD 
(46.83 ± 31.86 vs 60.80 ± 30.55 no./mm2) and intra epidermal nerve fiber density (IENFD) 
(5.12 ± 3.77 vs 6.89 ± 4.43 no./mm2) between the normotensive and hypertensive T1D groups 
(Table 6.2, Figure 6.1 and 6.2). CNFD, CNBD, CNFL and IENFD were comparable between the 
normotensive and hypertensive control groups. 
Figure 6.1. Corneal confocal microscopy (CCM) images of the sub-basal nerve plexus in a normotensive control 
(A), hypertensive control (B) showing normal corneal nerve morphology and a normotensive T1D patient (C) and 




Figure 6.2. Corneal nerve morphology in normotensive controls (blue), hypertensive controls (red), 
normotensive T1D participants (green) and hypertensive T1D participants (purple). Box plots of corneal nerve 
fiber density (CNFD), corneal nerve branch density (CNBD) and corneal nerve fiber length (CNFL). The line in the 
middle of the boxes represents the median and the boxes extend from the 25th to 75th percentiles. The whiskers 
extend from the highest to the lowest value. Significant differences between the groups were expressed as 
*P≤0.01 and *** P< 0.0001. 
6.4.4 Autonomic neuropathy 
There were no differences in deep breathing heart rate variability (DB-HRV) and Neuropad 
response between the T1D and control participants with and without hypertension. 
6.4.5 Quantitative sensory testing (QST) 
Vibration perception threshold (VPT) was significantly higher in hypertensive (15.37 ± 11.38 
compared to normotensive (9.40 ± 7.04 V, P=0.01) patients with T1D, but the difference was 
no longer significant after adjusting for age, gender, triglycerides and BMI. The cold (CPT) and 
warm perception threshold (WPT) were comparable. However, after adjusting for baseline 
imbalances the CPT was significantly higher in the hypertensive group (P=0.02). There were 





6.4.6 Nerve conduction studies 
T1D patients with hypertension had a significantly lower sural sensory nerve action potential 
(SNAP) (6.95 ± 6.75 µV vs 11.33 ± 7.31 µV, P=0.01), tibial compound motor action potential 
(TCMAP) (6.38 ± 4.62 mV vs 10.87 ± 4.10 mV, P<0.001), tibial motor nerve conduction velocity 
(TMNCV) (39.39 ± 5.82 m/s vs 44.92 ± 4.08 m/s, P<0.001) and peroneal compound motor 
action potential (PCMAP) (2.56 ± 2.06 mV vs 3.76 ± 2.20 mV, P=0.03). However, after adjusting 
for age, gender, triglycerides and BMI the differences were no longer significant apart from 
TCMAP and TMNCV. Sural nerve conduction velocity (SNCV) (39.63 ± 7.84 m/s vs 41.98 ± 10.31 
m/s) and peroneal motor nerve conduction velocity (PMNCV) (39.06 ± 6.52 m/s vs 41.87 ± 
6.93 m/s) were comparable between the two subgroups. In the control group, only SNAP 
(14.87 ± 6.92 µV vs 21.82 ± 10.43 µV, P=0.01) was lower in the hypertensive compared to the 
normotensive group but the difference was no longer significant after adjusting for age, 
gender and cholesterol and SNCV, TCMAP, TMNCV, PCMAP and PMNCV were comparable.  
6.4.7 Association between neuropathy and systolic blood pressure (Table 6.3) 
Simple linear regression analysis shows that all measures of DPN including CNFD, CNFL, HRV, 
SNAP, SNCV, TCMAP, TMNCV, PCMAP, PMNCV and VPT were associated with SBP in patients 
with T1D. However, after adjusting for confounding factors including age, gender, duration of 
diabetes, HbA1c, cholesterol, triglyceride and BMI, multiple linear regression analysis showed 
that only TCMAP (β=-1.12, P<0.0001, Cohen’s d = 1.09) and TMNCV (β=-0.10, P<0.01, Cohen’s 
d = 1.10) were independently associated with SBP (Table 6.3).  
In the control group, simple linear regression analysis showed that all nerve conduction 
parameters apart from PCMAP were associated with systolic BP. However, after adjusting for 




Table 6.3. Multiple linear regression analysis showing the association between measures of neuropathy and 
systolic blood pressure in subjects with T1D after adjusting for confounding factors. 
 
Coefficient 95% Confidence 
Interval 
P value 
Corneal nerve morphology 
CNFD  -0.09 -0.20 to 0.02 NS 
CNFL  -0.08 -0.16 to 0.003 NS 
Cardiac autonomic neuropathy 
HRV -0.02 -0.15 to 0.11 NS 
Quantitative sensory testing 
VPT 0.08 -0.03 to 0.19 NS 
Nerve conduction (NC) 
SNAP -0.05 -0.13 to 0.03 NS 
SNCV -0.1 -0.21 to 0.02 NS 
TCMAP -0.12 -1.17 to -0.07 <0.0001 
TMNCV -0.10 -0.16 to -0.03 <0.01 
PCMAP -0.01 -0.04 to 0.01 NS 
PMNCV 0.003 -0.08 to 0.08 NS 
Variables affecting diabetic neuropathy were considered in the fitted model with a P value ≤0.05. 
6.5 Discussion 
This study shows that DPN is associated with hypertension and raised systolic blood pressure 
in T1D. It also shows that the association of hypertension with DPN measures varied between 
small and large fibers. This might explain as to why previous studies of blood pressure 
lowering therapy have shown an improvement in some but not other measures of diabetic 
neuropathy, although other factors including severity of DPN, diabetes duration, different 
measures of DPN or type of study could have contributed to conflicting results. We show that 
hypertension worsens deficits in NCS and vibration perception in subjects with T1D, indicating 
an abnormality of large nerve fibers, but is also associated with loss of corneal nerve fibers 
using CCM. This is clinically relevant as small nerve fibers are the earliest to be damaged and 
underlie the pathogenesis of foot ulceration (Breiner et al., 2014, Quattrini et al., 2007b, 
Quattrini et al., 2007a) and painful diabetic peripheral neuropathy (DPN) (Haanpaa et al., 
2011). However, after adjusting for baseline imbalances including age, gender, triglyceride 
and BMI, only tibial compound motor action potential and motor nerve conduction velocity 
were affected by hypertension. Similarly, after adjusting for confounding factors including 
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age, gender, duration of diabetes, HbA1c, cholesterol, triglyceride and BMI, multiple linear 
regression analysis showed that only TCMAP and TMNCV remained independently associated 
with systolic blood pressure.  
Given that there are no disease modifying therapies for DPN, this encourages the need for 
clinical trials of blood pressure lowering agents in DPN and provides direction for the 
endpoints which should be utilised in these trials. Both clinical and experimental studies have 
shown that treatment with an ACE inhibitor leads to an improvement in NCS (Malik et al., 
1998, Ruggenenti et al., 2011, Reja et al., 1995, Davidson et al., 2015), but has no impact on 
symptoms, deficits, VPT or autonomic function. Indeed, we show that hypertension does not 
influence neuropathic symptoms or thermal thresholds, and therefore may not change. 
Istenes et al. (Istenes et al., 2008) reported an association between hypertension and cardiac 
autonomic neuropathy (CAN) in T2D, which is associated with silent myocardial ischemia, 
cardiac arrhythmias and cardio-respiratory instability (Vinik et al., 2003, Ziegler, 1994). In a 
study of T1D and T2D patients with CAN, 12 months of treatment with Quinapril, Losartan or 
a combination of both showed an improvement in CAN (Didangelos et al., 2006). However, in 
the present study we show a limited association between deep breathing heart rate variability 
(DB-HRV) and systolic blood pressure, which was lost after adjusting for age, gender, duration 
of diabetes, triglycerides and BMI. Additionally, there was no effect of hypertension on 
sudomotor dysfunction.  
Limitations of this study include the use of a single as opposed to cumulative burden of blood 
pressure and glucose control on DPN and the relatively small numbers of subjects studied. 
We acknowledge that a cross-sectional study showing an association between hypertension 
and nerve conduction cannot imply cause and effect. However, a major strength of this study 
is the homogeneity of age, gender and duration of diabetes as well as the detailed neuropathy 
assessments, which have enabled us to identify the exact associations between hypertension 
and specific measures of neuropathy. It provides an explanation as to why some studies 
assessing the effect of blood pressure treatment have been positive, whist others have been 
negative, depending on the measures chosen to assess DPN.  
This study shows that hypertension is associated with nerve conduction abnormalities in T1D 
but has no impact in subjects without diabetes. It also shows that the detrimental impact of 
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T1D on DPN may be mediated by hypertension on the myelinated fibers and by a number of 
metabolic risk factors including hyperglycemia, high triglycerides and obesity affecting the 
small fibers. These data suggest that nerve conduction studies should be used as the primary 
endpoints in clinical trials assessing the benefits of blood pressure lowering therapy on 
diabetic neuropathy. 
6.6 Acknowledgements 
We thank the staff at NIHR/Wellcome Trust Clinical Research Facility in Central Manchester 
University Hospitals NHS Foundation Trust and its Deputy Director, Mr. Paul Brown for 
providing a high-quality service and access to their state-of-the-art facilities to carry out the 
research. We thank Mitra Tavakoli for undertaking corneal confocal microscopy and Hassan 
Fadavi for neuropathy assessment, in a proportion of the subjects. Special thank you to the 
Nurse Manager, Ciaran Kilkelly and the study Lead Nurse, Stephen Mawn and Kamlesh Patel 
for their professional and helpful support in undertaking this study. 
6.7 Funding 
This study was funded by the National Institute of Health (NIH) Grant 5RO1 NS46259-03 




Chapter 7: Metformin use is not associated with B12 deficiency or 
neuropathy in patients with Type 2 Diabetes in Qatar 
Authors: Elhadd T, Ponirakis G, Dabbous Z, Siddique M, Chinnaiyan S, Malik R.A. Frontiers of 
Endocrinology. 2018 May 25;9:248. DOI: 10.3389/fendo.2018.00248 
7.1 Abstract 
Introduction: Metformin may lead to B12 deficiency and neuropathy. There are no published 
data on the prevalence of metformin related B12 deficiency and neuropathy in the Arabian 
Gulf. 
Objectives: Determine whether metformin intake is associated with B12 deficiency and 
whether B12 deficiency is associated with diabetic peripheral neuropathy (DPN) and painful 
diabetic neuropathy. 
Methods: Patients with Type 2 Diabetes (T2D) (n=362) attending outpatient clinics at HMC 
underwent assessment of B12 levels, the DN4 questionnaire, and vibration perception 
threshold (VPT).  
Results: Comparing metformin to non-metformin users there were no differences in B12 
levels, VPT or DN4. The prevalence of B12 deficiency (B12 < 133 pmol/l) was lower (P<0.01) in 
metformin (8%) compared to non-metformin (19%) users. Patients with B12 deficiency had a 
comparable prevalence and severity of sensory neuropathy and painful neuropathy to 
patients without B12 deficiency.  
Conclusion: Serum B12 levels were comparable between metformin and non-metformin users 
with T2D in Qatar. T2D patients on metformin had a lower prevalence of B12 deficiency. 
Furthermore, the prevalence and severity of neuropathy and painful diabetic neuropathy 




Metformin remains first-line therapy in Type 2 Diabetes (T2D), with around 120 million users 
worldwide. It is increasingly used in overweight T2D patients and those with polycystic ovary 
syndrome (Viollet et al., 2012). Most international guidelines recommend metformin after 
lifestyle measures for T2D patients.  
Metformin therapy was shown to be associated with a significant reduction in the level of 
vitamin B12 over 50 years ago (Berchtold et al., 1969, Tomkin et al., 1971). A number of 
observational and placebo-controlled studies have confirmed that metformin may reduce 
vitamin B12 levels (DeFronzo and Goodman, 1995, de Jager et al., 2010, de Groot-Kamphuis 
et al., 2013, Aroda et al., 2016, Kang et al., 2014, Reinstatler et al., 2012, Damiao et al., 2016). 
Indeed a recent study from Pakistan found that 29.7% of patients on metformin had B12 
deficiency (Khan et al., 2017) and another study from Brazil showed that B12 deficiency 
occurred in 22.4% of patients with T2D on metformin, and was further reduced in those on 
PPI/H2-antagonists (Damiao et al., 2016). However, a recent meta-analysis showed that 10/17 
studies found that metformin use led to B12 deficiency and in four prospective studies B12 was 
reduced by approximately 57pmol/L, within 6 weeks to 3 months of commencing metformin 
(Chapman et al., 2016).  
A potential consequence of B12 deficiency is that it could directly result in neuropathy or 
exacerbate diabetic neuropathy. Indeed, the recent 2017 ADA position statement on diabetic 
neuropathy has emphasized the importance of excluding B12 deficiency in patients with 
diabetic neuropathy (Pop-Busui et al., 2017). However, there are conflicting reports on the 
association between metformin induced B12 deficiency and neuropathy, with some reports 
showing an association (Singh et al., 2013, Roy et al., 2016) whilst others have refuted this 
(Khan et al., 2017, Russo et al., 2016, Ahmed et al., 2016, Ma et al., 2015). Furthermore, in a 
recent study from Turkey, whilst the prevalence of B12 deficiency was 38.4% there was no 
difference in B12 levels in those with and without neuropathy (Olt and Oznas, 2017). Despite 
this there is wide spread administration of vitamin B12 therapy in patients in the Middle East 
and Far East, with a recent analysis from 5 teaching hospitals in Jordan, indicating that 
cyanocobalamin (B12), was the 2nd most common injectable therapy after insulin (Al-Azayzih 
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et al., 2017). There are no published data on metformin related B12 deficiency or the 
relationship between B12 deficiency and diabetic neuropathy in the MENA region. 
We have compared vitamin B12 levels in outpatients with T2D in Qatar, in relation to 
metformin use and further assessed for the prevalence and severity of painful neuropathy 
and sensory neuropathy in patients with B12 deficiency. 
7.3 Materials and Methods 
Participants with T2D (n=362) were recruited from the National Diabetes & Endocrine Centers 
in Al-Wakra Hospital and Hamad General Hospital. The study was performed between 6th 
March 2017 and 28th September 2017. 
Exclusion criteria included patients with a prior history of pernicious anemia, chronic kidney 
disease, previous bariatric surgery, gastrectomy or small bowel resection for inflammatory 
bowel disease. This study was approved by the Institutional Review Board (IRB) of WCM-Q 
and HMC and all participants gave informed consent to take part in the study. The research 
adhered to the tenets of the declaration of Helsinki. 
7.3.1 Demographic and blood measures 
Data including age, duration of diabetes, blood pressure, body mass index (BMI) and 
medications including metformin were recorded. HbA1c, lipid profile, renal function and 
serum B12 were assessed. 
7.3.2 B12 assay 
Blood was drawn directly into a dedicated evacuated tube (BD Diagnostic – Preanalytical 
Systems, Oxford, UK) and centrifuged at 3500g for 10 minutes and serum analysed 
immediately or stored at -20 degrees centigrade until analysis on Beckman Dxi 600 (Beckman 
Coulter Inc, Brea, CA USA). The Vitamin B12 assay is a competitive-binding immunoenzymatic 
assay. The amount of analyte in the sample was determined by means of a stored, multipoint 
calibration curve (Beckman Coulter Assay Manual 2015, Beckman Coulter Inc, Brea, CA). 
Analytical Sensitivity <50 pg/ml, traceability; traceable to an internal standard manufactured 
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using the purified cyanocobalamin. Assay precision: 4.8 – 11.4%. B12 levels <133 pmol/l were 
considered deficient. 
7.3.3 Diabetic peripheral neuropathy assessment 
Vibration perception threshold (VPT) was measured on the pulp of the large toe with a 
Neurothesiometer (Horwell, Scientific Laboratory Supplies, Wilford, Nottingham, UK). The 
test was repeated three times and the average value was recorded. VPT at a cut-off point ≥ 
15 V was defined as diabetic peripheral neuropathy (DPN) (Wiles et al., 1991). 
7.3.4 Neuropathic pain assessment 
The Douleur Neuropathique en 4 questions (DN4) also known as the Neuropathic Pain 
Diagnostic Questionnaire was used to identify neuropathic pain (Harifi et al., 2011, Spallone 
et al., 2012). The DN4 is comprised of 10 questions (7 symptoms and 3 signs) and a score ≥4 
identifies neuropathic pain with high sensitivity (83%) and specificity (90%) (Unal-Cevik et al., 
2010). 
7.3.5 Statistical analysis 
Variables were compared between groups using a t-test and chi-squared test for continuous 
and categorical data, respectively. Data are expressed as mean [standard deviation (SD)] of 
mean.  
Univariate analysis by simple linear regression was applied to determine which variables are 
associated with B12 levels, VPT and DN4 as outcome measures. Multiple linear regression 
analysis was used to determine the association between B12 levels, VPT and DN4 after 
adjusting for confounding factors. Residual plots were used to determine for linearity, 
normality, constant variance and independence.  





Age, systolic (SBP), BMI, HbA1c, triglycerides, HDL and B12 levels were comparable between 
metformin (n=235) and non-metformin users (n=64). Metformin users had a shorter duration 
of diabetes (10.27 years ± 7.45 vs 12.89 years ± 8.89, P=0.03), but higher diastolic blood 
pressure (DBP) (77.72 mmHg ± 9.91 vs 74.52 mmHg ± 9.42, P=0.02), total cholesterol (4.48 
mmol/L ± 1.10 vs 4.15 ± 1.02 mmol/L, P=0.03) and LDL (2.56 ± 0.88 mmol/L vs 2.30 ± 0.82 
mmol/L, P=0.04). B12 levels were comparable between metformin and non-metformin users 
(P=0.87). However, the prevalence of B12 deficiency was lower in metformin (8%) compared 
to non-metformin (19%) users, P<0.01.  
The prevalence of neuropathy (30% vs 39%) and neuropathic pain (31% vs 33%) were 
comparable between metformin and non-metformin users, respectively. The proportion of 
patients taking medications, which could influence B12 levels, including proton pump 
inhibitors (PPI), calcium supplements, multivitamins, B12 supplements and sulfonylureas were 
comparable between metformin and non-metformin users (Table 7.1).  
Of the 362 T2D patients, 32 (8.8%) fulfilled the criteria for B12 deficiency (serum B12 <133 
pmol/l). However, in those with B12 deficiency, the percentage taking metformin was 
significantly lower than in those without B12 deficiency (60% vs 80%, P=0.03). Patients with 
B12 deficiency were significantly younger (49.16 years ± 9.72 vs 54.56 years ± 12.71, P =0.01) 
and had a shorter duration of diabetes (7.03 years ± 5.39 vs 11.68 years ± 7.89, P <0.001), but 
comparable SBP, DBP, BMI, HbA1c, cholesterol, triglycerides, HDL and LDL. The prevalence 
and severity of neuropathy and neuropathic pain was comparable between those with and 




Table 7.1. Comparison of demographic and clinical characteristics between non-metformin users and metformin 
users.  
 
Data are presented as mean SD unless otherwise stated. Unpaired t- and χ2 test were applied to compare 
continuous and categorical data, respectively between the groups. Abbreviations: SBP=systolic blood pressure, 
DBP=diastolic blood pressure, VPT=vibration perception threshold, DN4=Neuropathic Pain Diagnostic 
Questionnaire. 
  






Age (years) 52.67 (13.95) 54.19 (11.61) 0.43 
Diabetes duration (years) 12.89 (8.89) 10.27 (7.45) 0.03 
SBP (mmHg) 128.88 (18.37) 130.23 (18.72) 0.61 
DBP (mmHg) 74.52 (9.42) 77.72 (9.91) 0.02 
BMI (kg/m2) 31.79 (7.47) 32.10 (7.70) 0.78 
HbA1c (%) 8.41 (2.22) 7.86 (1.89) 0.07 
Total Cholesterol (mmol/l) 4.15 (1.02) 4.48 (1.10) 0.03 
Triglycerides (mmol/l) 1.67 (1.12) 1.82 (1.14) 0.35 
HDL (mmol/l) 1.15 (0.52) 1.05 (0.29) 0.18 
LDL (mmol/l) 2.30 (0.82) 2.56 (0.88) 0.04 
B12 levels 
B12 deficiency (<133 pmol/l) (%) 19 8 <0.01 
B12 (pmol/l) 337.80 (280.34) 331.24 (247.61) 0.87 
Medications 
Protein pump inhibitor (%) 45.8 42.9 0.81 
Calcium supplements (%) 19.4 10.5 0.09 
Multivitamins supplements (%) 14.5 14.5 0.99 
Vitamin B supplements (%) 30.6 33.8 0.76 
Sulfonylurea (%) 29.4 37.9 0.26 
Neuropathy assessments 
Diabetic peripheral neuropathy (%) 39 30 0.21 
Vibration perception threshold (V) 14.75 (12.15) 12.22 (9.07) 0.30 
Neuropathic pain (%) 33 31 0.91 
DN4 3.13 (3.08) 2.89 (2.63) 0.58 
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Table 7.2. Comparison of demographic and clinical characteristics between those with (serum B12 <133 pmol/l) 
and without B12 deficiency. Data are presented as mean SD. Unpaired t- and X2 test were used to compare 
continuous and categorical data, respectively between the groups. Abbreviations: SBP=systolic blood pressure, 
DBP=diastolic blood pressure, VPT=vibration perception threshold, DN4=Neuropathic Pain Diagnostic 
Questionnaire. 
 
 B12 deficiency  
 Yes (n= 32) No (n= 330) P value 
Demographics 
Metformin (%) 60 80 0.03 
Age (years) 49.16 (9.72) 54.56 (12.71) 0.01 
Diabetes duration (years) 7.03 (5.39) 11.68 (7.89) <0.001 
SBP (mmHg) 127.42 (15.47) 131.22 (19.58) 0.21 
DBP (mmHg) 77.93 (11.32) 76.95 (9.72) 0.66 
BMI (kg/m2) 31.39 (6.48) 32.16 (7.60) 0.55 
HbA1c (%) 7.76 (1.97) 7.99 (1.92) 0.52 
Total Cholesterol (mmol/l) 4.30 (1.04) 4.47 (1.14) 0.39 
Triglycerides (mmol/l) 1.53 (0.91) 1.77 (1.07) 0.19 
HDL (mmol/l) 1.07 (0.41) 1.08 (0.34) 0.94 
LDL (mmol/l) 2.61 (0.84) 2.49 (0.87) 0.49 
Neuropathy assessments 
DPN (%) 32 33 0.85 
VPT (V) 11.87 (9.51) 12.65 (9.19) 0.62 
Neuropathic pain (%) 31 32 0.79 
DN4  2.47 (2.98) 3.04 (2.59) 0.27 
 
7.4.1 Association between vibration perception threshold, DN4 score and B12  
Simple linear regression analysis showed that VPT was positively associated with B12 (r=0.18 
P<0.001). However, multiple linear regression analysis showed that this association was lost 
(β=0.003, P=0.25) after adjustment for confounding factors including, age, diabetes duration, 
SBP, HbA1c, and PPI use. DN4 had no association with B12 levels. 
Simple linear regression analysis shows that B12 levels were not associated with the use of 
metformin, sulfonylurea or calcium supplementation, but were associated with age (r=0.15, 
P<0.01), duration of diabetes (r=0.16, P<0.01), HbA1c (r=0.11, P=0.05), vitamin D (r=0.17, 
P<0.01), PPI use (r=0.11, P<0.05), multivitamin use (r=0.11, P<0.05), and B12 supplementation 
(r=0.13, P<0.05). However, multiple linear regression analysis showed that B12 levels 
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maintained an association only with HbA1c (β=12.72, P=0.04) and vitamin D use (β=2.72, 
P=0.02), after adjustment for confounding factors.  
7.5 Discussion  
This is the first study from the Middle East region to assess the association between 
metformin exposure and B12 levels and its relationship to diabetic neuropathy. We show no 
difference in B12 levels between metformin and non-metformin users and actually show that 
the prevalence of B12 deficiency was lower in patients on metformin. This is in contrast to 
some but not all previously published studies (Chapman et al., 2016). Furthermore, we show 
no difference in the prevalence of diabetic peripheral neuropathy or painful diabetic 
neuropathy in T2D patients with and without B12 deficiency. 
The 2018 ADA Clinical Practice Recommendations endorse screening metformin users for 
vitamin B12 deficiency (American Diabetes, 2018) and the 2017 ADA diabetic neuropathy 
statement recommends that all patients with diabetic neuropathy should be assessed for B12 
deficiency, to exclude a treatable cause of neuropathy (Pop-Busui et al., 2017). However, 
previous studies examining the relationship between metformin use and B12 deficiency 
(Chapman et al., 2016); and indeed between B12 deficiency and neuropathy have been 
conflicting (Singh et al., 2013, Roy et al., 2016, Khan et al., 2017, Russo et al., 2016, Ahmed et 
al., 2016, Ma et al., 2015). Indeed, a study has shown a lower prevalence of DPN in T2D 
patients on metformin compared to those not on metformin (de Groot-Kamphuis et al., 
2013). Marwan et al (2016) used the Neuropathy Total Scoring System (NTSS) and showed 
that subjects with normal B12 levels had a comparable prevalence of DPN to those with low 
B12 levels (36.8% vs 32.3%), and no correlation between B12 levels and NTSS (Ahmed et al., 
2016). Russo et al. compared 79 subjects with DPN and 184 without DPN and found no 
relationship to metformin use (Russo et al., 2016). Chen et al. using a Neurothesiometer and 
monofilaments in addition to a structured questionnaire also showed no relationship 
between metformin use and peripheral neuropathy (Chen et al., 2012). In contrast Singh et 
al. showed that metformin users had lower levels of B12 and a higher Toronto Neuropathy 
Scoring System (Singh et al., 2013). Roy et al. (2016) showed that patients on metformin had 
a lower level of B12 and a reduction in Median, Ulnar and Peroneal nerve conduction (Roy et 
al., 2016). In the DPPOS study, whilst metformin was associated with an increased risk of B12 
94 
 
deficiency, only 13 of the 56 participants on metformin with low vitamin B12 had neuropathy, 
but there was no difference in neuropathy symptoms or the total Michigan Neuropathy 
Screening Instrument score (Aroda et al., 2016). A recent study from India has shown an 
association between metformin use and B12 levels as well as DPN assessed using the Toronto 
Clinical Scoring System and median, ulnar, peroneal and posterior tibial nerve conduction 
velocity (Gupta et al., 2017). 
Given that we showed a lower prevalence of B12 deficiency in patients taking metformin, we 
assessed confounding factors such as other medications, which may alter B12 levels. 
Sulphonylurea use in combination with metformin is a significant independent risk factor for 
B12 deficiency (Kang et al., 2014). B12 levels have also been reported to be lower in older adults 
with prolonged PPI and H2 blocker use in one study (den Elzen et al., 2008) but not in another 
study (Dharmarajan et al., 2008). Vitamin B supplementation is prevalent in the Middle East 
and may also influence B12 levels (El-Khateeb et al., 2014, Asiri and Al-Arifi, 2011). We show 
no association between B12 levels and concomitant use of sulphonylureas or calcium 
supplementations, but we do show small but significant associations with age, duration of 
diabetes, HbA1c and treatment with vitamin D, PPI’s, multivitamins and B12. 
This is the first study to assess the relationship between metformin use B12 deficiency and the 
prevalence and severity of DPN and diabetic painful neuropathy in Qatar. The prevalence of 
both sensory neuropathy and painful diabetic neuropathy was comparable to previously 
published data (Malik et al., 2017, Almuhannadi et al., 2018, Petropoulos et al., 2016). A 
limitation of the present study is that it is a retrospective cohort study, but VPT and DN4 were 
assessed without the investigators being aware of the treatment or B12 status. The majority 
of patients had been prescribed metformin as first line therapy in accord with international 
guidelines, unless they were intolerant or it was withdrawn (American Diabetes, 2018), and 
therefore it was not possible to recruit a larger number of patients not on metformin. We 
cannot establish the exact duration of metformin exposure, although we can assume that 
metformin was prescribed shortly after diagnosis and therefore exposure is approximately 
equivalent to the duration of diabetes, which was approximately 10 years. As noted in the 
meta-analysis of Chapman et al the B12 lowering effect of metformin occurs within 6 weeks to 
3 months of commencing metformin (Chapman et al., 2016).In future studies, it will be useful 
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to include methylmalonic acid (MMA) test to detect mild or early B12 deficiency. It will also 
be useful to account for other cofounders including dietary intake, ranitidine use and 
pernicious anemia to assess the association between metformin use and B12 deficiency. 
In conclusion, we show no difference in B12 levels or the severity of DPN or painful diabetic 
neuropathy in metformin compared to non-metformin users. We also show no difference in 
vibration perception or painful diabetic neuropathy in those with and without B12 deficiency. 
These data urge the need for further larger, prospective studies to confirm or refute the 
current findings to support or challenge the highly prevalent practice of prescribing B12 for 
neuropathy across the Middle East. 
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8.1 Abstract 
Introduction and objectives: To assess the effect of exenatide and pioglitazone or basal-bolus 
insulin on changes in diabetic peripheral neuropathy (DPN) measures in patients with poorly 
controlled type 2 diabetes (T2D). 
Methods: This is a sub-study of the Qatar Study, an open label, randomized controlled trial. 
38 subjects with poorly controlled T2D were studied at baseline and 1-year follow-up and 18 
control subjects were assessed at baseline only. A combination of exenatide (2 mg/week) and 
pioglitazone (30 mg/day) or glargine with Aspart insulin were randomly assigned to patients 
to achieve an HbA1c <53 mmol/mol (<7%). DPN was assessed with CCM, DN4, vibration 
perception and sudomotor function.  
Results: Subjects with T2D had reduced corneal nerve fiber density (CNFD), length (CNFL), 
and branch density (CNBD) but other DPN measures were comparable with the control group. 
In the combination treatment arm (n=21), HbA1c decreased by 35.2 mmol/mol (3.8 %) 
(P<0.0001), body weight increased by 5.6 Kg (P<0.0001), CNBD increased (P<0.05), vibration 
perception worsened (P<0.05), DN4 and sudomotor function showed no change. In the insulin 
treatment arm, HbA1c decreased by 28.7 mmol/mol (2.7 %) (P<0.0001), body weight 
increased by 4.6 Kg (P<0.01), CNBD and CNFL increased (P≤0.01), vibration perception 
improved (P<0.01), DN4 and sudomotor function showed no change. There was no 
association between the change in CCM measures with change in HbA1c, weight or lipids. 
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Conclusions: Treatment with exenatide and pioglitazone or basal-bolus insulin results in 
corneal nerve regeneration, but no change in neuropathic symptoms or sudomotor function 
over 1 year. 
Keywords: Diabetic neuropathy; exenatide; pioglitazone; insulin; corneal confocal 
microscopy; type 2 diabetes 
8.2 Introduction 
Diabetic peripheral neuropathy (DPN) affects approximately 50% of patients with diabetes 
leading to neuropathic pain, erectile dysfunction and foot ulcers and imposes a significant 
health and economic burden to both the patient and health care providers (Pop-Busui et al., 
2017). Whilst intensive glycemic control can prevent the onset or delay progression of DPN in 
type 1 diabetes (T1D) (Diabetes et al., 1993), there are conflicting data in type 2 diabetes 
(T2D) (Ohkubo et al., 1995, Ismail-Beigi et al., 2010, Pop-Busui et al., 2013, Azad et al., 1999, 
Callaghan et al., 2012, Maranta et al., 2020). Other cardiovascular risk factors, such as obesity 
(Schlesinger et al., 2019), hypertension (Ponirakis et al., 2019b), and hyperlipidemia (Tesfaye 
et al., 2005) are independently associated with DPN in T2D. Indeed, treatment with 
angiotensin converting enzyme (ACE) inhibitors (Malik et al., 1998, Reja et al., 1995) or statins 
(Davis et al., 2008, Villegas-Rivera et al., 2015) may have a beneficial effect on DPN. 
Both glucagon-like peptide 1 (GLP-1) receptor agonists (Kan et al., 2012, Himeno et al., 2011) 
and thiazolidinediones (TZDs) (Qiang et al., 1998, Pop-Busui et al., 2013, Yamagishi et al., 
2008, Wiggin et al., 2008) produce a durable reduction in HbA1c (Abdul-Ghani et al., 2017). 
GLP-1 receptor agonists stimulate insulin secretion in response to hyperglycemia, delay 
gastric emptying leading to weight loss and inhibit hepatic glucose secretion. In preclinical 
studies, exendin-4, a GLP-1 receptor agonist prevented sensory (Kan et al., 2012) and motor 
nerve conduction slowing (Himeno et al., 2011) and a reduction in intraepidermal nerve fiber 
density (IENFD) in T1D mice. However, twice daily exenatide, showed no effect on DPN in 
patients with T2D (Jaiswal et al., 2015). TZDs are potent insulin sensitizers and improve β-cell 
function. TZDs prevent nerve conduction slowing (Qiang et al., 1998), maintain myelinated 
fiber density, and reduce macrophage infiltration in the sciatic nerve (Yamagishi et al., 2008). 
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TZDs have been shown to reduce the incidence of DPN in patients with T2D (Pop-Busui et al., 
2013). 
There are currently no European Medicines Agency (EMA) and FDA approved therapies for 
DPN, despite multiple clinical trials. It has been suggested that the endpoints in these trials 
may not be sufficiently sensitive to detect a change in DPN (Malik, 2016). Several studies have 
provided support for the prevailing hypothesis that early subclinical small fiber injury 
precedes large fiber damage in DPN (Malik et al., 2011, Breiner et al., 2014). In this study, 
CCM was utilised to assess early small nerve fiber repair. Several longitudinal studies have 
shown that a lower corneal nerve fiber length (CNFL) at baseline predicts those patients who 
develop DPN (Pritchard et al., 2015, Lovblom et al., 2015, Edwards et al., 2017). CCM has also 
been used to identify early small fiber repair in several small clinical trials (Brines et al., 2015, 
Petropoulos et al., 2019). Indeed, CCM identified early corneal nerve regeneration 6 months 
after pancreas and kidney transplantation which was followed by an improvement in 
neuropathic symptoms and nerve conduction after 24 months (Tavakoli et al., 2013, Azmi et 
al., 2019b). 
The Qatar Study (Abdul-Ghani et al., 2017) is an open-label, randomized controlled trial, 
which showed a rapid and effective reduction in HbA1c after treatment with a combination 
of exenatide and pioglitazone or basal-bolus insulin in patients with poorly controlled T2D. 
This is a sub-study of the Qatar study designed to assess the effect of the two treatment arms 
on changes in DPN measures with CCM as the primary outcome measure and DN4, vibration 
perception threshold (VPT) and sudomotor function as secondary outcome measures. This 
study also evaluated the effect of the treatments on diabetic retinopathy. 
8.3 Materials and methods 
This is an exploratory prospective sub-study of the Qatar Study (Abdul-Ghani et al., 2017), an 
open-label, randomized controlled trial (clinicaltrials.gov identifier NCT02887625) designed 
to examine the efficacy of exenatide plus pioglitazone versus basal-bolus insulin in patients 
with poorly controlled T2D on metformin plus sulfonylurea. This sub-study was added as an 
amendment to the Qatar study nearer to the completion date for recruitment and hence, it 
was not registered in a publicly available clinical trial database. Subjects with T2D were 
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enrolled from the National Diabetes Center in Hamad General Hospital and studied at 
baseline and 1-year follow-up and control subjects without diabetes were enrolled from 
Rumailah Hospital and studied between October 2016 and November 2018.  
This study obtained ethics approval by the Institutional Review Board of Hamad Medical 
Corporation (IRB#: 13-00076) and all participants gave informed consent before taking part 
in the study. The research adhered to the tenets of the declaration of Helsinki. 
8.3.1 Study cohort 
Subjects were eligible to participate if they were between 18-75 years old, had poorly 
controlled (HbA1c >58 mmol/mol [7.5%]) T2D treated with a maximal dose of metformin 
(>1,500 mg/day) plus sulfonylurea (>4 mg glimepiride or >60 mg gliclazide); normal kidney 
and liver function, electrocardiogram and stable body weight (±1 Kg within the preceding 
year). Healthy controls had a HbA1c <6%. 
Exclusion criteria were any cause of neuropathy other than diabetes (chemotherapy, HIV 
infection, and hepatitis C), factors that may affect the corneal nerves (severe dry eyes, severe 
corneal dystrophies, ocular trauma or surgery in the preceding 6 months), a hematocrit <34%, 
medications known to affect glucose metabolism other than sulfonylureas and metformin, 
evidence of diabetic proliferative retinopathy, albumin excretion >300 mg/day, and major 
organ system disease, as determined by physical examination, medical history, and screening 
blood tests. 
8.3.2 Interventions 
In the Qatar study, eligible subjects were randomized to receive exenatide plus pioglitazone 
or glargine and aspart to achieve and maintain an HbA1c <53 mmol/mol (<7%). There was no 
limit on the upper value of HbA1c for enrolment. Subjects randomized to combination 
treatment were started on weekly subcutaneous extended release exenatide (2 mg/week 
Bydureon) and pioglitazone (30 mg/day). Subjects receiving insulin were started on glargine 
before breakfast. The Treat-to-Target Trial (4T) algorithm was used to calculate the starting 
glargine dose, and the dose was adjusted weekly to achieve a fasting plasma glucose (FPG) of 
<6.11 mmol/L. After the FPG goal was achieved, if the HbA1c was >53 mmol/mol (>7.0%), 4–
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6 units of insulin aspart was started before each meal, and the dose was adjusted to achieve 
a post-prandial plasma glucose concentration of <7.78 mmol/L, 2 hours after meals. Patients 
were seen monthly during the first 4 months or as needed, based on the results of the plasma 
glucose concentration, and bimonthly thereafter. The percentage of subjects experiencing 
hypoglycemia during the 1-year trial was calculated as the number of subjects experiencing 
at least one single episode of hypoglycemia (blood glucose concentration <60 mg/dL with or 
without symptoms or hypoglycemic symptoms that subsided following glucose ingestion) 
divided by the number of patients in that arm as per the protocol in the Qatar study (Abdul-
Ghani et al., 2017). 
8.3.3 Diabetic neuropathy assessment 
CCM was performed using a Heidelberg Retina Tomograph 3 with the Rostock Cornea Module 
(Heidelberg Engineering GmbH). The CCM utilizes a 670 nm diode laser and provides digital 
images of the cornea. The technique has been previously described (Petropoulos et al., 
2013b). Briefly, both eyes were anesthetized using Oxybuprocaine hydrochloride 0.4% 
(Conjuncain EDO; Fabrik GmbH) followed by a drop of carbomer 0.2% eye gel (Blumont 
Healthcare Ltd.) and patients were instructed to fixate on a target. Several scans of the 
subbasal nerve plexus in the central cornea were captured per eye for 2 minutes. Adjacent 
images were separated by approximately 1-4 µm. CCM image extraction was carried out at a 
separate time by one investigator unaware of the treatment group. Three high clarity CCM 
images per eye were selected based on a previously published protocol (Petropoulos et al., 
2013b) and images were selected b a s e d  o n  depth, focus position and contrast 
(Kalteniece et al., 2017). Corneal nerve fiber density (CNFD) (fibers/mm2), corneal nerve 
branch density (CNBD) (branches/mm2), and corneal nerve fiber length (CNFL) (mm/mm2) 
were quantified using CCMetrics, a validated image analysis software (Dabbah et al., 2011). 
Vibration perception threshold (VPT) was measured using a Neurothesiometer (Horwell 
Scientific Laboratory Supplies) on the pulp of the large toe on both feet and the average value 
of three measurements was recorded as a VPT in Volts (V) ranging from 0-50V. 
Sudomotor function was measured by electrochemical skin conductance (ESC) using 
Sudoscan (Impeto Medical SAS) as described previously. Sudoscan evaluates sympathetic 
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innervation based on sweat chloride concentrations generated by the sweat gland in 
response to the voltage applied and is reported as ESC in microSiemens (µS). 
Neuropathic pain was assessed using the Douleur Neuropathique en 4 (DN4) questionnaire 
based on symptoms and signs as previously described (Azmi et al., 2019c). 
8.3.4 Diabetic retinopathy assessment 
Ophthalmic examination was carried using a non-contact slit-lamp biomicroscope (Topcon) 
with +90 D lens (Volk) and two digital retinal images of both eyes were taken using a digital 
fundus camera (Zeiss) after pupil dilatation with Tropicamide 1% in 16/21 patients in the 
combination treatment group and 9/17 patients in the insulin treatment group. Diabetic 
retinopathy was graded by two qualified investigators according to the NHS Diabetic Eye 
Screening Programme (Team, 2012). Diabetic retinopathy was graded as R0 for no diabetic 
retinopathy, R1 for the presence of microaneurysms, retinal hemorrhages, venous loops, 
exudates or cotton wool spots in the presence of other features of diabetic retinopathy and 
R2 for the presence of venous beading, reduplication, multiple blot hemorrhages or 
intraretinal microvascular abnormality. Diabetic proliferative retinopathy (R3) was an 
exclusion criterion. Maculopathy was defined as M0 for no maculopathy or for any 
microaneurysm or hemorrhage within 1 disc diameter of the center of the fovea if associated 
with a best VA of 6/12 where the cause of the reduced vision is known and is not diabetic 
macular edema and M1 for exudate, retinal thickening, microaneurysm or hemorrhage within 
1 disc diameter of the center of the fovea or a group of exudates within the macula. 
8.3.5 Outcome measures 
The primary outcome measures were the CCM measures and the secondary outcome 
measures were DN4, VPT and sudomotor function. 
8.3.6 Statistical analysis 
Due to the small cohort, this sub-study was not adjusted for multiple comparisons (Rothman, 
1990). The results were analysed as an exploratory study. Continuous variables between 
controls, subjects with T2D treated with exenatide plus pioglitazone and insulin were 
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compared using one-way ANOVA with Bonferroni’s post hoc test for pairwise comparisons. 
Continuous variables between the two groups were compared using an unpaired t-test. 
Categorical variables were compared using x2. Changes between baseline and 1-year follow-
up were compared using a paired t-test. Correlation of the change in CCM measures with the 
change in HbA1c, body weight and lipids were analyzed using the Pearson correlation 
coefficient. All analyses were performed using IBM-SPSS (version 23; SPSS Inc, Armonk NY). A 
two-tailed P value of ≤0.05 was considered significant. 
8.4 Results 
8.4.1 Baseline characteristics 
The exenatide plus pioglitazone (n=21) and insulin (n=17) group had comparable HbA1c 
(92.5±18.8 mmol/mol [10.6±1.7%] vs 89.9±22.5 mmol/mol [10.4±2.1%], P=0.7) and 
significantly higher than the control group (41.6±5.0 mmol/mol [6.0±0.5%], P<0.0001) (Table 
8.1). The mean age, gender, lipid profile, diastolic blood pressure (DBP), body weight and BMI 
were comparable between all three groups. The systolic blood pressure (SBP) in the 
combination treatment group was significantly lower than in the control group (126.4 mmHg 
vs 143.7 mmHg, P<0.05) and insulin treatment group (130.8±19.3, P=0.02). The percentage 
of patients with diabetic retinopathy was comparable between the two treatment groups 
(31.3% vs 44.4%, P=0.51). 
The combination treatment group had significantly lower corneal nerve fiber density (CNFD, 
fibers/mm2) (26.1 vs 33.7, P=0.01), branch density (CNBD, branches/mm2) (57.0 vs 110.4, 
P<0.001) and fiber length (CNFL, mm/mm2) (17.8 vs 25.1, P=0.0001) compared to the control 
group. The insulin treatment group had significantly lower CNBD (70.3 branches/mm2, 
P<0.01) and CNFL (19.4 mm/mm2, P<0.01) compared to the control group. There was no 
difference in vibration perception threshold and sudomotor function measured by 
electrochemical skin conductance between the three groups and the percentage of patients 




Table 8.1. Baseline characteristics of patients with type 2 diabetes who received exenatide plus pioglitazone or 
insulin treatment. 






P value  
Age, years 53.0±11.0 50.1 ±9.4 54.9 ±7.5 0.30 
Male, n (%) 13/18 (72.2) 11/21 (52.4) 12/17 (70.6) 0.35 
Duration of diabetes, years N/A 10.0 ±5.9 13.1 ±9.3 0.24 
HbA1c, mmol/mol 41.6±5.0 92.5 ±18.8††† 89.9 ±22.5††† <0.0001 
HbA1c, % 6.0±0.5 10.6 ±1.7††† 10.4 ±2.1†††  
Total cholesterol, mmol/l 5.0±1.0 4.7 ±0.6 5.3 ±1.3 0.17 
Triglyceride, mmol/l 1.4±0.5 2.0 ±1.4 1.8 ±1.0 0.37 
HDL, mmol/l 1.2±0.3 1.3 ±0.6 1.2 ±0.4 0.87 
LDL, mmol/l 3.2±0.9 2.6 ±0.7 3.1 ±1.0 0.10 
Systolic BP, mmHg  143.7±12.7 126.4 ±17.9‡ 130.8 ±19.3 0.02 
Diastolic BP, mmHg  82.1±6.6 78.2 ±13.9 77.6 ±10.4 0.50 
Body weight, Kg 75.8±4.7 87.9 ±19.5 84.3 ±13.7 0.07 
BMI, Kg/m2 28.8±3.4 32.4 ±6.7 30.4 ±5.9 0.2 
Diabetic retinopathy, n (%)  5/16 (31.3) 4/9 (44.4) 0.51 
Neuropathic pain, n (%)  4/18 (22.2) 2/12 (16.7) 0.71 
CNFD, fibers/mm2 33.7±5.7 26.1 ±7.9† 28.8 ±9.1 0.01 
CNBD, branches/mm2 110.4±45.0 57.0 ±31.6†† 70.3 ±31.2† <0.001 
CNFL, mm/mm2 25.1±4.3 17.8 ±4.9††† 19.4 ±5.7† 0.0001 
VPT, V 7.2±4.1 7.3 ±4.6 11.4 ±7.4 0.08 
ESC feet, µS 66.9±18.4 59.8 ±25.7 67.2 ±12.0 0.55 
Numeric variables and frequency distribution for categorical variables are summarized as means ±standard 
deviation or n (%). Variables were compared using one-way ANOVA except for duration of diabetes which was 
compared using unpaired t-test. Categorical variables were compared using x2. Variables that were significantly 
different between controls and patients with T2D were denoted as ‡P≤0.05, †P≤0.01, ††P≤0.001, †††P≤0.0001. 
Abbreviations: BP= blood pressure, CNFD=corneal nerve fiber density, CNBD=corneal nerve branch density, 
CNFL=corneal nerve fiber length, VPT=vibration perception threshold and ESC =electrochemical skin 
conductance. 
8.4.2 Change in clinical and metabolic variables 
HbA1c reduced significantly in both treatment groups (P<0.0001), more so with exenatide 
plus pioglitazone compared with basal-bolus insulin (35.2 mmol/mol [3.8%] vs 28.7 mmol/mol 
[2.7%], P<0.05) (Figure 8.1). The mean HbA1c at 1-year follow-up was lower but not significant 
in the combination treatment group (51.4±12.0 mmol/mol [6.9±1.1%] vs 60.2±18.2 
mmol/mol [7.7±1.7%], P=0.1) (Table 8.2). A higher percentage of patients achieved the ADA 
treatment goal of HbA1c <53 mmol/mol (<7.0%) in the combination treatment group 
compared to the insulin treatment group (15/21 [71.4%] vs 6/17 [35.3%], P<0.05). The 
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percentage of patients with hypoglycemia in the insulin group was significantly higher than 
the combination group (84.6% vs 38.1%, P=0.008). 
Body weight increased by 4.6 Kg in the insulin group and by 5.6 Kg in the combination 
treatment group (P<0.01) (Figure 8.2). 
In both treatment groups, total cholesterol decreased by 0.5-0.8 mmol/l (P<0.05-0.001). In 
the combination treatment group, triglycerides decreased by 0.4 mmol/l (P<0.05) and 
diastolic blood pressure decreased by 8.9 mmHg (P<0.0001) and high-density lipoprotein 
cholesterol (LDL) increased by 0.4 mmol/l (P<0.01). 
Figure 8.1. Effect of exenatide plus pioglitazone and insulin treatment on HbA1c over 1-year. Overall HbA1c 
changes between different time points across 12 months were compared using paired t-test: ‡P≤0.05, †P≤0.01, 






Table 8.2. Changes in clinical and metabolic variables and measures of DPN after 1-year of exenatide plus 
pioglitazone or insulin treatment. 
 
Exenatide plus pioglitazone 
(n=21) 
Basal-bolus insulin (n=17) 
P value1 P value2 




HbA1c, mmol/mol 51.4 ±12.0 -35.2††† 60.2 ±18.2 -28.7††† 0.1 <0.05 
Hb1Ac, % 6.9 ±1.1 -3.8††† 7.7 ±1.7 -2.7†††   
Total cholesterol, mmol/l 4.2 ±0.8 -0.5†† 4.5 ±0.9 -0.8‡ 0.28 0.40 
Triglyceride, mmol/l 1.6 ±1.3 -0.4‡ 1.4 ±0.7 -0.4 0.57 1.00 
HDL, mmol/l 1.2 ±0.3 -0.1 1.1 ±0.2 -0.1 0.40 0.82 
LDL, mmol/l 2.2 ±0.8 -0.4† 2.7 ±0.8 -0.3 0.06 0.92 
Systolic BP, mmHg  123.4 ±16.8 -3.0 130.4 ±15.8 -0.4 0.20 0.65 
Diastolic BP, mmHg  69.3 ±10.5 -8.9††† 73.9 ±10.6 -3.8 0.20 0.14 
Body weight, Kg 93.5 ±22.0 5.6††† 88.9 ±15.8 4.6† 0.47 0.62 
BMI, Kg/m2 33.2 ±7.3 0.8‡ 30.1 ±5.5 -0.3 0.17 0.09 
Diabetic retinopathy, n (%) 13/16 (81.3) 8† 6/9 (66.7) 2 0.41  
Neuropathic pain, n (%) 2/18 (11.1) -2 2/12 (16.7) 0 0.66  
CNFD, fibers/mm2 26.6 ±5.3 0.6 30.8 ±8.9 2.0 0.11 0.61 
CNBD, branches/mm2 76.0 ±38.6 19.0‡ 97.4 ±54.2 27.2† 0.20 0.51 
CNFL, mm/mm2 19.7 ±4.8 1.9 21.7 ±5.8 2.3† 0.28 0.79 
VPT, V 9.0 ±5.4 1.7‡ 8.7 ±5.9 -2.8† 0.87 0.001 
ESC feet µS 61.8 ±23.4 2.0 65.5 ±15.3 -1.7 0.65 0.53 
P value1 for combination vs insulin therapy at 1-year follow-up 
P value2 for combination vs insulin therapy changes at 1-year follow-up 
Numeric variables and frequency distribution for categorical variables are summarized as means ±standard 
deviation or n (%). Continuous variable between exenatide plus pioglitazone and insulin treatment were 
compared using unpaired t-test. Categorical variables were compared using x2. Changes between baseline and 
1-year follow-up were compared using paired t-test: ‡P≤0.05, †P≤0.01, ††P≤0.001, †††P≤0.0001. Abbreviations: 
BP= blood pressure, CNFD=corneal nerve fiber density, CNBD=corneal nerve branch density, CNFL=corneal nerve 




Figure 8.2. Effect of exenatide plus pioglitazone and insulin treatment on HbA1c, lipid profile, blood pressure, 
body weight, corneal nerve fiber measures, vibration perception threshold and sudomotor function in the feet 
over 1-year follow-up. Abbreviations: VPT=vibration perception threshold and ESC =electrochemical skin 
conductance. Combination treatment (n=21) and basal/bolus insulin treatment (n=17). Error bars show standard 
deviation. 
8.4.3 Change in neuropathy measures 
In the insulin treatment group, CNBD and CNFL increased by 27.2 branches/mm2 (P=0.01) and 
2.3 mm/mm2 (P<0.01), respectively, with no change in CNFD (Figure 8.2 and 8.3). In the 
exenatide plus pioglitazone treatment group, CNBD increased by 19.0 branches/mm2 (P=0.02) 
with no change in CNFD (P=0.76) and CNFL (P=0.12). Between the treatment groups the 
change in CNFD (26.6 fibers/mm2 vs 30.8 fibers/mm2, P=0.11), CNBD (76.0 branches/mm2 vs 




Vibration perception threshold decreased by 2.8 V (P<0.01) in the insulin treatment group 
and increased by 1.7 V (P<0.05) in the combination treatment group, with a significant 
difference between the two treatment groups at 1-year follow-up (P=0.001) (Table 8.2 and 
Figure 8.2). 
There was no significant change in the percentage of patients with neuropathic pain (DN4 >4).  
There was no change in sudomotor function in either treatment group (Table 8.2). 
Figure 8.3. Corneal confocal microscopy (CCM) images of the sub-basal nerve plexus. Corneal nerve morphology 
in: (A) healthy age-matched controls, people with T2D treated with exenatide and pioglitazone (B & C) and basal-
bolus insulin (D & E) at baseline and 1-year follow-up. The red arrows indicate the fibers that might have 






8.4.4 Correlation between change in CCM measures with change in Hb1Ac, lipids and weight 
There was no correlation between the percentage change in CNFD with percentage change 
in HbA1c (r=0.06, P=0.74), total cholesterol (r=0.16, P=0.37), triglycerides (r=0.20, P=0.25), 
HDL (r=0.08, P=0.66) and weight (r=0.24, P=0.17). There was no correlation between 
percentage change in CNBD with percentage change in HbA1c (r=0.01, P=0.95), total 
cholesterol (r=0.06, P=0.74), triglycerides (r=0.08, P=0.64), HDL (r=0.06, P=0.73) and weight 
(r=0.25, P=0.14). There was no correlation between percentage change in CNFL with 
percentage change in HbA1c (r=0.05, P=0.77), total cholesterol (r=0.12, P=0.49), triglycerides 
(r=0.14, P=0.42), HDL (r=0.04, P=0.82) and weight (r=0.03, P=0.84)  
8.4.5 Diabetic retinopathy 
The percentage of patients with new onset diabetic retinopathy increased significantly from 
31.3% to 81.3% (P<0.01) in the combination treatment group and whilst there was an increase 
in the insulin treatment group from 44.4% to 66.7%, this was not significant (Table 8.2). Eight 
subjects in the combination treatment group and two subjects in the insulin group progressed 
from R0 to R1. There was no progression of retinopathy in subjects graded R1, R2, M0 or M1 
at baseline. 
8.5 Discussion 
This study shows that combination treatment with exenatide plus pioglitazone or basal-bolus 
insulin over 12 months results in a marked improvement in HbA1c, but with weight gain, and 
hypoglycemia, consistent with the Qatar study (Abdul-Ghani et al., 2017). Insulin treatment 
was associated with a significant improvement in distal corneal nerve morphology 
characterised by an increase in corneal nerve branch density and length and an improvement 
in vibration perception, but no change in sudomotor function or incidence of neuropathic 
pain. Combination treatment was associated with an improvement in the lipid profile, blood 
pressure and an increase in distal corneal nerve branch density, but a small but significant 
deterioration in VPT with no change in sudomotor function or incidence of neuropathic pain. 
The improvement in CCM measures were independent of changes in HbA1c, body weight and 
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lipids. There was an increase in the incidence of diabetic retinopathy in the combination 
treatment group. 
Whilst exenatide results in weight loss (Jaiswal et al., 2015), pioglitazone is associated with 
weight gain, explaining the increase in weight observed in the combination treatment group. 
Obesity (Schlesinger et al., 2019) is a risk factor for DPN. Jaiswal et al. (Jaiswal et al., 2015) 
reported that exenatide resulted in 3 kg weight loss after 1-year, compared with 2 kg weight 
gain with glargine (Ismail-Beigi et al., 2010). Pioglitazone is associated with a lowering of 
diastolic blood pressure and triglycerides and we also observed a significant reduction in 
diastolic blood pressure and triglycerides in the combination treatment group. Hypertension 
(Ponirakis et al., 2019b) and hyperlipidemia (Tesfaye et al., 2005) are also risk factors for DPN. 
However, the weight gain in both treatment arms may have limited the overall benefit on 
neuropathy. 
Glucagon-like peptide 1 (GLP-1) receptor agonists have been reported to have a 
neuroprotective effect. In preclinical studies, Himeno et al. (Himeno et al., 2011) showed that 
exendin-4 prevented both sensory and motor nerve conduction slowing and reduction of 
IENFD. However, Kan et al. (Kan et al., 2012) reported that exendin-4 prevented sensory nerve 
conduction slowing but had no effect on motor nerve conduction slowing and epidermal 
innervation. Conversely, in T2D mice, exendin-4 prevented motor nerve conduction slowing 
but had no effect on sensory nerve conduction. In a clinical trial of patients with T2D treated 
with exenatide there was no effect on the incidence of DPN, cardiovascular autonomic 
neuropathy (CAN) or IENFD over 18 months (Jaiswal et al., 2015). Recently, the LEADER trial 
(Dhatariya et al., 2018) showed that liraglutide was associated with a significantly lower risk 
of amputations related to diabetic foot ulceration in patients with T2D. However, a study of 
39 patients with T1D and established neuropathy randomized to liraglutide or placebo over 
26 weeks recently failed to show a benefit on autonomic function or sensory and motor nerve 
conduction (Brock et al., 2019). Thiazolidinediones (TZDs) have also been reported to have a 
neuroprotective effect. In preclinical studies, Qiang et al. (Qiang et al., 1998) reported that 
troglitazone prevented nerve conduction slowing and maintained normal myelinated fiber 
architecture and density in T1D rats. Yamagishi et al. (Yamagishi et al., 2008) confirmed that 
pioglitazone prevented nerve conduction slowing and reduced macrophage infiltration in the 
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sciatic nerve in T1D rats. Wiggin et al. (Wiggin et al., 2008) showed that rosiglitazone 
prevented thermal hypoalgesia and reduced oxidative stress in the sciatic nerve of T1D mice. 
In the BARI 2D trial (Pop-Busui et al., 2013), rosiglitazone significantly reduced the 4-year 
cumulative incidence of DPN compared to insulin treatment. The neuroprotective effect of 
TZDs may be attributed to a reduction in oxidative stress and advanced glycated end products. 
Our data suggest that exenatide plus pioglitazone treatment may be associated with small 
fiber regeneration, assessed using CCM. 
In preclinical studies, Kan et al. (Kan et al., 2012) reported that high-dose insulin prevented a 
reduction of IENFD in T1D mice but had no effect in T2D mice. In the DCCT, intensive insulin 
treatment reduced the incidence of clinical DPN by 60% (Diabetes et al., 1993) and prevented 
peroneal nerve conduction velocity slowing over a 5-year period in patients with T1D. 
However, in patients with T2D the UKPDS (UK Prospective Diabetes Study (UKPDS) Group, 
1998) and VA-CSDM trial (Azad et al., 1999) reported that intensive treatment had no effect 
on the incidence of DPN and CAN compared with conventional treatment. The Kumamoto 
study (Ohkubo et al., 1995) showed that intensive treatment prevented nerve conduction 
slowing over 6 years and the ACCORD trial (Ismail-Beigi et al., 2010) showed a reduction in 
the incidence of loss of ankle reflexes but no effect on VPT over 6-years (Callaghan et al., 
2012). Our data suggest that insulin treatment might have a beneficial effect on DPN, 
independent of the improvement in glycemic control as there was evidence of greater small 
nerve fiber regeneration and an improvement in vibration perception. In a previous study 
comparing continuous subcutaneous insulin infusion (CSII) with multiple daily insulin injection 
(MDI) we showed that despite a comparable HbA1c, the CSII group showed an increase in 
CNFD, CNBD and CNFL (Azmi et al., 2015), which was attributed to a direct neurotrophic effect 
of insulin (Guo et al., 2011). 
Both combination and insulin treatment improved corneal nerve fiber measures but had no 
effect on neuropathic symptoms or sudomotor function over 1 year. This is consistent with 
studies showing corneal nerve regeneration 6 months after pancreas and kidney 
transplantation in T1D with no change in quantitative sensory testing and an improvement in 
neuropathic symptoms and nerve conduction at 24 and 36 months (Mehra et al., 2007, 
Tavakoli et al., 2013, Azmi et al., 2019b). Autonomic function has not been shown to improve 
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3, 8 and 10 years after kidney and pancreas transplantation (Azmi et al., 2019b, Navarro et 
al., 1997, Havrdova et al., 2016), but multifactorial risk factor reduction showed an 
improvement in cardiac autonomic function with no change in vibration perception threshold 
(Gaede et al., 2008). A recent study from Japan showed that multifactorial risk factor 
reduction achieved by improving and even normalizing glycemic control and reducing body 
weight and blood pressure in patients with T2D over 4 years, resulted in an improvement in 
CNFL, CNBD, neurophysiology and vibration perception, which correlated with the reduction 
in HbA1c (Ishibashi et al., 2019). The present study shows an improvement in CNBD and CNFL, 
but no change in sudomotor function over 12 months. Jaiswal et al. (Jaiswal et al., 2015) 
reported a trend for a greater increase in IENFD 1-year after capsaicin denervation in patients 
on insulin compared to exenatide. In a randomized placebo-controlled trial of once weekly C-
peptide there was no improvement in sural nerve conduction velocity or the modified 
Toronto Clinical Neuropathy Score and yet vibration perception threshold improved 
significantly (Wahren et al., 2016). These findings emphasize the importance of the type and 
duration of intervention and choice of end points in clinical trials of DPN. 
A large improvement in HbA1c (>2-3%) has been reported to be associated with treatment-
induced neuropathic pain, autonomic neuropathy and a worsening of retinopathy and 
microalbuminuria (Gibbons and Freeman, 2015). Our study shows that despite a reduction in 
HbA1c of 3.8% with a combination of exenatide and pioglitazone and 2.7% with insulin, there 
was no increase in the incidence of painful DPN. However, the genesis of painful neuropathy 
is complex and may involve alterations in transient receptor potential channels, which may 
not have been altered by the current interventions (Roa-Coria et al., 2019). The incidence of 
diabetic retinopathy increased, especially in the combination treatment group. GLP-1 therapy 
has been associated with an increase in the risk of retinopathy progression in patients with 
diabetic retinopathy in a large randomized trial with semaglutide (Marso et al., 2016), 
although two large population based analyses have failed to confirm this association (Douros 
et al., 2018, Pfeffer et al., 2015). Treatment with lixisenatide and once weekly exenatide have 
previously shown no adverse effect on retinopathy (Pfeffer et al., 2015). 
We acknowledge this is a small open-label study with a lack of blinding for participants and 
investigators due to weekly exenatide injections and multiple daily insulin injections. 
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However, the PhD student that evaluated the neuropathy outcome measures was masked to 
the treatment group. Our cohort of patients with T2D had minimal neuropathy and a very 
effective reduction in HbA1c over 12 months leading to early small nerve fiber repair as 
observed after simultaneous pancreas-kidney (SPK) transplantation (Azmi et al., 2019b) or 
optimal medical therapy (Ishibashi et al., 2019). 
In conclusion, exenatide plus pioglitazone or basal-bolus insulin treatment effectively reduces 
HbA1c and promotes small fiber regeneration. Whilst the incidence of diabetic retinopathy 
increased, especially in the combination treatment group, there was no impact on 
neuropathic pain. Our findings support the utility of CCM as an early surrogate marker of 
therapeutic response in clinical trials of diabetic neuropathy. 
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9.1 Abstract 
Introduction: CCM is a non-invasive ophthalmic technique that identifies corneal nerve 
degeneration in a range of peripheral neuropathies and in patients with multiple sclerosis, 
Parkinson’s disease and amyotrophic lateral sclerosis.  
Objectives: We sought to determine whether there is any association of corneal nerve fiber 
measures with cognitive function and functional independence in patients with MCI and 
dementia. 
Methods: In this study, 76 non-diabetic participants with MCI (n=30), dementia (n=26) and 
healthy age-matched controls (n=20) underwent assessment of cognitive and physical 
function and CCM. 
Results: There was a progressive reduction in corneal nerve fiber density (CNFD), branch 
density (CNBD) and fiber length (CNFL) (P<0.0001) in patients with MCI and dementia 
compared to healthy controls. Adjusted for confounders, all three corneal nerve fiber 
measures were significantly associated with cognitive function (P<0.05) and functional 
independence (P<0.01) in MCI and dementia. The area under the ROC curve to distinguish 
MCI with CNFD, CNBD and CNFL was 69.1%, 73.2% and 73.0% and for dementia it was 84.8%, 
84.2% and 86.2%, respectively. 
Conclusions: CCM demonstrates corneal nerve fiber loss, which is associated with a decline 




Dementia is a progressive neurodegenerative disease, which currently affects 47 million 
people world-wide (Prince et al., 2015). It is a cause of significant cognitive and functional 
disability, and is the most common cause of death in women over 80 years of age in the UK 
(Morgan and Rutty, 2016). Neurodegeneration underlies accelerated cognitive decline and 
can be identified by brain atrophy (Leung et al., 2013, Eskildsen et al., 2013, McDade et al., 
2018), hypometabolism (Landau et al., 2010, Herholz, 2010) and hypoperfusion (Metastasio 
et al., 2006). Neurodegeneration can be detected approximately 15 years before overt 
cognitive decline associated with Alzheimer’s disease (AD).(McDade et al., 2018) The National 
Institute of Aging and the Alzheimer’s Association (NIA-AA) have emphasized the need for 
biomarkers of neurodegeneration to identify those at greatest risk for cognitive decline or 
progression from mild cognitive impairment (MCI) to dementia (Albert et al., 2011, Sperling 
et al., 2011). 
There is an increasing focus on identifying markers for neurodegeneration, which can detect 
pre-clinical disease especially for disease modifying or preventative strategies (Cummings, 
2017). There is good evidence that the neurodegenerative process in AD is not limited to the 
brain but also occurs in the retina as a thinner retinal nerve fiber layer (RNFL) is associated 
with cognitive decline in patients with MCI and AD (Ko et al., 2018, Khawaja et al., 2016, Shi 
et al., 2014). Corneal confocal microscopy (CCM) is a non-invasive ophthalmic imaging 
technique which allows quantification of corneal nerve morphology and may act as a potential 
marker for neurodegeneration. It has been most extensively used to study patients with 
diabetic neuropathy (Malik et al., 2003, Quattrini et al., 2007b, Perkins et al., 2018) and other 
peripheral neuropathies including those associated with CIDP (Stettner et al., 2016), HIV 
(Kemp et al., 2017), Fabry disease (Bitirgen et al., 2018) and inherited neuropathies such as 
CMT1A (Tavakoli et al., 2012) and Friedreich’s ataxia (Pagovich et al., 2018). However, more 
recent studies have shown that CCM can also identify nerve fiber loss in patients with 
Parkinson’s disease (Kass-Iliyya et al., 2015, Podgorny et al., 2016), amyotrophic lateral 
sclerosis (Ferrari et al., 2014), and multiple sclerosis (Bitirgen et al., 2017a, Petropoulos et al., 
2017, Bitirgen et al., 2017b, Mikolajczak et al., 2016). 
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The objectives of this study were to: (1) determine whether there is significant corneal nerve 
fiber loss in patients with MCI and dementia compared to age-matched controls and (2) 
determine the association between corneal nerve fiber measurements with cognitive 
function and functional independence. 
9.3 Methods 
Patients with mild cognitive impairment (MCI), dementia and healthy age-matched controls 
were recruited from the Geriatric clinic in Rumailah Hospital, Doha, Qatar between 
September 2016 and May 2018. Patients with severe anxiety, depression, Parkinson’s disease, 
frontotemporal and Lewy body dementia, hypomania and severe dementia who were unable 
to cooperate were excluded. Furthermore, patients with systemic diseases that may affect 
corneal nerve fibers, including diabetes, vitamin B12 deficiency, hypothyroidism, HIV 
infection and hepatitis C, were excluded. In addition, patients with dry eyes, corneal 
dystrophies, ocular trauma or surgery in the preceding 6 months were also excluded. We 
enrolled 222 people and excluded 117 patients with diabetes, 1 patient with depression, 1 
patient with hypomania, 3 people younger than the inclusion age and 24 people who did not 
complete the assessments to leave a sample size of 76. This study was approved by the 
Institutional Review Board (IRB) of Weill Cornell Medicine in Qatar (WCM-Q) and Hamad 
Medical Corporation (HMC) and all participants gave informed consent to take part in the 
study. The research adhered to the tenets of the declaration of Helsinki. 
9.3.1 Demographic and metabolic measures 
Data including age, ethnicity, gender, blood pressure, weight, and body mass index (BMI) 
were recorded. HbA1c, lipids, creatinine, hemoglobin (Hgb), mean corpuscular volume (MCV), 
serum vitamin B12, vitamin D, free thyroxine (FT4) and thyroid stimulating hormone (TSH) 
were assessed. 
9.3.2 Cognitive screening 
Cognitive screening was administered by the occupational therapist using the Montreal 
cognitive assessment (MoCA) Arabic and English version. The MoCA is a 30 point test and 
includes seven cognitive domains: visuospatial abilities (clock-drawing, cube copy, and 
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alternation task adapted from the Trail-Making B task), naming (confrontation naming of 3 
animals), attention (including the sum of attention, concentration, and working memory 
items), language (the sum of repetition of sentences and verbal fluency task scores), abstract 
thinking/executive functions (the 2-item verbal abstraction), short-term memory/recall, and 
orientation. MoCA scores below 26 were considered to indicate cognitive impairment 
(Nasreddine et al., 2012). A point was added for individuals who had formal education ≤6th 
grade. Patients with cognitive symptoms of depression were determined based on clinical 
interview and were excluded from the study. Cognitive symptom duration was estimated 
from the clinical history obtained from relatives and participants. 
9.3.3 Functional Independence assessment 
The Functional Independence Measure (FIM) was administered by the occupational therapist 
and is an 18-point screening test of which 13 are for motor and 5 for cognitive function and 
each point is scored from 1 to 7. The total FIM score ranges from 18 to 126. There is no cut-
off point for FIM, but a higher score indicates greater independence (Tanaka et al., 2013). 
9.3.4 Diagnosis 
The diagnosis of MCI and dementia were based on the NIA-AA guideline (McKhann et al., 
2011) and the Diagnostic and Statistical Manual 4th edition (DSM IV) diagnostic criteria (Trull 
et al., 2012). A joint consultative model in the Department of Geriatric Medicine run by 
geriatricians and geriatric psychiatrists with advice and consultation from the neurologists 
was applied to ensure the correct diagnosis, especially to exclude reversible, complex and 
young-onset dementia. The diagnosis of MCI or dementia was based on a comprehensive 
history and examination, which includes 1) presenting complaint and history of illness; 2) 
comprehensive history of each of the cognitive domains; 3) psychiatric history for ruling out 
depression, mood disorders and psychosis; 4) medical history including episodes of delirium 
and other medical comorbidities; 5) medication history; 6) functional history of basic daily 
living activities; 7) components of comprehensive geriatric assessment; 8) detailed psychiatric 
mental status examination and cognitive screening using MoCA. Subsequent analysis included 
comprehensive organic work-up which are blood investigation and brain imaging. It is through 
this robust diagnostic process that the psychiatrists applied the diagnostic criteria. The final 
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diagnosis (control, MCI, dementia) was made according to consensus decision. Radiological 
evidence for Alzheimer’s disease (AD), included volume loss of hippocampi, entorhinal cortex, 
and amygdala on MRI, based on the criteria described by Dubois et al. (Dubois et al., 2009) 
For vascular dementia, the NINDS-AIREN criteria (Roman et al., 1993) which specify evidence 
of cerebrovascular disease by brain imaging (MRI) were applied and includes multiple large 
vessel infarcts or a single strategically placed infarct (angular gyrus, thalamus, basal forebrain, 
or posterior (PCA) or anterior cerebral artery (ACA) territories), multiple basal ganglia and 
white matter lacunes, extensive periventricular white matter lesions, or combinations 
thereof. The neuroradiologists also looked for potentially reversible causes of cognitive 
decline such as tumors, subdural hematoma or normal pressure hydrocephalus. 
9.3.5 Corneal Confocal Microscopy 
Participants underwent corneal confocal microscopy (CCM), a non-invasive ophthalmic 
imaging technique using the Heidelberg Retina Tomograph and the Rostock Cornea Module 
(Heidelberg Engineering GmbH, Heidelberg, Germany) (Petropoulos et al., 2013d, 
Petropoulos et al., 2013b). The p a t i e n t ’s eyes were anesthetized using a drop of 0.4% 
benoxinate hydrochloride, and Viscotears were applied on the front of the eye for 
lubrication. A drop of Viscotears was placed between the tip of the objective lens and a 
sterile disposable TomoCap allowing optical coupling of the objective lens to the cornea. 
The patient was instructed to fixate on a target with the eye not being examined. Several 
scans of the sub-basal nerve plexus in the central cornea were captured per eye for ~2 
minutes. The field of view of each image is 400X400 µm.  At a separate time, three high 
clarity images per eye were selected by one researcher blind to the patient diagnosis. Criteria 
for image selection were depth, focus position and contrast (Kalteniece et al., 2017). Three 
corneal measures: corneal nerve fiber density (CNFD) (number of main nerve fibers/mm2), 
branch density (CNBD) (number of branches/mm2), and fiber length (CNFL) (length of main 
nerves and branches mm/mm2) were quantified manually using CCMetrics, a validated image 
analysis software (Dabbah et al., 2011). 
9.3.6 Statistical analysis 
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The sample size required to determine a significant difference in corneal nerve fiber measures 
between the control, MCI, and dementia group was calculated from our previously published 
data (Chen et al., 2015). Given a reported difference in population means of 8 no./mm2 for 
CNFD, with an estimated standard deviation of 7, we estimated that ~17 participants for each 
group would be needed to provide a study power of 80% and an alpha of 0.05. 
Patients’ demographic and clinical characteristics were summarized using means and 
standard deviations for numeric variables and frequency distribution for categorical variables. 
Variables were compared between the controls; MCI and dementia group using one-way 
analysis of variance (ANOVA) with Bonferroni’s post hoc test for pairwise comparisons and 
Chi-square test, respectively. Correlation analysis between the three corneal nerve fiber 
measures was performed using Pearson’s method. 
Univariate analysis by simple linear regression was performed with age, gender, systolic and 
diastolic blood pressure, weight, BMI, HbA1c, cholesterol, triglyceride, HDL, LDL, Hgb, MCV, 
TSH, FT4, vitamin B12, cognitive function, duration of cognitive impairment, functional 
independence, MCI and dementia as independent variables, and the corneal nerve fiber 
measures as the dependent variable. The multiple linear regression analysis included all 
variables with P≤0.05 at the bivariate level. The regression coefficient (beta) and the 
corresponding 95% confidence intervals (95% CI) are presented. Residual plots were used to 
determine for linearity, normality, constant variance, and independence.  
Receiver operating characteristic (ROC) curve analysis was used to determine the ability of 
CNFD, CNBD and CNFL to distinguish patients with MCI and dementia from healthy controls. 
The area under curve (AUC), and two cut-off point with the maximal sum of sensitivity and 
specificity was calculated. 
All analyses were performed using IBM-SPSS (version 23; SPSS Inc, Armonk NY). Dot plots 
were generated using GraphPad Prism, version 6.05. A two-tailed P value of ≤0.05 was 
considered significant. 
9.4 Results 
9.4.1 Demographic and clinical characteristics 
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The demographic and clinical characteristics are summarized in Table 9.1. Participants (n=76) 
with mild cognitive impairment (MCI) (n=30) and dementia (n=26) were compared with a 
control group (n=20). The groups had comparable age, gender, systolic blood pressure (SBP), 
weight, body mass index (BMI), HbA1c, triglycerides, high density lipoprotein (HDL), 
creatinine, hemoglobin (Hgb) and mean corpuscular volume (MCV). The dementia group had 
a significantly lower diastolic blood pressure compared to the MCI group (P<0.05), a lower 
cholesterol than both the control and MCI group (P<0.05) and lower low-density lipoprotein 
(LDL) compared to the control group (P<0.05). More patients with dementia were on a statin 
(n=12, 46%) compared to controls (n=4, 20%), which may explain the lower total cholesterol 
in the dementia group. There was a progressive reduction in cognitive function measured by 
the Montreal Cognitive Assessment (MoCA) between the control (27.30 ± 4.21), MCI (24.04 ± 
2.93, P<0.05) and dementia group (12.96 ± 5.65, P<0.0001). The duration of cognitive 
impairment was significantly longer in the dementia (3.35 ±3.07 years) compared to the MCI 
(1.48 ± 1.66 years, P<0.01) group. The Functional Independence Measure (FIM) was lower in 
the dementia group (84.80 ± 29.01) compared to the MCI (120.9 ± 6.5, P<0.0001) and control 
(125.23 ± 1.30, P<0.0001) group, but did not differ between the control and MCI group. The 
dementia group consisted of participants with Alzheimer’s disease (n=7, 27%), vascular 
dementia (n=6, 23%) and mixed dementia (n=13, 50%).The study cohort was comprised of 16 
(21.1%) Qatari Arabs, 30 (39.5%) other Arabs, 21 (27.6%) South Asians, 7 (9.2%) Africans and 
2 (2.6%) Caucasians. 
9.4.2 Corneal nerve fiber measures 
The corneal nerve fiber morphology and measures in patients with MCI and dementia, and 
healthy age-matched controls are shown in Figure 9.1. The MCI group compared to the 
control group had a significantly lower corneal nerve branch density (CNBD) (P<0.01) and 
corneal nerve fiber length (CNFL) (P<0.05), with no significant difference in the corneal nerve 
fiber density (CNFD). CNBD, CNFL and CNFD (P<0.0001) were all significantly reduced in the 
dementia group compared to the control group and CNFD (P<0.01) and CNFL (P<0.05) were 
significantly lower in the dementia group compared to the MCI group. All three corneal nerve 
fiber measures were significantly correlated to each other; CNFD with CNBD (r= 0.70, 
P<0.0001) and CNFL (r= 0.70, P<0.0001) and CNBD with CNFL (r= 0.92, P<0.0001).  
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P value1 P value2 P value3 
Demographics 
Age, mean ± SD, years 67.65 ±9.02 67.83 ±8.48 72.62 ±8.53 NS NS NS 
Gender, n (%) Male 14 (28.6) 19 (38.8) 16 (32.7) NS NS NS 
 Female 6 (22.2) 11 (40.7) 10 (37.0)    
BP sys, mean ± SD, mmHg 137.75 ±11.39 140.62 ±14.20 138.35 ±24.95 NS NS NS 
BP dias, mean ± SD, mmHg 76.85 ±10.86 76.97 ±6.59 70.56 ±10.37 NS NS <0.05 
Weight, mean ± SD, Kg 73.30 ±8.74 80.78 ±18.61 76.61 ±12.90 NS NS NS 
BMI, mean ± SD, Kg/m2 27.39 ±3.06 35.12 ±24.68 30.14 ±5.32 NS NS NS 
HbA1c, mean ± SD, % 5.74 ±0.41 5.64 ±0.59 5.61 ±0.42 NS NS NS 
Chol. mean ± SD, mmol/l 5.11 ±0.95 4.96 ±0.89 4.24 ±1.10 NS <0.05 <0.05 
Trig. mean ± SD, mmol/l 1.27 ±0.53 1.28 ±0.63 1.39 ±0.68 NS NS NS 
HDL mean ± SD, mmol/l 1.34 ±0.37 1.34 ±0.54 1.27 ±0.47 NS NS NS 
LDL mean ± SD, mmol/l 3.18 ±0.86 2.98 ±0.83 2.36 ±0.94 NS <0.05 NS 
Creatinine mean ± SD, µmol/l 82.10 ±25.39 79.79 ±27.20 82.75 ±28.28 NS NS NS 
Hgb, mean ± SD, gm/dL 14.11 ±1.65 13.30 ±1.84 13.28 ±1.01 NS NS NS 
MCV, mean ± SD, fL 88.41 ±5.28 82.59 ±10.52 86.69 ±5.90 NS NS NS 
Cognitive function 
MoCA, mean ± SD 27.30 ±4.21 24.04 ±2.93 12.96 ±5.65 <0.05 <0.0001 <0.0001 
Cognitive impairment duration, 
mean ± SD, years 0 ±0 1.48 ±1.66 3.35 ±3.07 0.05 <0.0001 <0.01 
Physical and social function 
FIM, mean ± SD 125.23 ±1.30 120.9 ±6.5 84.80 ±29.01 NS <0.0001 <0.0001 
Corneal nerve fiber measures 
CNFD, mean ± SD, no./mm2 32.95 ±6.60 27.38 ±8.42 20.88 ±9.36 NS <0.0001 <0.01 
CNBD, mean ± SD, no./mm2 113.29 ±51.76 72.83 ±35.62 52.91 ±34.88 <0.01 <0.0001 NS 
CNFL, mean ± SD, mm/mm2 24.93 ±5.70 19.97 ±6.21 15.58 ±6.51 <0.05 <0.0001 <0.05 
1 Control vs MCI 
2 Control vs dementia 
3 MCI vs dementia 
Characteristics of 76 participants presented as mean ± standard deviation for numeric variables and frequency 
distribution for categorical variables for healthy age-matched controls, people with mild cognitive impairment 
(MCI) and dementia. Continuous and categorical variables were compared using one-way ANOVA with 
Bonferroni’s post hoc test and Chi-square test, respectively. Abbreviations: MoCA=Montreal cognitive 
assessment, FIM=Functional independence measure, CNFD=corneal nerve fiber density, CNBD=corneal nerve 
branch density and CNFL=corneal nerve fiber length.  
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Figure 9.1. Corneal nerve fiber morphology and measures in healthy age-matched controls, people with mild 
cognitive impairment (MCI) and dementia. 
 
(1) Corneal confocal microscopy (CCM) images of the sub-basal nerve plexus in (A) a 70 year-old control showing 
normal corneal nerve fiber morphology; (B) a 69 year old patient with MCI and (C) a 69 year old patient with 
dementia showing a progressive reduction in corneal nerve fiber density, branch density and length. (2) Dot 
plots of corneal nerve fiber density (CNFD) (red), corneal nerve branch density (CNBD) (green) and corneal nerve 
fiber length (CNFL) (blue) in controls, people with MCI and dementia. The line that extends from the middle of 
the vertical line represents the mean and the lines that extend to the top and bottom are the standard deviation 
with significant differences between the control, MCI and dementia group (*P≤0.05, **P≤0.01, ***P<0.0001).  
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9.4.3 Association of corneal nerve fiber measures with cognitive function, duration of 
cognitive impairment and functional independence in MCI and dementia 
Univariate analysis with CNFD and CNBD as dependent variables showed a significant 
association with cognitive function (β=0.41 and 0.39, P≤0.01), duration of cognitive 
impairment (β= -0.32 and -0.30, P<0.05), functional independence (β=0.52 and 0.45, P≤0.01), 
MCI (β= -0.30 and -0.28, P≤0.05), dementia (β= -0.59 and -0.58, P<0.0001) and total 
cholesterol (β=0.26 and 0.25, P≤0.05). Univariate analysis with CNFL as a dependent variable 
showed a significant association with cognitive function (β=0.42, P<0.0001), duration of 
cognitive impairment (β= -0.30, P<0.01), functional independence (β=0.54, P<0.0001), MCI 
(β= -0.27, P=0.05), dementia (β= -0.61, P<0.0001), age (β= -0.23, P=0.05) and total cholesterol 
(β=0.29, P≤0.05).  
Multiple linear regression analyses to determine the association of corneal nerve fiber 
measures with cognitive function, functional independence, MCI, dementia and duration of 
cognitive impairment are summarised in Table 9.2. Adjusted for cholesterol, CNFD and CNBD 
were associated with cognitive function (β=0.31, 0.33, P<0.05), functional independence 
(β=0.50, 0.67, P<0.01) and dementia (β= -0.48, -0.55, P<0.01), but only CNBD was associated 
with MCI (β= -0.38, P<0.01). Adjusted for age and cholesterol, CNFL was associated with 
cognitive function (β=0.31, P<0.05), functional independence (β=0.56, P=0.001), MCI (β= -
0.33, P<0.05) and dementia (β= -0.51, P<0.01). However, the association of corneal nerve 
fiber measures with duration of cognitive impairment was lost after adjusting for confounding 
factors. 
9.4.4 CCM sensitivity and specificity 
The AUC for MCI with CNFD, CNBD and CNFL was 69.1% (95% CI, 53.7% - 84.4%), 73.2% (95% 
CI, 58.6% - 87.9%) and 73.0% (95% CI, 58.7% - 87.3%), respectively and for dementia it was 
84.8% (95% CI, 73.6% - 96.0%), 84.2% (95% CI, 72.2% - 96.3%) and 86.2% (95% CI, 75.5% - 
96.9%), respectively (Figure 9.2). Using a CNFD cut-off of <34 no./mm2, the sensitivity for MCI 
and dementia was 76.7% and 92.3%, respectively and the specificity was 55%. Using a CNBD 
cut-off of <78 no./mm2, the sensitivity for MCI and dementia was 53.3% and 80.8%, and the 
specificity was 70% and 75%, respectively. Using a CNFL cut-off of <23 mm/mm2 CNFL, the 
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sensitivity for MCI and dementia was 70.0% and 84.6%, respectively and the specificity was 
75%. 
Table 9.2. Multiple linear regression analysis to determine the association of corneal nerve fiber measures with 




Interval P value 
Montreal Cognitive assessment (MoCA) 
CNFD, no./mm2 0.31 0.06, 0.80 <0.05 
CNBD, no./mm2 0.33 0.54, 4.87 0.01 
CNFL, mm/mm2 0.31 0.04, 0.66 <0.05 
Function Independence Measure (FIM) 
CNFD, no./mm2 0.67 0.16, 0.38 <0.0001 
CNBD, no./mm2 0.50 0.46, 2.08 <0.01 
CNFL, mm/mm2 0.56 0.08, 0.31 0.001 
Mild cognitive impairment (MCI) 
CNFD, no./mm2 -0.27 -8.21, 0.28 NS 
CNBD, no./mm2 -0.38 -61.08, -9.24 <0.01 
CNFL, mm/mm2 -0.33 -7.67, -0.37 <0.05 
Dementia 
CNFD, no./mm2 -0.48 -7.57, -1.66 <0.01 
CNBD, no./mm2 -0.55 -45.64, -12.50 0.001 
CNFL, mm/mm2 -0.51 -6.20, -1.45 <0.01 
Duration of cognitive impairment 
CNFD, no./mm2 -0.24 -2.19, 0.08 NS 
CNBD, no./mm2 -0.24 -12.76, 0.54 NS 
CNFL, mm/mm2 -0.23 -1.74, 0.10 NS 
The following confounding variables were considered: cholesterol for CNFD and CNBD, and age and cholesterol 
for CNFL. All the variables considered in the fitted model had P<0.05. Abbreviations: CNFD=corneal nerve fiber 




Figure 9.2. ROC analysis showing the area under the curve for CCM measures in distinguishing people with MCI 
and dementia from healthy controls. The area under the ROC curve to distinguish MCI with CNFD, CNBD and 
CNFL was 69.1%, 73.2% and 73.0% and for dementia it was 84.8%, 84.2% and 86.2%, respectively. 
 
9.5 Discussion 
This study shows that CCM detects corneal nerve fiber loss in people with mild cognitive 
impairment (MCI) and people with dementia, compared to age-matched healthy controls. 
Furthermore, after adjusting for confounding factors, corneal nerve fiber loss was significantly 
associated with decline in cognitive function and functional independence in patients with 
MCI and dementia. This is an important observation as it demonstrates cognitive decline is 
not only associated with brain atrophy (Leung et al., 2013, Eskildsen et al., 2013) and retinal 
nerve fiber layer (RNFL) thinning (Ko et al., 2018, Khawaja et al., 2016, Shi et al., 2014), but 
also with corneal nerve fiber loss.  
The diagnosis of MCI and dementia are based on clinical, cognitive, and functional criteria as 
well as clinical judgment (Albert et al., 2011). However, there is no sharp demarcation 
between aging cognition and MCI and between MCI and dementia. The NIA-AA proposed a 
classification scheme for preclinical AD based on biomarkers of β-amyloid, tauopathy and 
neurodegeneration to determine the level of certainty for progression from MCI to 
Alzheimer’s disease (AD) (Albert et al., 2011, Sperling et al., 2011). Current NIA-AA 
recommended markers for neurodegeneration include brain atrophy (Leung et al., 2013, 
Eskildsen et al., 2013, McDade et al., 2018), hypometabolism (Landau et al., 2010, Herholz, 
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2010) and hypoperfusion (Metastasio et al., 2006) using magnetic resonance imaging (MRI), 
PET, and single-photon emission computed tomography (SPECT) imaging, respectively. 
However, the clinical utility of these biomarkers is hampered by the invasiveness of 
cerebrospinal fluid (CSF) sampling and high costs or limited availability of MRI, PET, and SPECT 
(Albert et al., 2011, McKhann et al., 2011). 
There are several studies suggesting that the eye may be a biomarker for dementia (Ko et al., 
2018, Khawaja et al., 2016, Misra et al., 2017). The European Prospective Investigation of 
Cancer study of 8,623 people in the UK showed that RNFL thinning was associated with 
cognitive decline (Khawaja et al., 2016). Similarly, in 32,038 healthy UK Biobank participants 
RNFL thinning was associated with future cognitive decline (Ko et al., 2018). A recent study in 
patients with Parkinson’s disease has shown that a reduction in corneal nerve fiber length 
was associated with cognitive function as assessed using the Addenbrooke’s cognitive 
examination-revised (ACE-R) score (Misra et al., 2017). There are no prior published data 
examining the association between corneal nerve morphology and cognitive function in 
people with MCI or dementia. In the present study, the diagnostic workup employed the 
Arabic and English version of the Montreal cognitive assessment (MoCA), which is considered 
to be a good index of cognitive impairment compared to the Mini-Mental State Examination 
(MMSE), especially for MCI (Nasreddine et al., 2005). All three corneal nerve fiber measures 
were associated with a decline in cognitive function and functional independence. The ROC 
curve analysis suggests that CCM may have a good discriminative power to distinguish 
between healthy people and people with dementia. Paradoxically, we show that patients with 
a lower CNFL have a lower total cholesterol, which is counter to previous studies showing that 
corneal nerve fiber loss is associated with increased levels of cholesterol (Alamri et al., 2019, 
Andersen et al., 2018). However, this may be explained by the 2-fold greater use of statins in 
patients with dementia. 
The association between corneal nerve fiber loss and cognitive function should be interpreted 
with caution, especially with the small cohorts studied. Sub-analysis to assess any difference 
in the corneal nerve fiber measurements for Alzheimer’s disease and vascular dementia will 
be undertaken in future larger cohort studies. We acknowledge, there may be other causes 
of corneal nerve fiber loss such as impaired glucose tolerance and metabolic syndrome, 
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although we carefully excluded participants with ocular diseases, corneal dystrophies, 
diabetes and other causes of neuropathy that may influence corneal nerves. Nevertheless, 
this study suggests corneal confocal microscopy can identify neurodegeneration in people 
with MCI and dementia and is associated with cognitive decline and functional independence. 
In the present study the diagnostic workup employed was detailed and we used the Arabic 
and English version of the Montreal cognitive assessment (MoCA), which is considered to be 
a good index of cognitive impairment compared to the Mini-Mental State Examination 
(MMSE), especially for MCI (Nasreddine et al., 2005). Larger, longitudinal studies are required 
to establish the diagnostic and prognostic utility of CCM in people with MCI and dementia. 
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10.1 Abstract 
Introduction: Visual rating of medial temporal lobe atrophy (MTA) is an accepted structural 
neuroimaging marker of Alzheimer’s disease. Corneal confocal microscopy (CCM) is a non-
invasive ophthalmic technique that detects neuronal loss in peripheral and central 
neurodegenerative disorders. 
Objectives: To determine the diagnostic accuracy of CCM for mild cognitive impairment (MCI) 
and dementia compared to medial temporal lobe atrophy (MTA) rating on MRI.  
Methods: Subjects aged 60-85 with no cognitive impairment (NCI), MCI and dementia based 
on the ICD-10 criteria were recruited. Subjects underwent cognitive screening, CCM and MTA 
rating on MRI.  
Results: 182 subjects with NCI (n=36), MCI (n=80) and dementia (n=66), including AD (n=19, 
28.8%), VaD (n=13, 19.7%) and mixed AD (n=34, 51.5%) were studied. CCM showed a 
progressive reduction in corneal nerve fiber density (CNFD, fibers/mm2) (32.07.5 vs 24.59.6 
vs 20.89.3, p<0.0001), branch density (CNBD, branches/mm2) (90.946.5 vs 59.335.7 vs 
53.938.7, p<0.0001) and fiber length (CNFL, mm/mm2) (22.96.1 vs 17.26.5 vs 15.87.4, 
p<0.0001) in subjects with MCI and dementia compared to NCI. The area under the ROC curve 
(95% CI) for the diagnostic accuracy of CNFD, CNBD, CNFL compared to MTA-right and MTA-
left for MCI was 78% (67-90%), 82% (72-92%), 86% (77-95%) vs 53% (36-69%) and 40% (25-
128 
 
55%), respectively, and for dementia it was 85% (76-94%), 84% (75-93%), 85% (76-94%) vs 
86% (76-96%) and 82% (72-92%), respectively. 
Conclusions: The diagnostic accuracy of CCM, a non-invasive ophthalmic biomarker of 
neurodegeneration was high and comparable with MTA rating for dementia but was superior 
to MTA rating for MCI. 
10.2 Introduction 
Dementia is a progressive neurodegenerative disease affecting 40-50 million people 
worldwide (Wu et al., 2017, Prince et al., 2013). Therapeutic and psychological interventions 
for people with early stage dementia can improve cognition, independence, and quality of life 
(Prince et al., 2011). However, the clinical diagnosis of mild cognitive impairment (MCI) or 
early dementia is challenging due to the insidious onset of disease and gradual cognitive 
decline. The National Institute on Aging and the Alzheimer’s Association (NIA-AA) has 
proposed a number of biomarkers that reflect the underlying pathology of the disease to 
support the diagnosis of MCI and dementia (Albert et al., 2011, McKhann et al., 2011). 
Medial temporal lobe atrophy (MTA) rating is an established biomarker for 
neurodegeneration in Alzheimer’s disease (AD) but not for MCI or dementia (Albert et al., 
2011, McKhann et al., 2011). There is progressive MTA in subjects with MCI and dementia 
compared to those with no cognitive impairment (NCI) (Du et al., 2001, Urs et al., 2009). MTA 
rating has been shown to have high diagnostic accuracy for probable (Thies et al., 1999) and 
established AD (Heo et al., 2013, Cavedo et al., 2014). It can distinguish subjects with and 
without amnesic MCI and predict transition from NCI to MCI and from MCI to probable AD 
(Duara et al., 2008) as well as cognitive decline (Velickaite et al., 2018). MTA has also been 
reported in patients with vascular dementia (VaD) (Barber et al., 2000, Cho et al., 2009).  
CCM is a rapid non-invasive ophthalmic imaging technique which was originally pioneered for 
identifying neurodegeneration in diabetic peripheral neuropathy (Petropoulos et al., 2013c, 
Petropoulos et al., 2014, Petropoulos et al., 2013a, Malik et al., 2003, Ahmed et al., 2012) and 
subsequently in a range of other peripheral neuropathies (Petropoulos et al., 2019). CCM has 
recently also been used to identify neuronal injury in a number of central neurodegenerative 
disorders, including MCI and dementia (Ponirakis et al., 2019a), Parkinson’s disease (Misra et 
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al., 2017), amyotrophic lateral sclerosis (Ferrari et al., 2014) and multiple sclerosis 
(Petropoulos et al., 2017, Bitirgen et al., 2017b, Mikolajczak et al., 2016). CCM generates in 
vivo images of the sub-basal nerve plexus and image analysis of corneal nerves is performed 
using validated image analysis software (Dabbah et al., 2011) to reduce inter- and intra-rater 
variability and quantify corneal nerve morphology (Vagenas et al., 2012, Petropoulos et al., 
2013c, Kalteniece et al., 2017). 
The objective of this study was to compare the diagnostic accuracy of CCM with MTA rating 
for MCI and dementia, including AD, VaD and mixed AD. 
10.3 Methods 
Patients with MCI, dementia, including AD, VaD and mixed AD and no cognitive impairment 
(NCI) were recruited from the Geriatric and Memory clinic in Rumailah Hospital, Doha, Qatar 
between 18/09/16 and 31/07/19. Patients with severe anxiety, severe depression, 
Parkinson’s disease, frontotemporal dementia and Lewy body dementia, hypomania, and 
severe dementia who were unable to cooperate were excluded. Additionally, patients with 
other potential causes of peripheral neuropathy including vitamin B12 deficiency, 
hypothyroidism, HIV infection and hepatitis C were excluded. Diabetes was not excluded 
because there is a high prevalence of diabetes in patients aged ≥50 years in Qatar (Bener et 
al., 2009). Patients with dry eyes, corneal dystrophies, ocular trauma or surgery in the 
preceding 6 months were excluded. This study was approved by the Institutional Review 
Board of Weill Cornell Medicine in Qatar and Hamad Medical Corporation and all participants 
gave informed consent to take part in the study. The research adhered to the tenets of the 
declaration of Helsinki. 
10.3.1 Demographic and metabolic measures 
Age, gender, ethnicity, blood pressure, weight, body mass index (BMI), HbA1c, cholesterol, 
triglycerides, thyroid stimulating hormone (TSH), free thyroxine (FT4) and vitamin B12 were 
recorded. 
10.3.2 Cognitive screening  
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Cognitive screening was performed using the Montreal Cognitive Assessment (MoCA) test. 
The MoCA assesses seven cognitive domains including visuospatial/executive, naming, 
memory, attention, language, abstraction and delayed recall giving a total score of 30. A score 
of  26 indicates cognitive impairment. A point was added for individuals who had formal 
education ≤6th grade. Cognitive symptom duration was estimated from the clinical history 
obtained from relatives and participants. 
10.3.3 Diagnosis 
The diagnosis of MCI and dementia, including AD, VaD and mixed AD were based on the ICD-
10 criteria (Organization, 1992). The diagnosis was made according to consensus decision by 
geriatricians, geriatric psychiatrists and neurologists to exclude reversible, complex and 
young-onset dementia. The diagnoses of MCI and dementia were based on a patient history 
and examination, which include (1) presenting complaint and history of illness; (2) 
comprehensive history of each of the cognitive domains using MoCA; (3) psychiatric history 
for ruling out depression, mood disorders, and psychosis; (4) medical history including 
episodes of delirium and other medical comorbidities; (5) medication history; (6) functional 
history of basic daily living activities. A comprehensive organic work-up including blood tests 
and brain imaging was undertaken to exclude other potentially reversible causes of cognitive 
decline such as tumors, subdural hematoma or normal pressure hydrocephalus. The diagnosis 
of mixed AD was based on the presence of AD and significant vascular changes. Subjects with 
typical features of AD and no significant decline in functioning were classified as AD. 
Neuroradiologists blinded to the diagnosis and clinical data assessed for volume loss of 
hippocampi, entorhinal cortex, and amygdala on MRI, based on the criteria of Dubois et al 
(Dubois et al., 2009). The diagnosis of probable or possible VaD was based on the NINDS-
AIREN criteria (Roman et al., 1993), which include multiple large vessel infarcts or a single 
strategically placed infarct in the angular gyrus, thalamus, basal forebrain, or posterior (PCA) 
or anterior cerebral artery (ACA) territories, and multiple basal ganglia and white matter 
lacunes, extensive periventricular white matter lesions, or combinations thereof. 
10.3.4 MRI brain procedures 
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MRI was performed on a superconductive magnet operated at 3T (Skyra, Siemens). A T1-
weighted 3D magnetisation prepared rapid acquisition gradient echo sequence (MPRAGE) 
was obtained in the sagittal plane with a 1 mm slice thickness, repetition time of 1900 ms, 
echo time of 2.67 ms and 2.46 ms, inversion time of 1100 ms and 900 ms, flip angle of 9 
degree and 15 degree, and FOV= 240 x 100. Coronal and axial reformatted MPRAGE images 
were made from the sagittal 3D sequence. 
10.3.5 Medial temporal lobe atrophy visual rating 
A board certified neuroradiologist blinded to diagnosis and clinical data assessed MRI images. 
T1-coronal images at the level of the midbrain were used to score for right and left medial 
temporal lobe atrophy (MTA). The right and left hippocampi, entorhinal cortices, perirhinal 
cortices were separately rated according to the five-point scale developed and validated by 
Duara et al, and a combined visual MTA score for each hemisphere was calculated averaging 
the three measurements (Duara et al., 2008). The coronal reformatted MRI slice at the level 
of the mammillary bodies seen in the sagittal plane was used to define the outline of the 
medial temporal lobe. The outline of the entorhinal cortex in this slice was defined by the 
anterior parahippocampal gyrus and adjacent white matter (seen medial to the collateral 
sulcus and inferior to the hippocampus). The outline of the perirhinal cortex was defined by 
the fusiform gyrus and adjacent white matter (seen lateral to the collateral sulcus and medial 
to the occipitotemporal sulcus) (Figure 10.1). 
10.3.6 Corneal confocal microscopy 
CCM analysis was performed with the Heidelberg Retinal Tomograph III Rostock Cornea 
Module (Heidelberg Engineering GmbH, Heidelberg, Germany).  The cornea was locally 
anesthetized by instilling 1 drop of 0.4% benoxinate hydrochloride (Chauvin Pharmaceuticals, 
Chefaro, UK) and Viscotears (Carbomer 980, 0.2%, Novartis, UK) was used as the coupling 
agent between the cornea and the TomoCap as well as between the TomoCap and the 
objective lens. Subjects were instructed to fixate on a target with the eye not being 
examined. Several scans of the sub-basal nerve plexus in the central cornea were captured 
per eye for ~2 minutes. The field of view of each image is 400X400 µm.  At a separate time, 
three high clarity images per eye were selected by one researcher blind to the patient 
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diagnosis using established criteria b a s e d  o n  depth, focus position and contrast 
(Kalteniece et al., 2017). Corneal nerve fiber density (CNFD) (fibers/mm2), branch density 
(CNBD) (branches/mm2) and fiber length (CNFL) (total fiber length mm/mm2) were quantified 
using CCMetrics, a validated image analysis software (Dabbah et al., 2011).  
10.3.7 Statistical analysis 
This is an exploratory study as the diagnostic accuracy of CCM for MCI and dementia has not 
been compared with MTA visual rating before. 
Patients’ demographics and clinical characteristics were summarized using means and 
standard deviations for numeric variables and frequency distribution for categorical variables. 
Variables were compared between the NCI, MCI and dementia group using one-way analysis 
of variance (ANOVA) with Bonferroni’s post hoc test for pairwise comparisons and Chi-square 
test, respectively.  
The neuroradiologist scored for MTA in 30 subjects with NCI (n=10), MCI (n=10), and dementia 
(n=10), blind to the identity and diagnosis of the subjects. To assess intra-rater reliability, the 
neuroradiologist repeated ratings in all 30 subjects after an interval of approximately four 
weeks. Intra-rater reliability was assessed using kappa statistics. 
Receiver operating characteristic (ROC) curve analysis was used to determine the ability of 
CNFD, CNBD, CNFL, MTA-R, and MTA-L to distinguish between patients with MCI and 
dementia from NCI. The area under the ROC curve (AUC) and a cut-off point with the maximal 
sensitivity and specificity were calculated.  
All analyses were performed using IBM-SPSS (version 23; SPSS Inc, Armonk NY). Dot plots 
were generated using GraphPad Prism, version 6.05. A two-tailed P value of ≤0.05 was 
considered significant. 
10.4 Results 
We enrolled 207 people and excluded 1 patient with severe depression, 1 patient with 




10.4.1 Demographic and clinical characteristics 
182 subjects with NCI (n=36), MCI (n=80) and dementia (n=66) were studied. The 
demographic and clinical characteristics of these three groups are summarized (Table 10.1). 
The study cohort comprised of 111 (61.0%) males and 71 (39.0%) females. There were 63 
(34.6%) Qatari Arabs, 62 (34.1%) other Arabs, 37 (20.3%) South Asians, and 20 (11.0%) other 
ethnicities. The prevalence of Type 2 diabetes was 110 (60.4%) and was comparable between 
subjects with NCI (n=22, 61.1%), MCI (n=46, 57.5%) and dementia (n=42, 63.6%), p=0.71. 
Gender proportion and the mean age, systolic blood pressure (SBP), diastolic blood pressure 
(DBP), body weight, BMI, HbA1c, cholesterol and triglycerides were comparable between 
groups. There was a progressive reduction in cognitive function measured by MoCA between 
NCI (27.4  4.1), MCI (22.1  5.5, p<0.0001) and dementia (12.7  4.1, p<0.0001) group. The 
mean duration of cognitive impairment was significantly shorter in the MCI group compared 
to the dementia group (1.5  1.6 years vs 3.2  2.8 years, p<0.0001). The dementia group 








(n = 36) 
MCI 
(n = 80) 
Dementia 
(n = 66) 
P value1 P value2 P value3 
Demographics       
Age, years 71.7  6.2 71.6  5.4 73.9  6.9 NS NS NS 
Female 11 (30.6%) 34 (42.5%) 26 (39.4%) NS NS NS 
Systolic BP, mmHg 140.3  17.0 138.6  17.4 138.6  21.4 NS NS NS 
Diastolic BP, mmHg 73.7  19.8 71.4  8.3 69.1  10.0 NS NS NS 
Weight, kg 76.4  10.7 80.7  19.2 75.8  13.8 NS NS NS 
BMI, Kg/m2 27.6  4.0 30.6  7.2 30.0  4.9 NS NS NS 
HbA1c, % 6.7  1.3 7.0  1.7 6.6  1.3 NS NS NS 
Chol. mmol/L 4.3  1.1 4.3  1.0 3.9  1.2 NS NS NS 
Trig. mmol/L 1.5  0.7 1.5  0.7 1.4  0.7 NS NS NS 
Cognitive function       
MoCA 27.4  4.1 22.1  5.5 12.7  4.1 <0.0001 <0.0001 <0.0001 
Cognitive impairment duration, years N/A 1.51.6 3.22.8   <0.0001 
Corneal nerve fiber measures       
CNFD, fibers/mm2 32.0  7.5 24.5  9.6 20.8  9.3 <0.0001 <0.0001 NS 
CNBD, branches/mm2 90.9  46.5 59.3  35.7 53.9  38.7 0.001 <0.0001 NS 
CNFL, mm/mm2 22.9  6.1 17.2  6.5 15.8  7.4 <0.0001 <0.0001 NS 
Medial Temporal Atrophy Measures 
Medial temporal atrophy (right & left) 0.7  0.7 0.6  0.6 2.0  1.0 NS <0.0001 <0.0001 
Medial temporal atrophy (right) 0.6  0.8 0.5  0.6 1.9  1.0 NS <0.0001 <0.0001 
Hippocampus (right) 1.1  1.1 1.3  0.9 2.8  0.9 NS <0.0001 <0.0001 
Entorhinal cortex (right) 0.4  0.9 0.2  0.6 1.6  1.2 NS <0.0001 <0.0001 
Perirhinal cortex (right) 0.3  0.6 0.2  0.5 1.4  1.1 NS <0.0001 <0.0001 
Medial temporal atrophy (left) 0.8  0.8 0.6  0.7 2.1  1.1 NS <0.0001 <0.0001 
Hippocampus (left) 1.3  0.9 1.2  1.0 2.8  0.9 NS <0.0001 <0.0001 
Entorhinal cortex (left) 0.7  0.9 0.3  0.7 1.8  1.3 NS <0.0001 <0.0001 
Perirhinal cortex (left) 0.6  0.7 0.3  0.7 1.8  1.3 NS <0.0001 <0.0001 
1NCI versus MCI.       
2NCI versus Dementia       
3MCI versus Dementia       
Characteristics of 182 participants presented as mean  standard deviation for numeric variables and frequency 
distribution for NCI, MCI and dementia. Continuous and categorical variables were compared using one-way 
ANOVA with Bonferroni’s post hoc test and Chi-square test, respectively. Abbreviations: MoCA, Montreal 
cognitive assessment; NCI, no cognitive impairment, MCI, mild cognitive impairment, CNFD, corneal nerve fiber 
density; CNBD, corneal nerve branch density; CNFL, corneal nerve fiber length.  
10.4.2 Visual rating of medial temporal lobe atrophy 
The inter-rater reliability for MTA rating between two raters was 0.57 and 0.67 for the right 
and left MTA, respectively. The intra-rater reliability was 1.00 for both the right and left MTA.  
The atrophy rating of the right and left hippocampi, entorhinal cortices, perirhinal cortices 
and medial temporal lobe were comparable between the NCI and MCI group (Figure 10.1 & 
Table 10.1). The MTA rating of the dementia group was significantly higher compared with 
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the NCI and MCI group on the right (1.91.0 vs 0.50.6 and 0.60.8, p<0.0001) and left 
(2.11.1 vs 0.60.7 and 0.80.8, p<0.0001) hemispheres. The average MTA rating in the group 
with AD (1.91.0) and mixed AD with vascular lesions (2.31.0) was higher than in the group 
with VaD (1.50.8) but the difference was not significant (P=0.08).  
Figure 10.1. Visual rating system for assessing medial temporal atrophy. The three regions of interest are 
outlined in the right hemisphere in color (hippocampus in magenta; entorhinal cortex in blue; perirhinal cortex 
in green). Control subject (A) and subject with MCI (B), all showing no atrophy (MTA score=0) in both 
hemispheres. Subject with dementia (C), all structures have atrophy, (right MTA score=3.3 and left MTA 
score=2.3). 
10.4.3 Corneal nerve fiber measures 
The corneal nerve fiber measures in subjects with NCI, MCI and dementia are shown in Figure 
10.2. Compared to NCI the MCI and dementia group had a significantly lower corneal nerve 
fiber density (CNFD, fibers/mm2) (32.07.5 vs 24.59.6 and 20.89.3, p<0.0001), branch 
density (CNBD, branches/mm2) (90.946.5 vs 59.335.7 and 53.938.7, p0.001) and fiber 
length (CNFL, mm/mm2) (22.96.1 vs 17.26.5 and 15.87.4, p<0.0001). CNFD (20.810.7 vs 
19.89.1 vs 21.08.8, P=0.93), CNBD (58.145.8 vs 51.237.2 vs 51.936.0, P=0.84) and CNFL 
(16.48.7 vs 15.98.4 vs 15.36.4, P=0.88) were comparable between subjects with AD, VaD 
and dementia with mixed AD, respectively. 
The difference in corneal nerve fiber measures between subjects with NCI, MCI and dementia 
remained significant after controlling for T2D (P<0.0001) (Table 10.1). CNFD was significantly 




Figure 10.2. Corneal nerve fiber measures, and medial temporal lobe atrophy in subjects with NCI, MCI and 
dementia. (1) Corneal confocal microscopy (CCM) images of the sub-basal nerve plexus in (A) a 73-year old 
subject with NCI showing normal corneal nerve fiber morphology; (B) a 69-year old subject with MCI and (C) a 
74-year old subject with dementia showing a progressive reduction in corneal nerve fiber density, branch density 
and length. (2) Dot plots of corneal nerve fiber density (CNFD) (red), branch density (CNBD) (green), fiber length 
(CNFL) (blue) and MTA scoring (grey) in controls, subjects with MCI and dementia. The line that extends from 
the middle of the vertical line represents the mean and the lines that extend to the top and bottom are the 




10.4.4 MTA sensitivity and specificity  
The area under the ROC curve (AUC) (95% CI) to distinguish MCI from NCI for MTA-R and MTA-
L was not significant 53% (36-69%) and 40% (25-55%), respectively, whilst for dementia it was 
86% (76-96%) and 82% (72-92%) (p<0.0001), respectively (Figure 10.3 & Table 10.2). The 
sensitivity and specificity for dementia was 85% and 71% with MTA-R cut-off <0.8 and 79% 




Figure 10.3. The diagnostic accuracy of corneal nerve fiber measures and medial temporal lobe atrophy rating 
for MCI and dementia. ROC analysis showing the area under the curve for corneal nerve fiber measures and right 






Table 10.2. Receiver operating characteristic (ROC) curve analysis for the diagnostic accuracy of corneal confocal 
microscopy and medial temporal lobe atrophy rating for MCI and dementia. 
 AUC (95% Cl) Cutoff 
value 
Sensitivity Specificity P-value 
NCI vs. MCI     
CNFD, fibers/mm2 0.78 (0.67-0.90) 26.6 57% 81% <0.0001 
CNBD, branches/mm2 0.82 (0.72-0.92) 84.9 77% 76% <0.0001 
CNFL, mm/mm2 0.86 (0.77-0.95) 22.1 81% 81% <0.0001 
MTA-R 0.53 (0.36-0.69)    NS 
MTA-L 0.40 (0.25-0.55)    NS 
NCI vs. Dementia     
CNFD, fibers/mm2 0.85 (0.76-0.94) 26.8 77% 81% <0.0001 
CNBD, branches/mm2 0.84 (0.75-0.93) 77.9 79% 81% <0.0001 
CNFL, mm/mm2 0.85 (0.76-0.94) 21.1 79% 91% <0.0001 
MTA-R 0.86 (0.76-0.96) 0.8 85% 71% <0.0001 
MTA-L 0.82 (0.72-0.92) 1.2 79% 62% <0.0001 
Abbreviations: no cognitive impairment (NCI), mild cognitive impairment (MCI), corneal nerve fiber density 
(CNFD), corneal nerve branch density (CNBD), corneal nerve fiber length (CNFL), medial temporal atrophy (MTA). 
10.4.5 CCM sensitivity and specificity  
The area under the ROC curve (95% CI) to distinguish MCI from NCI for CNFD, CNBD, and CNFL 
was 78% (67-90%), 82% (72-92%), and 86% (77-95%) (p<0.0001), respectively, and for 
dementia it was 85% (76-94%), 84% (75-93%), and 85% (76-94%) (p<0.0001), respectively 
(Figure 10.3 and Table 10.2). The sensitivity and specificity for MCI was 57% and 81% with 
CNFD cut-off <27 fibers/mm2, 77% and 76% with CNBD cut-off <85 branches/mm2 and 81% 
and 81% with a CNFL cut-off <22 mm/mm2. The sensitivity and specificity for dementia was 
77% and 81% with a CNFD cut-off <27 fibers/mm2, 79% and 81% with a CNBD cut-off <78 
branches/mm2 and 79% and 91% with a CNFL cut-off of <21mm/mm2. 
10.5 Discussion 
This study compared the diagnostic accuracy of corneal confocal microscopy (CCM) a non-
invasive ophthalmic imaging biomarker of neurodegeneration for mild cognitive impairment 
(MCI) and dementia (Ponirakis et al., 2019a) with medial temporal lobe atrophy (MTA) rating, 
an established biomarker for Alzheimer’s disease (Albert et al., 2011, McKhann et al., 2011). 
The diagnostic accuracy of corneal nerve measures of neurodegeneration was high and 
equivalent to MTA rating for dementia, but it was superior to MTA rating for MCI. MTA rating 
could not distinguish subjects with MCI from subjects with NCI. Dementia is a 
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neurodegenerative condition characterized with an insidious onset and a slow progression 
(Albert et al., 2011). A diagnosis of MCI requires a change in cognition, evidence of 
impairment in at least one cognitive domain and preserved ability to function independently 
in daily life (McKhann et al., 2011). However, cognitive assessment tests are influenced by 
age, educational and cultural background (Albert et al., 2011). A method that allows for 
greater diagnostic certainty to distinguish normal cognition due to aging from MCI and 
dementia is required. Biomarkers can support the diagnosis of MCI and dementia by providing 
direct or indirect evidence of the underlying pathology of the disease and identify subtypes 
of MCI which do or do not progress to dementia (Albert et al., 2011). 
MTA rating as a biomarker of neuronal injury is included in the NIA-AA guidelines to support 
the diagnosis of AD (Albert et al., 2011, McKhann et al., 2011). Pathological changes occurring 
in the medial temporal lobe have been demonstrated at autopsy in patients with dementia in 
the earliest stages of the disease (Barkhof et al., 2007). MTA also occurs in vascular dementia 
(VaD) but not to the same extent as in AD (Barber et al., 2000, Cho et al., 2009). A gradual 
accumulation of infarcts or white matter ischemia is associated with hippocampal neuronal 
loss. In this study, MTA was detected in subjects with AD, VaD and mixed AD and vascular 
lesions. MTA visual rating was developed for use in clinical practice as it is easy to learn and 
can be quickly scored to support the diagnosis of AD (van de Pol and Scheltens, 2014). 
However, there are conflicting data about the diagnostic accuracy of MTA visual rating for AD. 
Duara et al. (Duara et al., 2008) reported that MTA can discriminate probable AD from no 
cognitive impairment with a good sensitivity (85%) and specificity (82%), above the 80% 
threshold (Thies et al., 1999). Heo et al. (Heo et al., 2013) and Cavedo et al. (Cavedo et al., 
2014) also reported that MTA scoring has high diagnostic accuracy for AD. Our findings are in 
line with the study of Falgas et al. (Falgas et al., 2019) showing that MTA visual rating can 
distinguish between AD and healthy controls with 94% specificity but 77% sensitivity using 
≥1.5 cut-off or 90% sensitivity with 56% specificity using ≥1 cut-off. However, previous studies 
reporting a high diagnostic accuracy for AD with MTA rating assessed patients with late-onset 
AD who have more atrophy compared to patients with early-onset AD. Furthermore, Duara 
et al. (Duara et al., 2008) used different MTA visual rating cut-offs for different age groups, ≥2 
for 63-75 years and ≥3 for ≥75 years, whilst our cut-off was independent of age. Falgas et al. 
(Falgas et al., 2019) also reported that MTA rating cannot distinguish patients with early-onset 
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AD and subjects with MCI. The AUC/sensitivity/specificity were 63%/30%/93% for non-
amnesic and 67%/34%/93% for amnesic early-onset AD. In this study, the left and right MTA 
scores could not distinguish subjects with NCI from MCI. 
Corneal nerve morphology has been evaluated using CCM in a number of central 
neurodegenerative disorders, including MCI and dementia (Ponirakis et al., 2019a), 
Parkinson’s disease (Misra et al., 2017), amyotrophic lateral sclerosis (Ferrari et al., 2014) and 
multiple sclerosis (Petropoulos et al., 2017, Bitirgen et al., 2017b, Mikolajczak et al., 2016). 
Previously, we have reported corneal nerve loss associated with cognitive decline and 
functional independence and reasonable diagnostic accuracy in a smaller cohort of subjects 
with MCI and dementia (Ponirakis et al., 2019a). In the present study with a greater number 
of participants we show improved diagnostic accuracy with an AUC (86% vs 73%), sensitivity 
(81% vs 70%) and specificity (81% vs 75%) for MCI, superior to MTA rating and a comparable 
AUC (85% vs 86%) and sensitivity (79% vs 85%) but improved specificity (91% vs 75%) for 
dementia. This study also shows that the severity of corneal nerve loss was comparable 
between AD, VaD and dementia with mixed AD and vascular lesions. 
It is important to account for other causes of corneal nerve fiber loss such as impaired glucose 
tolerance (Asghar et al., 2014) and diabetes (Azmi et al., 2015). Whilst a large body of data 
shows that diabetes has a major influence on corneal nerve pathology (Petropoulos et al., 
2013c, Petropoulos et al., 2014, Petropoulos et al., 2013a, Malik et al., 2003, Ahmed et al., 
2012), diabetes was not excluded from the study as diabetes is more prevalent in people with 
cognitive impairment and has a high prevalence in patients aged ≥50 years in Qatar (Bener et 
al., 2009). Indeed, our analysis shows that the difference in corneal nerve fiber measures 
between subjects with NCI, MCI and dementia remained significant after controlling for 
diabetes. 
Epidemiological studies also show that individuals with T2D have an increased risk of 
dementia (Zhang et al., 2017a, Gudala et al., 2013). The relative risk for AD and VaD for people 
with diabetes compared to people without diabetes is 1.53 (95% CI 1.42-1.63) (Zhang et al., 
2017a) and 2.27 (95% CI 1.94-2.66) (Gudala et al., 2013), respectively. The increased risk of 
dementia in patients with T2D is attributed to non-AD mechanisms of neurodegeneration. 
Diabetes is not associated with excess Aß plaques and neurofibrillary tangles of 
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hyperphosphorylated tau protein in the brain (Abner et al., 2016, Dos Santos Matioli et al., 
2017). However, patients with T2D have a 1.57-times increased odds of an infarct, and 1.71-
times increased odds of lacunes in the brain (Abner et al., 2016). Infarcts and lacunes double 
the risk of dementia occurring within 5 years (Vermeer et al., 2003) and could further 
decrease cognitive reserve in patients who have accumulating plaques and tangles (Snowdon 
et al., 1997).  
The diagnostic accuracy of MTA visual rating and CCM for MCI should be interpreted with 
caution because diagnosis of MCI was based on clinical evaluation and cognitive examination 
using the ICD-10 criteria (International Advisory Group for the Revision of and Behavioural, 
2011). This is a significant limitation when comparing the diagnostic accuracy of these two 
techniques for MCI without biological confirmation of the disease including cerebrospinal 
fluid (CSF) concentrations of amyloid beta (Aβ) 42, Aβ40, tau/phosphorylated tau (Mattsson 
et al., 2009, Hansson et al., 2006) or Aβ deposition using positron emission tomography (PET) 
(Forsberg et al., 2008, Grimmer et al., 2013). This could have led to higher rate of misdiagnosis 
of MCI. The overlap of corneal nerve measures between MCI and dementia may be attributed 
to the absence or presence, severity of neurodegeneration and stage of the disease. The 
optimal role of biomarkers for AD should be to identify the disease in its prodromal stages 
(Jack et al., 2018). All three corneal nerve measures are reduced in both MCI and dementia 
and future larger studies may inform us as to which measure is optimal. A longitudinal study 
is currently underway to compare the prognostic ability of CCM and quantitative brain 
atrophy on progression of participants with MCI to dementia. CCM may lack specificity for 
dementia as it occurs in a range of peripheral and central neurodegenerative diseases, 
therefore future studies should attempt to define specific patterns of corneal nerve fiber 
alteration in MCI and dementia and assess its utility alongside more specific biomarkers such 
as Aβ and tau.  
In conclusion, this study shows that CCM has high diagnostic accuracy for MCI and dementia, 
whereas MTA rating has high diagnostic accuracy for dementia but cannot distinguish 
subjects with NCI from those with MCI. This suggests that CCM is a promising ophthalmic 
imaging biomarker of neurodegeneration that could be utilized to screen, diagnose and follow 
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Chapter 11: Conclusions 
The prevalence of diabetes in Qatar is almost two-fold higher than the global average of 8.3% 
and is associated with an increasing prevalence of the long-term complications (IDF Middle 
East and North Africa Region, 2020, , International Diabetes Federation, 2019, ). A common 
complication of diabetes is diabetic peripheral neuropathy (DPN) a progressive 
neurodegenerative disorder affecting ~50% of people with diabetes. The clinical diagnosis of 
DPN is challenging due to the insidious onset of disease and gradual decline of peripheral 
nerve function (Malik, 2020). It imposes a significant health and economic burden to both the 
patient and health care providers (Raghav et al., 2018). DPN leads to painful DPN (pDPN) 
(Ponirakis et al., 2019b), erectile dysfunction (Kouidrat et al., 2017) and diabetic foot 
ulceration (DFU) (Raghav et al., 2018) in patients with diabetes. Painful DPN has a significant 
impact on the patient’s quality of life (Van Acker et al., 2009, Bohlega et al., 2010) as it is 
accompanied by depression, anxiety and sleep disturbance (Bohlega et al., 2010).  
The prevalence of DPN, pDPN and those at high risk of DFU have not been systematically 
studied in Qatar. Using a large cohort of randomly selected patients with T2D (n=1,095) 
attending the two National Diabetes Centers in Qatar, Chapter 3 shows that the prevalence 
of DPN was 23%, of whom one-third were at high risk of DFU, and 6% had diabetic foot ulcers. 
However, 82% of patients with DPN had not been previously diagnosed. Chapter 4 shows that 
1 in 3 patients with T2D had pDPN, but ~80% of patients had not been diagnosed or treated 
for this condition. Chapter 5 identified a lower prevalence of DPN and pDPN in primary health 
care (PHC) compared to secondary health care (SHC), which may be attributed to better 
overall risk factor control in PHC and referral bias due to patients who are poorly managed 
with complications being referred to SHC. Alarmingly, ~80% of patients with DPN in PHC were 
also undiagnosed, highlighting the need for implementing annual DPN screening. PHC had a 
much lower prevalence of patients with undiagnosed pDPN compared to SHC, which may 
reflect a more systematic approach to identify neuropathic symptoms as part of a general 
screen for complications as opposed to SHC where there is no formal screening unless the 
physician refers for further assessment. Predictors of DPN are age, duration of diabetes, poor 
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glycemic control, hyperlipidemia and hypertension, whereas for pDPN they are the presence 
of DPN, obesity, physical activity and smoking. This argues for annual screening and 
identification of patients with DPN for more aggressive treatment of the identified modifiable 
risk factors. 
Clinical and experimental studies suggest that hypertension is an independent risk factor for 
DPN in patients with T1D (Tesfaye et al., 2005, Forrest et al., 1997, Cavusoglu et al., 2015, 
Elliott et al., 2009, Sanada et al., 2015, Gregory et al., 2012) and T2D (Cardoso et al., 2015, De 
Visser et al., 2014, Kesavamoorthy et al., 2015, Yang et al., 2015). ACE inhibitors  have been 
shown to improve NCS but there are conflicting data about their effect on neuropathic 
symptoms and other neuropathy measures (Malik et al., 1998, Ruggenenti et al., 2011, Reja 
et al., 1995). Chapter 6 assessed the impact of hypertension on both large and small fiber 
measures in subjects with and without T1D. It shows that hypertension contributes to 
neuropathy in a cohort of patients with T1D but has no impact in subjects without diabetes. 
The detrimental impact of hypertension on neuropathy is mediated together with high 
HbA1c, cholesterol, triglycerides, and BMI. These data also suggest that nerve conduction 
studies (NCS) should be adopted as the primary endpoints in clinical trials assessing the 
benefits of blood pressure lowering therapy on DPN. 
Most international guidelines recommend metformin after lifestyle intervention for T2D 
patients. This rational is based on its 40-year long-term safety record and the fact that it has 
shown a 31% reduced incidence of T2D and 17% reduced incidence of metabolic syndrome at 
2.8-years (Knowler et al., 2002). Despite conflicting data regarding the effect of metformin 
therapy on B12 deficiency (Chapman et al., 2016), a number of observational and placebo-
controlled studies have confirmed that metformin may reduce vitamin B12 levels (Chapman 
et al., 2016). A potential consequence of B12 deficiency is that it could directly result in 
neuropathy or exacerbate DPN. However, there are conflicting reports on the association 
between metformin induced B12 deficiency and neuropathy, with some reports showing an 
association (Singh et al., 2013, Roy et al., 2016) whilst others have refuted this (Khan et al., 
2017, Russo et al., 2016, Ahmed et al., 2016, Ma et al., 2015). Chapter 7 shows no difference 
in B12 levels or the severity of DPN or pDPN in metformin compared to non-metformin users. 
It also shows no difference in DPN or pDPN in those with and without B12 deficiency. 
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There are currently no FDA approved therapies for DPN. There are conflicting data regarding 
the beneficial effect of GLP-1 receptor agonists on DPN (Kan et al., 2012, Himeno et al., 2011, 
Jaiswal et al., 2015, Brock et al., 2019). There is evidence showing that pioglitazone might 
have a neuroprotective effect (Yamagishi et al., 2008). Chapter 8 is an exploratory sub-study 
of the Qatar study (Abdul-Ghani et al., 2017), an open-label, randomized controlled trial 
(clinicaltrials.gov identifier NCT02887625), which showed a rapid and effective reduction in 
HbA1c after treatment with the combination treatment or basal-bolus insulin in patients with 
poorly controlled T2D. Chapter 8 shows that a combination of exenatide once weekly and 
pioglitazone or basal bolus insulin results in corneal nerve regeneration detecting by CCM, 
but no change in neuropathic symptoms or sudomotor function. This shows that DPN is 
amenable to treatment, however, it highlights the importance of selecting appropriate 
endpoints to show treatment efficacy in clinical trials of DPN. 
CCM was originally pioneered for identifying neurodegeneration in DPN (Petropoulos et al., 
2013c, Petropoulos et al., 2014, Petropoulos et al., 2013a, Malik et al., 2003, Ahmed et al., 
2012) and subsequently in a range of other peripheral neuropathies (Petropoulos et al., 2019) 
and a large group of healthy people (Tavakoli et al., 2010). It generates in vivo images of the 
sub-basal nerve plexus from which corneal nerve morphology is analysed using validated 
image analysis software (Dabbah et al., 2011) which reduces inter- and intra-rater variability 
and enables objective quantification of corneal nerve morphology (Vagenas et al., 2012, 
Petropoulos et al., 2013c, Kalteniece et al., 2017). CCM has also been used to identify corneal 
nerve degeneration in a number of central neurodegenerative diseases, including Parkinson’s 
disease (Kass-Iliyya et al., 2015, Podgorny et al., 2016), amyotrophic lateral sclerosis (Ferrari 
et al., 2014) and multiple sclerosis (Petropoulos et al., 2017, Bitirgen et al., 2017b, Mikolajczak 
et al., 2016). However, the association between corneal nerve fiber pathology and 
neurodegeneration in dementia has not been studied. There is an increasing focus on 
identifying biomarkers for neurodegeneration, which can detect pre-clinical dementia which 
may be more amenable to disease modifying strategies. Clinical diagnosis of mild cognitive 
impairment (MCI) or early dementia can be challenging due to the insidious onset of disease 
and gradual cognitive decline. Biomarkers can support the diagnosis of MCI and dementia by 
providing direct or indirect evidence of the underlying pathology of the disease. Chapter 9 a 
proof-of-concept study shows that CCM identified neurodegeneration, which was associated 
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with cognitive and functional decline in people with MCI and dementia. Furthermore, the ROC 
curve analysis shows that CCM might have a good discriminative power to distinguish subjects 
with MCI or dementia from subjects with no cognitive impairment (NCI). Chapter 10 
compared the diagnostic accuracy of CCM with visual rating of medial temporal lobe atrophy 
(MTA) using brain MRI to distinguish subjects with MCI or dementia, including Alzheimer’s 
disease, vascular dementia and combined Alzheimer’s disease from subjects with NCI. The 
results show that MTA and CCM have comparable diagnostic ability for dementia, whilst only 
CCM can distinguish subjects with MCI from those with NCI. This suggests that CCM should 
be considered as an objective imaging marker of neurodegeneration to support the diagnosis 
of MCI and dementia.  
It is important to account for other causes of corneal nerve fiber loss such as impaired glucose 
tolerance (Asghar et al., 2014) and diabetes (Azmi et al., 2015). Whilst a large body of data 
shows that diabetes has a major influence on corneal nerve pathology (Petropoulos et al., 
2013c, Petropoulos et al., 2014, Petropoulos et al., 2013a, Malik et al., 2003, Ahmed et al., 
2012), diabetes was not excluded from the study for Chapter 10 as diabetes is highly prevalent 
in people with cognitive impairment and has a high prevalence in patients aged ≥50 years in 
Qatar (Bener et al., 2009). Our analysis shows that the difference in corneal nerve fiber 
measures between subjects with NCI, MCI and dementia remained significant after 




Chapter 12: Future work 
After the completion of my PhD I plan to find a research and teaching position in academia. I 
would like to remain with Professor Rayaz Malik’s supportive and efficient team to continue 
the ongoing longitudinal studies in dementia, schizophrenia and diabetes in Qatar. We have 
established a strong collaboration with the hospitals from which subjects are recruited, 
Neuroradiology where MRI scans are analysed and Qatar Biomedical Research Institute 
(QBRI) where transcriptomics, metabolomics and proteomics can be undertaken from the 
blood samples collected from the studies. 
From the dementia project I aim to achieve the following objectives: 
1. Compare the diagnostic accuracy of CCM with quantitative brain atrophy for MCI and 
dementia. 
2. Determine whether CCM can differentiate subjects with amyloid pathology or AD 
hypometabolism pattern in subjects with MCI and AD. 
3. Assess the impact of vascular lesions and diabetes on CCM measures. 
4. Define the change in corneal nerve fiber measures and brain atrophy in subjects with NCI, 
MCI and dementia over a 2-year period. 
5. Compare the prognostic ability of CCM and quantitative brain atrophy on progression to 
dementia. 
6. Determine if a change in corneal nerve measures is associated with a change in cognitive 
function, disease severity or brain atrophy in subjects with MCI after adjusting for change 
in metabolic and cardiovascular risk factors over a 2-year period. 
From the Schizophrenia study I aim to achieve the following objectives: 
1. To determine the association of corneal nerve morphology with cognitive function, 
disease severity and subtype in subjects with schizophrenia. 
2. To compare the diagnostic accuracy of CCM with quantitative brain atrophy as a 
biomarker of neurodegeneration in schizophrenia. 
149 
 
3. To assess the impact of metabolic syndrome on CCM measures in subjects with 
schizophrenia. 
4. To compare the prognostic ability of CCM and quantitative brain atrophy on 
progression of symptoms in subjects with schizophrenia. 
5. To determine if a change in corneal nerve measures is associated with a change in 
cognitive function, disease severity or quantitative brain atrophy in subjects with 
schizophrenia after adjusting for a change in metabolic and cardiovascular risk factors. 
From the diabetes study I aim to achieve the following objectives: 
1. Establish a research pathway for subject selection, recruitment and assessment of CCM 
and DPN in the National Diabetes Center in Hamad General Hospital.  
2. Apply for a grant to study the predictive validity of CCM for and the association of change 
in CCM with 1) progression of DPN symptoms and deficits, 2) diabetic retinopathy and 3) 
coronary artery disease, peripheral arterial disease and stroke in subjects with diabetes 
and sub-clinical neuropathy, small fiber neuropathy or those at high risk of DPN based on 
duration of diabetes, hyperglycemia, hypertension or hyperlipidemia. 
3. Undertake further trials to investigate the effect of life-style interventions (i.e. diet and 
physical activity) or anti-diabetic agents (i.e. Semaglutide and SGLT2 inhibitors) or weight 
lowering agents (i.e. phentermine-topiramate, bupropion-naltrexone and orlistat) on 
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